Inhibitor Compounds

Small molecule inhibitors targeting PMS2 protein activity address the limitations of current treatments for MMR-deficient cancers by enhancing immune responses and restoring DNA MMR function, offering improved therapeutic options for cancers like Lynch syndrome and CMMRD.

JP2024543183AInactive Publication Date: 2024-11-19NEOPHORE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024531696
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-29
Filing Date
2022-11-28
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for cancers with mismatch repair (MMR) deficiencies, such as Lynch syndrome and congenital mismatch repair disorder (CMMRD), are limited in efficacy due to the lack of targeted inhibitors for the PMS2 protein, which is crucial for DNA MMR, and there is a need for compounds that can modulate PMS2 activity to enhance anti-tumor immune responses.

Method used

Development of small molecule compounds that covalently inhibit PMS2 protein activity, either alone or in combination with immunotherapeutic agents, to restore DNA MMR function and enhance immune activation through the cGAS-STING pathway.

Benefits of technology

The compounds effectively inhibit PMS2 activity, potentially improving treatment outcomes for MMR-deficient cancers by enhancing immune responses and activating the cGAS-STING pathway, thereby promoting tumor control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543183000001_ABST
    Figure 2024543183000001_ABST
Patent Text Reader

Abstract

The present invention relates to compounds of formula (II) that target the PMS2 protein, a component of the DNA mismatch repair (MMR) process. [Formula 1] JPEG2024543183000117.jpg66170[where, R 2 , R 4 , R 6 , Y1, Y2, A1, A2, A3, and A4 are each as defined herein.] The invention also relates to methods for the preparation of these compounds, pharmaceutical compositions containing them, and their use in the treatment of proliferative disorders, e.g., cancer, and other diseases or conditions associated with PMS2 activity.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] [preface] The present invention relates to several compounds that function as inhibitors of PMS2 protein activity. In particular, the compounds of the present invention can be used as covalent binding agents that inhibit PMS2. Thus, the compounds of the present invention can be used to treat diseases or conditions mediated, at least in part, by inappropriate PMS2 activity, such as cancer. The present invention further relates to uses of the compounds and pharmaceutical compositions containing them. [Background technology]

[0002] Cancer is caused by alterations in cell proliferation. What exactly causes cells to become malignant and grow in a controlled and unregulated manner has been the focus of intensive research over the past decades. Such studies have identified the most important pathways and associated molecular targets that enable such malignancies.

[0003] Mismatch repair (MMR) is a highly conserved DNA repair pathway that plays a major role during DNA replication, repair, and recombination, as well as during meiosis in eukaryotes and immunoglobulin maturation / diversification in mammals. MMR promotes genome stability in all organisms by correcting DNA base mismatches and insertion / deletion (indel) loops that can occasionally arise during the normal DNA replication process. Base pair mismatches occur when an incorrect nucleotide is inserted into a newly synthesized DNA strand and circumvents the proofreading function of DNA polymerase. Indel loops commonly occur in association with microsatellites, which are highly polymorphic short, repetitive DNA sequences distributed throughout prokaryotic and eukaryotic genomes. Normally, in microsatellites, the template and primer strands are prone to slippage (dissociation and reannealing) during replication, which can generate loop structures and discordant numbers of repeat units between the template and newly synthesized strands.

[0004] DNA mismatch repair is a bidirectional excision and resynthesis system that initiates with a defined strand break 3'- or 5'-to the mismatch; the excision tract extends just beyond the mismatch. MMR can be divided into four steps: 1) mismatch recognition by MSH proteins; 2) recruitment of MLH / PMS proteins that link the mismatch recognition signal to the site of DNA strand break initiation; 3) excision of the erroneous DNA strand; and 4) resynthesis of the excision gap using the remaining DNA strand as a template [1]. MMR is a highly conserved biological pathway. In humans, the MMR pathway is initiated by mismatch recognition by hMutSα (MSH2-MSH6) or hMutSβ (MSH2-MSH3). Binding of hMutSα or hMutSβ to the mismatch site leads to the recruitment of MutLα (MLH1-PMS2), forming a ternary complex whose protein-protein, protein-DNA interactions, and endonuclease activity are modulated by ATP / ADP cofactors. Proliferating cell nuclear antigen (PCNA) may play a role in recruiting MMR proteins to the vicinity of replication forks [1]. PCNA can also activate the latent endonuclease activity of eukaryotic MutLα proteins. After DNA cleavage, exonuclease 1 (EXO1) is recruited, which excises the newly synthesized DNA strand, and the DNA excision gap is resynthesized by DNA polymerase δ (Polδ). If DNA resynthesis is complete, the remaining nick is ligated by DNA ligase, restoring double-strand integrity [2]. Consistent with this function, MMR is an important tumor suppressor pathway that reduces sporadic cancers by up to 40%. Furthermore, individuals with germline mutations in MMR genes develop a cancer predisposing state.

[0005] Lynch syndrome (LS, formerly named hereditary nonpolyposis colorectal cancer) is the most common cause of hereditary colorectal cancer (CRC), accounting for 2–5% of all cases. LS is also characterized by an increased risk of malignant lesions at several extracolonic sites, including the endometrium, ovaries, stomach, and small intestine, among others. [3] LS has an autosomal dominant inheritance pattern and is caused by germline mutations in the MMR genes MLH1, MSH2, MSH6, or PMS2. Gene expression from one wild-type allele is sufficient for adequate MMR activity until a second hit inactivates the wild-type allele, resulting in MMR deficiency.

[0006] Congenital mismatch repair disorder (CMMRD) syndromes are distinct childhood cancer predisposition syndromes that result from biallelic germline mutations in one of four MMR genes: MLH1, MSH2, MSH6, or PMS2. Patients can have homozygous biallelic alterations or heterozygous alterations in the MMR genes.

[0007] MMR-abnormal cancers are generally characterized by the accumulation of DNA mutations at a rate faster than normal cells and other tumors; for example, CMMRD tumors typically have a hypermutated phenotype (>250 substitution mutations / Mb) [4]. MMR deficiency also results in an increase or decrease in microsatellite repeat length, termed microsatellite instability (MSI). Cancers with greater than 40% microsatellite mutations (positive for two or more of five routinely tested microsatellite markers) are described as MSI-high (MSI-H). Tumors lacking MSI are microsatellite stable (MSS), while those with less than 40% microsatellite mutations (one of the five markers indicating microsatellite instability) are MSI-low (MSI-L) [5]. MSI analysis is a widely used diagnostic biomarker for MMR-deficient tumors, and MSI status is associated with a high prevalence of frameshift (FS) mutations, which can occur due to insertions / deletions within coding microsatellites. In addition to altering downstream protein functions, FS creates new amino acid sequences that act as substrates for antigen processing and presentation [6], stimulating CD8+ T cell activation (class I) and CD4+ T cell "helper" function (class II).

[0008] Cancers with a higher number of neoantigens are more prone to immune surveillance and are more likely to respond to immunotherapy [7]; a higher neoantigen load is associated with total lymphocyte infiltration, TILs, memory T cells, and survival in colorectal cancer [8, 9]. This characteristic supports the rationale for immunotherapy-based therapeutic strategies [6]. Consistent with this concept, immune checkpoint inhibitors now represent an important therapeutic advance in the treatment of MMR-abnormal cancers. PD-1 inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), have been approved by the US Food and Drug Administration (FDA) for patients with MMR-D or MSI-H metastatic CRC based on their significant survival benefit. The CTLA-4 inhibitor ipilimumab (Yervoy) has been approved for use in combination with nivolumab for the treatment of patients with MMR-D or MSI-H CRC previously treated with chemotherapy. Importantly, the FDA approved the use of pembrolizumab in MMR-D / MSI-H cancers, regardless of histological tumor type

[10] .

[0009] It is now accepted that clinical response to immune checkpoint inhibitors requires the presence of tumor neoantigens and the infiltration of T cells that recognize these neoantigens. Higher neoantigen burden is associated with a better response to CTLA-4 and PD-1 blockade in patients with melanoma and non-small cell lung cancer [11, 12, 13]. The number of neoantigens is associated with TMB, and several large studies have confirmed that high TMB correlates with enhanced checkpoint inhibitor response and improved overall survival in several tumor types, such as urothelial carcinoma

[14] , non-small cell lung cancer [15-18], and small cell lung cancer

[19] .

[0010] Germano et al. recently proposed that MMR inactivation by silencing MLH1 increases TMB, resulting in a "dynamic mutational profile" and persistent neoantigen regeneration in vitro and in vivo. This induces immune surveillance and, particularly in combination with immune checkpoint inhibition in mouse models, results in tumor growth control

[20] . Similar results have been observed with silencing MSH2

[21] .

[0011] Guan et al. and Lu et al. reported that MLH1 deficiency leads to the release of cytosolic DNA and activation of the cGAS-STING pathway and IFN-β production. Guan et al. demonstrated that loss of MLH1 leads to DNA hyperexcision, RPA depletion, chromosomal instability, and cytosolic DNA accumulation

[22] . Lu et al. reported that cytosolic DNA sensing by the cGAS-STING pathway contributes to the clinical benefit of immunotherapy in patients with MMR-deficient tumors

[23] . Together, these reports suggest that suppressing MMR activity can induce beneficial immune activation by activating the cGAS-STING pathway.

[0012] MLH1 and PMS2 generally form heterodimers; loss of the MLH1 protein typically results in the concomitant loss of the PMS2 protein, suggesting that one or both of the proteins may be essential for MMR function and cGAS / STING pathway regulation.

[0013] Thus, there is biological and clinical evidence that highlights the need for inhibitors that target the PMS2 protein, a key component of DNA MMR, to restore anti-tumor immune responses.

[0014] Thus, the present invention provides methods for the treatment of cancer by binding to and modulating the function of the DNA MMR component PMS2 using small molecules as single agents and in combination with immunotherapeutics, other DNA damage response pathway modulators and / or standard of care chemotherapeutics.

[0015] Outside of the cancer field, triplet repeat disorders include more than 30 human neurodegenerative and neuromuscular genetic disorders, such as Huntington's disease (HD), myotonic dystrophy type 1 (DM1), fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar ataxias (SCAs). Such disorders are characterized by the expansion of simple repeats in genomic DNA. These unstable repeats are generally found in different regions of several genes, and their expansions can cause disease through various loss-of-function and gain-of-function pathways, for example, by interfering with the expression or characteristics of gene products or by affecting splicing or antisense regulation. Several mechanisms have been proposed to contribute to repeat instability, including errors during DNA replication, meiotic recombination, transcription, DNA repair, and chromatin remodeling, which can occur at various stages of the cell cycle. There is evidence that a functional MMR pathway is required to maintain the stability of microsatellite sequences: for example, Msh2- / - transgenic mice carrying a copy of human HD exon 1 (containing a CAG repeat) show a reduced expansion of the introduced (CAG)n repeat when compared to their Msh2+ / +HD exon 1 mouse counterparts

[24] .

[0016] Thus, there is a further need for compounds that target components of the DNA MMR process, including PMS2, for the treatment of triplet repeat disorders. It is with the foregoing in mind that the present invention has been discovered. [References] 1.Martin-Lopez, J.V. and R. Fishel, The mechanism of mismatch repair and the functional analysis of mismatch repair defects in Lynch syndrome. Fam Cancer, 2013. 12(2): p. 159-68. 2.Liu, D., G. Keijzers, and L.J. Rasmussen, DNA mismatch repair and its many roles in eukaryotic cells. Mutat Res, 2017. 773: p. 174-187. 3.Lynch, H.T., et al., Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet, 2009. 76(1): p. 1-18. 4.Shlien, A., et al., Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet, 2015. 47(3): p. 257-62 5.Sehgal, R., et al., Lynch syndrome: an updated review. Genes (Basel), 2014. 5(3): p. 497-507 6.Willis, J.A., et al., Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate. Clin Cancer Res, 2019. 7.Gubin, M.M. and R.D. Schreiber, CANCER. The odds of immunotherapy success. Science, 2015. 350(6257): p. 158-9. 8.Kloor, M. and M. von Knebel Doeberitz, The Immune Biology of Microsatellite-Unstable Cancer. Trends Cancer, 2016. 2(3): p. 121-133. 9.Giannakis, M., et al., Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep, 2016. 17(4): p. 1206. 10.Lemery, S., P. Keegan, and R. Pazdur, First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. N Engl J Med, 2017. 377(15): p. 1409-1412. 11.Le, D.T., et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med, 2015. 372(26): p. 2509-20. 12.Rizvi, N.A., et al., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 2015. 348(6230): p. 124-8. 13.Van Allen, E.M., et al., Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 2015. 350(6257): p. 207-211. 14.Rosenberg, J.E., et al., Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, 2016. 387(10031): p. 1909-20. 15.Hellmann, M.D., et al., Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018. 33(5): p. 843-852 e4. 16.Rizvi, H., et al., Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol, 2018. 36(7): p. 633-641. 17.Carbone, D.P., et al., First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med, 2017. 376(25): p. 2415-2426. 18.Hellmann, M.D., et al., Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med, 2018. 378(22): p. 2093-2104. 19.Hellmann, M.D., et al., Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell, 2018. 33(5): p. 853-861 e4. 20.Germano, G., et al., Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature, 2017. 552(7683): p. 116-120. 21.Mandal, R., et al., Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science, 2019. 364(6439): p. 485-491. 22.Guan J., et al., MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway. Cancer Cell. 2021, 39 (1), 109 - 121, 23.Lu, C., et al. DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity. Cancer Cell. 2021, 39 (1), 96 - 108. 24.Manley, K., et al., Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nat Genet, 1999. 23(4): p. 471-3. Summary of the Invention

[0017] According to a first aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0018] According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in admixture with a pharmaceutically acceptable diluent or carrier.

[0019] According to a further aspect of the present invention there is provided a method of inhibiting PMS2 activity in vitro or in vivo, said method comprising the step of contacting a cell with an effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0020] According to a further aspect of the present invention there is provided a method of treating a disease or disorder in which PMS2 activity is associated in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0021] According to a further aspect of the present invention there is provided a method of treating a proliferative disorder in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0022] According to a further aspect of the present invention there is provided a method of treating cancer in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0023] According to a further aspect of the present invention there is provided a method of treating a triplet repeat disorder (e.g. Huntington's disease (HD), myotonic dystrophy type 1 (DM1), Fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar ataxias (SCAs)) in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0024] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use in therapy.

[0025] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use as a medicament.

[0026] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a proliferative disorder.

[0027] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition thereof, for use in the treatment of cancer, hi a particular embodiment the cancer is a human cancer.

[0028] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use in the treatment of a triplet repeat disorder, in particular embodiments, the triplet repeat disorder is selected from the group consisting of Huntington's disease (HD), myotonic dystrophy type 1 (DM1), fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar degeneration (SCAs).

[0029] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in inhibiting PMS2 activity.

[0030] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a disease or disorder associated with PMS2 activity.

[0031] According to a further aspect of the invention there is provided the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of a proliferative disorder.

[0032] According to a further aspect of the invention there is provided the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of cancer.

[0033] According to a further aspect of the present invention there is provided the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of a triplet repeat disorder, in particular embodiments, the triplet repeat disorder is selected from the group consisting of Huntington's disease (HD), myotonic dystrophy type 1 (DM1), fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar degeneration (SCAs).

[0034] According to a further aspect of the present invention there is provided the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the inhibition of PMS2 activity.

[0035] According to a further aspect of the present invention there is provided the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of a disease or disorder associated with PMS2 activity.

[0036] According to a further aspect of the present invention there is provided a process for preparing a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0037] According to a further aspect of the present invention there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, obtainable by, or obtained directly by, a process for preparing a compound as defined herein.

[0038] According to a further aspect of the present invention there is provided a novel intermediate, as defined herein, suitable for use in any one of the synthetic methods described herein.

[0039] In the above-outlined aspect of the invention, the proliferative disorder is suitably cancer, and the cancer is suitably a human cancer. In particular, the compounds of the invention are useful in the treatment of any cancer in which mismatch repair inhibition and / or cGAS-STING pathway activation is beneficial. Any suitable cancer can be targeted (e.g., adenoid cystic carcinoma, adrenal tumor, amyloidosis, anal cancer, appendix cancer, astrocytoma, ataxia-telangiectasia, Beckwith-Wiedemann syndrome, bile duct cancer (cholangiocarcinoma), Birt-Hogg-Dubé syndrome, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, Carney complex, central nervous system tumor, cervical cancer, colorectal cancer, Cowden disease, craniopharyngioma, desmoplastic infantile ganglioglioma, ependymoma, esophageal cancer, Ewing's sarcoma, eye cancer, eyelid cancer, familial adenomatous polyposis, familial GIST, familial malignant melanoma, familial non-VHL clear cell renal cell carcinoma, familial pancreatic cancer, gallbladder cancer, gastrointestinal stromal tumor -GIST, germ cell tumors, gestational trophoblastic disease, head and neck cancer, hereditary breast and ovarian cancer, hereditary diffuse gastric cancer, hereditary leiomyomatosis and renal cell carcinoma, hereditary mixed polyposis syndrome, hereditary pancreatitis, hereditary papillary renal cell carcinoma, juvenile polyposis syndrome, kidney cancer, lacrimal gland tumors, laryngeal and hypopharyngeal cancer, leukemia (acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), B-cell prolymphocytic leukemia Disease, hairy cell leukemia, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic T-cell lymphocytic leukemia, eosinophilic leukemia), Li-Fraumeni syndrome, liver cancer, lung cancer (non-small cell lung cancer, small cell lung cancer), lymphoma (Hodgkin, non-Hodgkin), Lynch syndrome, mastocytosis, medulloblastoma, melanoma, meningioma, mesothelioma, multiple endocrine neoplasia type 1 and type 2, multiple myeloma, MUTYH (or MYH)-associated polyposis, myelodysplastic syndrome (MDS), nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, neuroendocrine tumors (e.g., of the gastrointestinal tract, lung, or pancreas), neurofibromatosis types 1 and 2, nevoid basal cell carcinoma syndrome, oral or oropharyngeal cancer, osteosarcoma, ovarian / fallopian tube / peritoneal cancer, pancreatic cancer, parathyroid cancer, penile cancer, Peutz-Jeghers syndrome, pheochromocytoma, paraganglioma , pituitary tumors, pleuropulmonary blastoma, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma (e.g., Kaposi's or soft tissue), skin cancer, small intestine cancer, stomach cancer, testicular cancer, thymoma and thymic carcinoma, thyroid cancer, tuberous sclerosis, uterine cancer, vaginal cancer, von Hippel-Lindau syndrome, vulvar cancer, Waldenström's macroglobulinemia, Werner's syndrome, Wilms' tumor, and xeroderma pigmentosum). Particular cancers of interest include hematological cancers, such as lymphomas (including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt's lymphoma (BL), and angioimmunoblastic T-cell lymphoma (AITL)), leukemias (including acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML)), multiple myeloma, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, endometrial cancer, gastro-esophageal cancer, neuroendocrine cancer, osteosarcoma, prostate cancer, pancreatic cancer, small intestine cancer, bladder cancer, rectal cancer, cholangiocarcinoma, CNS cancer, thyroid cancer, head and neck cancer, esophageal cancer, and ovarian cancer.

[0040] Features, including optional, suitable and preferred features, with respect to one aspect of the invention may also be features, including optional, suitable and preferred features, with respect to any other aspect of the invention. DETAILED DESCRIPTION OF THE INVENTION

[0041] [Definition] Unless otherwise stated, the following terms used in the specification and claims have the following meanings, as set forth below.

[0042] References to "treating" or "treatment" shall be understood to include prevention as well as the alleviation of established symptoms of a condition. Thus, "treating" a situation, disorder, or condition or "treatment" of a situation, disorder, or condition includes (1) preventing or delaying the appearance of clinical symptoms of the situation, disorder, or condition occurring in a person who may be afflicted with or predisposed to the situation, disorder, or condition, but who has not yet experienced or exhibited clinical or subclinical symptoms of the situation, disorder, or condition; (2) inhibiting the situation, disorder, or condition, i.e., (in the case of maintenance treatment) arresting, reducing, or delaying the onset of the disease or its recurrence or at least one of its clinical or subclinical symptoms; or (3) relieving or attenuating the disease, i.e., causing regression of the situation, disorder, or condition or at least one of its clinical or subclinical symptoms.

[0043] "Therapeutically effective amount" means the amount of a compound that, when administered to a mammal to treat a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" varies depending on the compound, the disease and its severity, and the age, weight, etc., of the mammal to be treated. For example, in humans or other mammals, it should be understood that a therapeutically effective amount can be determined experimentally in a laboratory or clinical setting, or the therapeutically effective amount can be the amount required by the guidelines of the U.S. Food and Drug Administration (FDA) or a corresponding foreign regulatory agency for a particular disease and subject to be treated. It should be understood that the determination of appropriate dosage forms, dosage amounts, and routes of administration is within the level of ordinary skill in the pharmaceutical and medical fields.

[0044] "Subject(s)" and "patient(s)," as used herein alone or in combination with one or more other terms, refer to animals (e.g., mammals), particularly humans. Suitably, "subject(s)" and "patient(s)" may be non-human animals (e.g., livestock or household pets) or humans.

[0045] "Pharmaceutically acceptable," as used herein alone or in combination with one or more other terms, generally refers to a material that is chemically and / or physically compatible with other ingredients (e.g., as with respect to a formulation), and / or generally physiologically compatible with its recipient (e.g., a subject).

[0046] As used herein, "alkyl" includes straight-chain and branched-chain alkyl groups. Reference to a particular alkyl group, such as "propyl," is specific for the straight-chain version only, and reference to a particular branched-chain alkyl group, such as "isopropyl," is specific for the branched-chain version only. For example, "(1-6C)alkyl" includes (1-4C)alkyl, (1-3C)alkyl, propyl, isopropyl, and t-butyl.

[0047] The terms "(m-nC)" or "(m-nC) group" used alone or as a prefix, refer to any group having m to n carbon atoms.

[0048] An "alkylene" group is an alkyl group that is positioned between and serves to connect two other chemical groups. Thus, "(1-6C)alkylene" means a straight-chain saturated divalent hydrocarbon group of 1 to 6 carbon atoms or a branched saturated divalent hydrocarbon group of 3 to 6 carbon atoms, such as methylene (-CH-), the ethylene isomers (-CH(CH)- and -CHCH-), the propylene isomers (-CH(CH)CH-, -CH(CHCH)-, -C(CH)-, and -CHCHCH-), pentylene (-CHCHCHCHCHCH-), and the like.

[0049] "Alkenyl" refers to straight- and branched-chain alkyl groups containing two or more carbon atoms and at least one carbon-carbon double bond is present within the group. Alkenyl groups include, for example, ethenyl, propenyl, and but-2,3-enyl, and include all possible geometric (E / Z) isomers.

[0050] "Alkynyl" refers to straight- and branched-chain alkyl groups containing two or more carbon atoms and at least one carbon-carbon triple bond is present within the group. Alkynyl groups include, for example, acetylenyl and propynyl.

[0051] "(m-nC)cycloalkyl" means a saturated hydrocarbon ring system containing m to n carbon atoms. Exemplary cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and bicyclo[2.2.1]heptyl.

[0052] "Alkoxy" refers to O-linked straight and branched chain alkyl groups. Alkoxy groups include, for example, methoxy, ethoxy, and t-butoxy.

[0053] "Haloalkyl," as used herein, refers to an alkyl group in which one or more hydrogen atoms are replaced by halogen (e.g., fluorine) atoms. Haloalkyl groups include, for example, -CHF, -CHF, and -CF.

[0054] "Halo" or "halogeno" refers to fluoro, chloro, bromo and iodo, suitably fluoro, chloro and bromo, more suitably fluoro and chloro.

[0055] "Carbocyclyl," "carbocyclic," or "carbocycle" means a non-aromatic saturated or partially saturated monocyclic, fused, bridged, or spiro bicyclic carbon-containing ring system(s). Monocyclic carbocyclic rings contain about 3 to 12 (suitably 3 to 7) ring atoms. Bicyclic carbocyclic rings contain 6 to 17 member atoms, suitably 7 to 12 member atoms in the ring. Bicyclic carbocyclic ring(s) can be fused, spiro, or bridged ring systems. Carbocyclic groups include, for example, cyclopropyl, cyclobutyl, cyclohexyl, cyclohexenyl, and spiro[3.3]heptanyl.

[0056] "Heterocyclyl," "heterocyclic," or "heterocycle" means a non-aromatic saturated or partially saturated monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring system(s). Monocyclic heterocyclic rings contain about 3 to 12 (suitably 3 to 7) ring atoms, with 1 to 5 (suitably 1, 2, or 3) heteroatoms selected from nitrogen, oxygen, or sulfur in the ring. Bicyclic heterocyclic rings contain 7 to 17 member atoms, suitably 7 to 12 member atoms, in the ring. Bicyclic heterocyclic ring(s) can be fused, spiro, or bridged ring systems. Heterocyclic groups include, for example, cyclic ethers, such as oxiranyl, oxetanyl, tetrahydrofuranyl, dioxanyl, and substituted cyclic ethers. Nitrogen-containing heterocycles include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrotriazinyl, tetrahydropyrazolyl, etc. Sulfur-containing heterocycles typically include tetrahydrothienyl, dihydro-1,3-dithiol, tetrahydro-2H-thiopyran, and hexahydrothiepin. Other heterocycles include dihydrooxathiolyl, tetrahydrooxazolyl, tetrahydrooxadiazolyl, tetrahydrodioxazolyl, tetrahydrooxathiazolyl, hexahydrotriazinyl, tetrahydrooxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. In the case of sulfur-containing heterocycles, sulfur-oxide heterocycles containing SO or SO groups are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothienyl and thiomorpholinyl, such as tetrahydrothienyl 1,1-dioxide and thiomorpholinyl 1,1-dioxide, etc. The heterocycle can contain one or two oxo (=O) or thioxo (=S) substituents.Suitable values ​​for a heterocyclyl group bearing one or two oxo (=O) or thioxo (=S) substituents are, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl. Particular heterocyclyl groups are saturated monocyclic 3- to 7-membered heterocyclyls containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, or sulfur, such as azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, tetrahydrothienyl, tetrahydrothienyl 1,1-dioxide, thiomorpholinyl, thiomorpholinyl 1,1-dioxide, piperidinyl, homopiperidinyl, piperazinyl, or homopiperazinyl. As would be understood by one of ordinary skill in the art, any heterocycle can be linked to another group by any suitable atom, for example, a carbon or nitrogen atom. Meanwhile, reference herein to piperidino or morpholino refers to a piperidin-1-yl or morpholin-4-yl ring linked by the ring nitrogen.

[0057] "Bridged ring system" means a ring system in which two rings share two or more atoms, see, for example, Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages 131-133, 1992. Bridged heterocyclyl ring systems include, for example, aza-bicyclo[2.2.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, aza-bicyclo[3.2.1]octane, and quinuclidine.

[0058] By "spiro bicyclic ring system," we mean that two ring systems share one common spiro carbon atom, i.e., a heterocyclic ring is linked to an additional carbocyclic or heterocyclic ring by a single common spiro carbon atom. Spiro ring systems include, for example, 6-azaspiro[3.4]octane, 2-oxa-6-azaspiro[3.4]octane, 2-azaspiro[3.3]heptane, 2-oxa-6-azaspiro[3.3]heptane, 7-oxa-2-azaspiro[3.5]nonane, 6-oxa-2-azaspiro[3.4]octane, 2-oxa-7-azaspiro[3.5]nonane, and 2-oxa-6-azaspiro[3.5]nonane.

[0059] "Aromatic," as used herein alone or in combination with another term or terms, refers to monocyclic and polycyclic ring systems containing 4n+2 π-electrons, where n is an integer. Aromatic should be understood to refer to and include ring systems containing only carbon atoms (i.e., "aryl") as well as ring systems containing at least one heteroatom selected from N, O, or S (i.e., "heteroaromatic" or "heteroaryl"). Aromatic ring systems may be substituted or unsubstituted.

[0060] "Non-aromatic," as used herein alone or in combination with one or more other terms, refers to a monocyclic or polycyclic ring system having at least one double bond that is not part of an extended conjugated π system. As used herein, non-aromatic refers to and includes ring systems containing only carbon atoms as well as ring systems containing at least one heteroatom selected from N, O, or S. Non-aromatic ring systems may be substituted or unsubstituted.

[0061] "Heteroaryl" or "heteroaromatic ring" refers to an aromatic monocyclic, bicyclic, or polycyclic ring incorporating one or more (e.g., 1 to 4, particularly 1, 2, or 3) heteroatoms selected from nitrogen, oxygen, or sulfur. The term heteroaryl includes monovalent and divalent species. Examples of heteroaryl groups are monocyclic and bicyclic groups containing 5 to 12 ring members, more usually 5 to 10 ring members. A heteroaryl group can be, for example, a 5- or 6-membered monocyclic ring or a 9- or 10-membered bicyclic ring, e.g., a 5- and 6-membered fused ring or a bicyclic structure formed from two 6-membered fused rings. Each ring can contain up to about four heteroatoms, typically selected from nitrogen, sulfur, and oxygen. Typically, a heteroaryl ring contains up to three heteroatoms, more usually up to two, e.g., a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl ring can be basic, as in the case of an imidazole or pyridine, or essentially non-basic, as in the case of an indole or pyrrole nitrogen. Generally, the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents on the ring, is less than five.

[0062] Heteroaryl includes, for example, furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolyl, and the like. These include linyl, quinoxalinyl, cinnolinyl, pteridinyl, naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl, thieno[2,3-b]furanyl, 2H-furo[3,2-b]-pyranyl, 5H-pyrido[2,3-d]-o-oxazinyl, 1H-pyrazolo[4,3-d]-oxazolyl, 4H-imidazo[4,5-d]thiazolyl, pyrazino[2,3-d]pyridazinyl, imidazo[2,1-b]thiazolyl, and imidazo[1,2-b][1,2,4]triazinyl. "Heteroaryl" also encompasses partially aromatic bicyclic or polycyclic ring systems in which at least one ring is aromatic and one or more of the other ring(s) is non-aromatic, saturated or partially saturated, provided that at least one ring contains one or more heteroatoms selected from nitrogen, oxygen, or sulfur. Partially aromatic heteroaryl groups include, for example, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 2-oxo-1,2,3,4-tetrahydroquinolinyl, dihydrobenzthienyl, dihydrobenzfuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, 2,2-dioxo-1,3-dihydro-2-benzothienyl, 4,5,6,7-tetrahydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydro-1,8-naphthyridinyl, 1,2,3,4-tetrahydropyrido[2,3-b]pyrazinyl, and 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl.

[0063] Five-membered heteroaryl groups include, but are not limited to, for example, pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, and tetrazolyl groups.

[0064] 6-membered heteroaryl groups include, but are not limited to, for example, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, and triazinyl.

[0065] Bicyclic heteroaryl groups include, for example: a benzene ring fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms; a pyridine ring fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms; a pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a pyrrole ring fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms; a pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a pyrazine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an imidazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an oxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an isoxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a thiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an isothiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a thiophene ring fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms; a furan ring fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms; a cyclohexyl ring fused to a 5- or 6-membered aromatic heterocycle containing 1, 2, or 3 ring heteroatoms; and a cyclopentyl ring fused to a 5- or 6-membered aromatic heterocycle containing 1, 2 or 3 ring heteroatoms; It may be a group selected from:

[0066] Bicyclic heteroaryl groups containing a 6-membered ring fused to a 5-membered ring specifically include, but are not limited to, benzfuranyl, benzthiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolinyl, isoindolinyl, purinyl (e.g., adeninyl, guaninyl), indazolyl, benzodioxolyl, and pyrazolopyridinyl groups.

[0067] Bicyclic heteroaryl groups containing two 6-membered fused rings specifically include, but are not limited to, quinolinyl, isoquinolinyl, chromanyl, thiochromanyl, chromenyl, isochromenyl, chromanyl, isochromanyl, benzodioxanyl, quinolidinyl, benzoxazinyl, benzodiazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, and pteridinyl groups.

[0068] "Aryl" means a cyclic or polycyclic aromatic ring having 5 to 12 carbon atoms. The term aryl includes monovalent and divalent species. Aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, and the like. In a particular embodiment, the aryl is phenyl.

[0069] This specification also uses some compound terms to describe groups containing two or more functional groups. Such terms are understood by those skilled in the art. For example, (3-6C)cycloalkyl(m-nC)alkyl includes (m-nC)alkyl substituted with (3-6C)cycloalkyl.

[0070] "Optionally substituted" refers to groups, structures, or molecules that are substituted and groups, structures, or molecules that are not substituted. 1 "One / any CH, CH, CH group or heteroatom (i.e., NH) within the group is optionally substituted" is R 1 Suitably, it means that one (any) of the hydrogen radicals of the group is replaced by the associated defined group.

[0071] When an optional substituent is selected from "one or more" groups, it is to be understood that this definition includes all substituents selected from one of the specified groups or substituents selected from two or more of the specified groups. In some embodiments, one or more refers to one, two, or three. In other embodiments, one or more refers to one or two. In particular embodiments, one or more refers to one.

[0072] "Compounds of the invention" means, generically and specifically, the compounds disclosed herein.

[0073] As used herein in connection with a measurable value, such as an amount or duration, "about" is meant to encompass a reasonable variation of the value, for example, allowing for experimental error in determining said value.

[0074] [Compound] In one aspect, the present invention provides a compound of structural formula (I) shown below: [ka] [In the formula, R 2is hydrogen or fluoro; R 4 is selected from the group consisting of hydrogen, halogen, (1-6C)alkyl, (1-6C)haloalkyl, (3-6C)cycloalkyl, and (3-6C)cycloalkyl(1-2C)alkyl, wherein said (1-6C)alkyl is selected from the group consisting of one or more R 5a and the (3-6C)cycloalkyl and (3-6C)cycloalkyl(1-2C)alkyl groups are optionally substituted by one or more R 5b each R 5a are independently selected from halogen or (1-4C)alkoxy; and each R 5b are independently selected from the group consisting of halogen, (1-4C) alkyl, and (1-4C) alkoxy; R 6 is a (1-6C)alkyl, (3-8C)cycloalkyl, or 4- to 7-membered heterocyclyl ring containing one heteroatom selected from N, O, or S; Or a group having a structure according to formula (A) shown below: [ka] (In the formula, R 7 is hydrogen or (1-3C) alkyl; n is 1 or 2; R 8 is (3-8C)cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is selected from one or more R 9 each R 9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, or (1-3C)haloalkoxy; Y1 is -CH2-, -C(=O)-, or -CHR y2a - and R y2a is selected from halo, cyano, methyl, methoxy, CF3, -OCF3 or hydroxymethyl; Y2 is -CH2-, -C(=O)-, -CHR y2a -, -CH2-CH2-, -CH2-CHR y2b -, or -CHR y2a -CH2-; R y2a is selected from halo, cyano, methyl, methoxy, CF, -OCF or hydroxymethyl; R y2b is selected from halo, cyano, hydroxy, methyl, methoxy, CF3, -OCF3 or hydroxymethyl; R 11A is hydrogen or (1-3C) alkyl; R 11 is a group of formula (A) or (B) shown below: [ka] (In the formula, R 11B and R 11C are each independently selected from the group consisting of hydrogen, halo, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, where any (1-4C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl-(1-2C)alkyl group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, (3-6C)cycloalkoxy, phenyl, or 4- to 6-membered heterocyclyl; and any phenyl or 4- to 6-membered heterocyclic ring is optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkoxy; R 11D is hydrogen, halo, or (1-3C)alkyl; R 11Eis selected from the group consisting of hydrogen, halo, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, where any (1-4C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl-(1-2C)alkyl group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, (3-6C)cycloalkoxy, phenyl, or 4- to 6-membered heterocyclyl; and any phenyl or 4- to 6-membered heterocyclic ring is optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkoxy; A2 is N, CH or CR 12 Selected from; A3 is N, CH or CR 13 Selected from; A4 is N, CH or CR 14 Selected from; provided that only one or two of A2, A3 or A4 may be N; R 12 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy; or R 12 is -(CHR p ) f -Z 12 (In the formula, R p is hydrogen or methyl; f is 0 or 1; Z 12 -OR 20 , -NR 21 R 22 , -C(O)NR 21 R 22 or -NR 23 C(O)R 24and; R 20 is (1-4C) alkyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR q ) e -(3-7C)cycloalkyl, -(CHR q ) e -phenyl, -(CHR q ) e -[4- to 6-membered heterocyclyl] or -(CHR q ) e -[5- or 6-membered heteroaryl], and R q is hydrogen or methyl, and e is 0 or 1; R 21 and R 22 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR r ) d -(3-7C)cycloalkyl, -(CHR r ) d -phenyl, -(CHR r ) d -[4- to 6-membered heterocyclyl] or -(CHR r ) d -[5- or 6-membered heteroaryl]; R r is hydrogen or methyl, and d is 0 or 1; or R 21 and R 22 are linked together with the nitrogen atom to which they are attached so that they form a 4- to 6-membered heterocyclic ring; R 23 is hydrogen or (1-2C) alkyl; R 24 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR s ) c-(3-7C)cycloalkyl, -(CHR s ) c -phenyl, -(CHR s ) c -[4- to 6-membered heterocyclyl] or -(CHR s ) c -[5- or 6-membered heteroaryl], and R s is hydrogen or methyl, and c is 0 or 1; R 20 , R 21 , R 22 , R 23 Or R 24 or R 21 and R 22 Any ring formed when R are linked may each contain one or more R a ) and optionally substituted with; R 13 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted with one or more halo or (1-2C)alkoxy; or R 13 is -(CHR o ) h -Z 13 (In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 13 -OR 25 , -NR 26 R 27 , -C(O)NR 26 R 27 or -NR 28 C(O)R 29 and; R 25 is (1-4C) alkyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR n ) i -(3-7C)cycloalkyl, -(CHR n ) i-phenyl, -(CHR n ) i -[4- to 6-membered heterocyclyl] or -(CHR n ) i -[5- or 6-membered heteroaryl], and R n is hydrogen or methyl, and i is 0 or 1; R 26 and R 27 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR m ) j -(3-7C)cycloalkyl, -(CHR m ) j -phenyl, -(CHR m ) j -[4- to 6-membered heterocyclyl] or -(CHR m ) j -[5- or 6-membered heteroaryl]; R m is hydrogen or methyl, and j is 0 or 1; or R 26 and R 27 are linked together with the nitrogen atom to which they are attached so that they form a 4- to 6-membered heterocyclic ring; R 28 is hydrogen or (1-2C) alkyl; R 29 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR l ) k -(3-7C)cycloalkyl, -(CHR l ) k -phenyl, -(CHR l ) k -[4- to 6-membered heterocyclyl] or -(CHR l ) k -[5- or 6-membered heteroaryl], and R lis hydrogen or methyl, and k is 0 or 1; R 25 , R 26 , R 27 , R 28 Or R 29 or R 26 and R 27 Any ring formed when R are linked may each contain one or more R a ) and optionally substituted with; R 14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy; or R 14 is -(CHR k ) m -Z 14 (In the formula, R k is hydrogen or methyl; m is 0 or 1; Z 14 -OR 30 , -NR 31 R 32 , -C(O)NR 31 R 32 or -NR 33 C(O)R 34 and; R 30 is (1-4C) alkyl, (3-7C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR j ) o -(3-7C)cycloalkyl, -(CHR j ) o -[4- to 6-membered heterocyclyl] or -(CHR j ) o -[5- or 6-membered heteroaryl], and R j is hydrogen or methyl, and o is 0 or 1; R 31 and R 32is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR i ) p -(3-7C)cycloalkyl, -(CHR i ) p -[4- to 6-membered heterocyclyl] or -(CHR i ) p -[5- or 6-membered heteroaryl]; R i is hydrogen or methyl, and p is 0 or 1. or R 31 and R 32 are linked together with the nitrogen atom to which they are attached so that they form a 4- to 6-membered heterocyclic ring; R 33 is hydrogen or (1-2C) alkyl; R 34 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR h ) q -(3-7C)cycloalkyl, -(CHR h ) q -[4- to 6-membered heterocyclyl] or -(CHR h ) q -[5- or 6-membered heteroaryl], and R h is hydrogen or methyl, and q is 0 or 1; R 30 , R 31 , R 32 , R 33 Or R 34 , or R 31 and R 32 Any ring formed when R are linked may be formed by one or more R a ) and optionally substituted with; Each R a is oxo, halogen, cyano, hydroxy, (1-4C) alkyl, or -L 1 -X1 -Q 1 base are independently selected from the group consisting of: L 1 is absent or is (1-2C) alkylene; X 1 is absent or -O-, -C(O)-, -C(O)-O-, -OC(O)-, -S(O) 0~2 -, -C(O)-N(R 14a )-, -N(R 14a )-C(O)-, -NR 14a -, -N(R 14a )-C(O)-NR 14a -, -SO2N(R 14a )- or -N(R 14a )SO2-, and R 14a is hydrogen or (1-2C) alkyl; Q 1 is selected from the group consisting of hydrogen, (1-4C) alkyl, (2-4C) alkenyl, (2-4C) alkynyl, or (3-6C) cycloalkyl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

[0075] In one aspect, the present invention also provides a compound of structural formula (II) shown below: [ka] [In the formula, R 2 is hydrogen or fluoro; R 4 is selected from the group consisting of hydrogen, halogen, (1-6C)alkyl, (1-6C)haloalkyl, (3-6C)cycloalkyl, and (3-6C)cycloalkyl(1-2C)alkyl, wherein said (1-6C)alkyl is selected from the group consisting of one or more R 5a and the (3-6C)cycloalkyl and (3-6C)cycloalkyl(1-2C)alkyl groups are optionally substituted by one or more R 5b each R 5aare independently selected from halogen or (1-4C)alkoxy; and each R 5b are independently selected from the group consisting of halogen, (1-4C) alkyl, and (1-4C) alkoxy; R 6 is a (1-6C)alkyl, (1-6C)haloalkyl, (3-8C)cycloalkyl, or a 4- to 7-membered heterocyclyl ring containing one heteroatom selected from N, O, or S; or a group having a structure according to formula (A) shown below: [ka] (In the formula, R 7 is hydrogen or (1-3C) alkyl; n is 1 or 2; R 8 is (3-8C)cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is selected from one or more R 9 each R 9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, or (1-3C)haloalkoxy; Y1 is -CH2-, -C(=O)-, or -CHR y2a - and R y2a is selected from halo, cyano, methyl, methoxy, CF3, -OCF3 or hydroxymethyl; Y2 is -CH2-, -C(=O)-, -CHR y2a -, -CH2-CH2-, -CH2-CHR y2b -, or -CHR y2a -CH2-; R y2a is selected from halo, cyano, methyl, methoxy, CF, -OCF or hydroxymethyl; R y2b is selected from halo, cyano, hydroxy, methyl, methoxy, CF3, -OCF3 or hydroxymethyl; A1 is N, CH, CR 10 or CR12 Selected from; A2 is N, CH, CR 10 or CR 12 Selected from; A3 is N, CH or CR 13 Selected from; A4 is N, CH or CR 14 Selected from; however, Only one or two of A1, A2, A3 or A4 may be N; One of A1 and A2 is CR 10 and; R 10 is a group of formula (IIA) or (IIB) shown below: [ka] (In the formula, [ka] represents the attachment point to A1 or A2, R 11A is hydrogen or (1-3C) alkyl; R 11 is a group of formula (A) or (B) shown below: [ka] (In the formula, R 11B and R 11C is hydrogen, halo, (1-4C) alkyl, (3-6C) cycloalkyl, (3-6C) cycloalkyl-(1-2C) alkyl, and -C(O)NR 11F R 11G R 11F and R 11G are each independently selected from hydrogen or (1-4C)alkyl; R 11B and / or R 11CAny (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl present in the group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, (3-6C)cycloalkoxy, phenyl, or 4- to 6-membered heterocyclyl; any phenyl or 4- to 6-membered heterocyclic ring is optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkoxy; R 11D is selected from hydrogen, halo, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl and —C(O)H, wherein any (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl or —C(O)H group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, (3-6C)cycloalkoxy, phenyl or 4- to 6-membered heterocyclyl; any phenyl or 4- to 6-membered heterocyclic ring is optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkoxy or (1-3C)alkyl; R 11Eis selected from the group consisting of hydrogen, halo, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, where any (1-4C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl-(1-2C)alkyl group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, (3-6C)cycloalkoxy, phenyl, or 4- to 6-membered heterocyclyl; and any phenyl or 4- to 6-membered heterocyclic ring is optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkoxy. R 12 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy; or R 12 is -(CHR p ) f -Z 12 (In the formula, R p is hydrogen or methyl; f is 0 or 1; Z 12 -OR 20 , -NR 21 R 22 , -C(O)NR 21 R 22 or -NR 23 C(O)R 24 and; R 20 is (1-4C) alkyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR q ) e -(3-7C)cycloalkyl, -(CHR q ) e-phenyl, -(CHR q ) e -[4- to 6-membered heterocyclyl] or -(CHR q ) e -[5- or 6-membered heteroaryl], and R q is hydrogen or methyl, and e is 0 or 1; R 21 and R 22 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR r ) d -(3-7C)cycloalkyl, -(CHR r ) d -phenyl, -(CHR r ) d -[4- to 6-membered heterocyclyl] or -(CHR r ) d -[5- or 6-membered heteroaryl]; R r is hydrogen or methyl, and d is 0 or 1; or R 21 and R 22 are linked together with the nitrogen atom to which they are attached so that they form a 4- to 6-membered heterocyclic ring; R 23 is hydrogen or (1-2C) alkyl; R 24 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR s ) c -(3-7C)cycloalkyl, -(CHR s ) c -phenyl, -(CHR s ) c -[4- to 6-membered heterocyclyl] or -(CHR s ) c -[5- or 6-membered heteroaryl], and R sis hydrogen or methyl, and c is 0 or 1; R 20 , R 21 , R 22 , R 23 Or R 24 or R 21 and R 22 Any ring formed when R are linked may each contain one or more R a ) optionally substituted with; or R 13 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted with one or more halo or (1-2C)alkoxy; or R 13 is -(CHR o ) h -Z 13 (In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 13 -OR 25 , -NR 26 R 27 , -C(O)NR 26 R 27 or -NR 28 C(O)R 29 and; R 25 is (1-4C) alkyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR n ) i -(3-7C)cycloalkyl, -(CHR n ) i -phenyl, -(CHR n ) i -[4- to 6-membered heterocyclyl] or -(CHR n ) i -[5- or 6-membered heteroaryl], and R n is hydrogen or methyl, and i is 0 or 1; R 26and R 27 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR m ) j -(3-7C)cycloalkyl, -(CHR m ) j -phenyl, -(CHR m ) j -[4- to 6-membered heterocyclyl] or -(CHR m ) j -[5- or 6-membered heteroaryl]; R m is hydrogen or methyl, and j is 0 or 1; or R 26 and R 27 are linked together with the nitrogen atom to which they are attached so that they form a 4- to 6-membered heterocyclic ring; R 28 is hydrogen or (1-2C) alkyl; R 29 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR l ) k -(3-7C)cycloalkyl, -(CHR l ) k -phenyl, -(CHR l ) k -[4- to 6-membered heterocyclyl] or -(CHR l ) k -[5- or 6-membered heteroaryl], and R l is hydrogen or methyl, and k is 0 or 1; R 25 , R 26 , R 27 , R 28 Or R 29 or R 26 and R 27 Any ring formed when R are linked may each contain one or more R a) and optionally substituted with; R 14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy; or R 14 is -(CHR k ) m -Z 14 (In the formula, R k is hydrogen or methyl; m is 0 or 1; Z 14 -OR 30 , -NR 31 R 32 , -C(O)NR 31 R 32 or -NR 33 C(O)R 34 and; R 30 is (1-4C) alkyl, (3-7C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR j ) o -(3-7C)cycloalkyl, -(CHR j ) o -[4- to 6-membered heterocyclyl] or -(CHR j ) o -[5- or 6-membered heteroaryl], and R j is hydrogen or methyl, and o is 0 or 1; R 31 and R 32 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR i ) p -(3-7C)cycloalkyl, -(CHR i ) p -[4- to 6-membered heterocyclyl] or -(CHR i ) p-[5- or 6-membered heteroaryl]; R i is hydrogen or methyl, and p is 0 or 1. or R 31 and R 32 are linked together with the nitrogen atom to which they are attached so that they form a 4- to 6-membered heterocyclic ring; R 33 is hydrogen or (1-2C) alkyl; R 34 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR h ) q -(3-7C)cycloalkyl, -(CHR h ) q -[4- to 6-membered heterocyclyl] or -(CHR h ) q -[5- or 6-membered heteroaryl], and R h is hydrogen or methyl, and q is 0 or 1; R 30 , R 31 , R 32 , R 33 Or R 34 , or R 31 and R 32 Any ring formed when R are linked may be formed by one or more R a ) and optionally substituted with; Each R a is oxo, halogen, cyano, hydroxy, (1-4C) alkyl, or -L 1 -X 1 -Q 1 base are independently selected from the group consisting of: L 1 is absent or (1-2C) alkylene; X 1 is absent or -O-, -C(O)-, -C(O)-O-, -OC(O)-, -S(O) 0~2 -, -C(O)-N(R14a )-, -N(R 14a )-C(O)-, -NR 14a -, -N(R 14a )-C(O)-NR 14a -, -SO2N(R 14a )- or -N(R 14a )SO2-, and R 14a is hydrogen or (1-2C) alkyl; Q 1 is selected from the group consisting of hydrogen, (1-4C) alkyl, (2-4C) alkenyl, (2-4C) alkynyl, or (3-6C) cycloalkyl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

[0076] Particular compounds of the present invention include, for example, compounds of formula (I) or formula (II), or pharmaceutically acceptable salts, hydrates and / or solvates thereof, unless otherwise specified, wherein R 2 , R 4 (and R 5a and R 5b ), R 6 (and R 7 ,n,R 8 , m, and R 9 ), R 11 (and R 11B , R 11C and R 11d ), R 11A , Y1, Y2, A2 (and R 12 ), A3 (and R 13 ), A4 (and R 14 ) and R a Each of these, as well as any associated substituents, has one of the meanings defined above or in any of the following paragraphs (1) to (102): (1)R 2 is fluoro. (2)R 2 is hydrogen. (3)R 4is selected from the group consisting of hydrogen, halogen, (1-4C)alkyl, (1-4C)haloalkyl, (3-6C)cycloalkyl, and (3-6C)cycloalkyl(1-2C)alkyl, wherein said (1-4C)alkyl is selected from the group consisting of one or more R 5a and the (3-6C)cycloalkyl and (3-6C)cycloalkyl(1-2C)alkyl groups are optionally substituted by one or more R 5b optionally substituted with R 5a and R 5b are as defined above, or R 5a is as defined in paragraphs (14), (15) or (16) below, and / or R 5b is as defined in paragraph (17), (18), (19) or (20) below. (4)R 4 is selected from the group consisting of hydrogen, halogen, (1-4C)alkyl, (1-4C)haloalkyl, (3-5C)cycloalkyl, and (3-5C)cycloalkyl(1-2C)alkyl, wherein said (1-4C)alkyl is selected from the group consisting of one, two, or three R 5a and the (3-5C)cycloalkyl and (3-5C)cycloalkyl(1-2C)alkyl groups are optionally substituted with one, two or three R 5b optionally substituted by R 5a and R 5b are as defined above, or R 5a is as defined in paragraphs (14), (15) or (16) below, and / or R 5b is as defined in paragraph (17), (18), (19) or (20) below. (5)R 4 is selected from the group consisting of hydrogen, halogen, (1-4C)alkyl, (1-4C)haloalkyl, (3-5C)cycloalkyl, and (3-5C)cycloalkyl(1C)alkyl, wherein said (1-4C)alkyl is selected from the group consisting of one, two, or three R 5aand the (3-5C)cycloalkyl and (3-5C)cycloalkyl(1C)alkyl groups are optionally substituted with one, two or three R 5b optionally substituted by R 5a and R 5b are as defined above, or R 5a is as defined in paragraphs (14), (15) or (16) below, and / or R 5b is as defined in paragraph (17), (18), (19) or (20) below. (6)R 4 is selected from the group consisting of hydrogen, halogen, (1-4C) alkyl, (1-2C) haloalkyl, and (3-5C) cycloalkyl, wherein said (1-4C) alkyl is selected from the group consisting of one or two R 5a and the (3-5C)cycloalkyl group is optionally substituted with one or two R 5b optionally substituted by R 5a and R 5b are as defined above, or R 5a is as defined in paragraphs (14), (15) or (16) below, and / or R 5b is as defined in paragraph (17), (18), (19) or (20) below. (7)R 4 is selected from the group consisting of hydrogen, fluoro, chloro, (1-4C)alkyl, CHF, CHF, CF, cyclopropyl, and cyclobutyl, and said (1-4C)alkyl is selected from the group consisting of one R 5a and the cyclopropyl and cyclobutyl groups are optionally substituted by one R 5b optionally substituted by R 5a and R 5b are as defined above, or R 5a is as defined in paragraphs (14), (15) or (16) below, and / or R 5bis as defined in paragraph (17), (18), (19) or (20) below. (8)R 4 is selected from the group consisting of hydrogen, fluoro, chloro, methyl, ethyl, isopropyl, CH2F, CHF2, CF3, cyclopropyl, and cyclobutyl. (9)R 4 is selected from the group consisting of hydrogen, methyl, ethyl, CHF2, CF3, isopropyl, cyclopropyl, and cyclobutyl. (10)R 4 is selected from the group consisting of hydrogen, methyl, ethyl, CHF2, CF3, and cyclopropyl. (11)R 4 is selected from the group consisting of hydrogen and methyl. (12)R 4 is hydrogen. (13)R 4 is methyl. (14)Each R 5a are independently selected from halogen or (1-3C)alkoxy. (15)Each R 5a is independently selected from fluoro, chloro or (1-2C)alkoxy. (16)Each R 5a is independently selected from fluoro, chloro or methoxy. (17)Each R 5b are independently selected from the group consisting of halogen, (1-3C)alkyl and (1-3C)alkoxy. (18)Each R 5b are independently selected from the group consisting of halogen, (1-2C) alkyl and (1-2C) alkoxy. (19)Each R 5b is independently selected from the group consisting of fluoro, chloro, (1-2C)alkyl and (1-2C)alkoxy. (20) Each R 5b is independently selected from the group consisting of fluoro, chloro, methyl and methoxy. (21)R 6is a (1-6C)alkyl, (3-6C)cycloalkyl, or 4- to 6-membered heterocyclyl ring containing one heteroatom selected from N, O, or S; or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined above, or n is as defined in paragraphs (31) or (32) below, and R 7 is as defined in paragraphs (27), (28), (29) or (30) below, and R 8 is as defined in paragraphs (33), (34), (35), (36), (37), (38), (39), (40), (41), (42), (43), (44), or (107) below. (22)R 6 is a (1-4C)alkyl, (3-6C)cycloalkyl, or 4- to 6-membered heterocyclyl ring containing one heteroatom selected from N, O, or S; or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined herein, or n is as defined in paragraphs (31) or (32) below, and R 7 is as defined in paragraphs (27), (28), (29) or (30) below, and R 8 is as defined in paragraphs (33), (34), (35), (36), (37), (38), (39), (40), (41), (42), (43), (44), or (107) below. (23)R 6is a (1-4C)alkyl, (3-6C)cycloalkyl, or 4- to 6-membered heterocyclyl ring containing one heteroatom selected from O or S; or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined herein, or n is as defined in paragraphs (31) or (32) below, and R 7 is as defined in paragraphs (27), (28), (29) or (30) below, and R 8 is as defined in paragraphs (33), (34), (35), (36), (37), (38), (39), (40), (41), (42), (43), (44), or (107) below. (24)R 6 is a 5- or 6-membered heterocyclyl ring containing one heteroatom selected from (1-4C)alkyl or O or S; or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined herein, or n is as defined in paragraphs (31) or (32) below, and R 7 is as defined in paragraphs (27), (28), (29) or (30) below, and R 8 is as defined in paragraphs (33), (34), (35), (36), (37), (38), (39), (40), (41), (42), (43), (44), or (107) below. (25)R 6 is (1-3C) alkyl, tetrahydrofuran, tetrahydropyran, or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined herein, or n is as defined in paragraphs (31) or (32) below, and R 7 is as defined in paragraphs (27), (28), (29) or (30) below, and R 8 is as defined in paragraphs (33), (34), (35), (36), (37), (38), (39), (40), (41), (42), (43), (44) or (107) below. (26)R 6 is a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined herein, or n is as defined in paragraphs (31) or (32) below, and R 7 is as defined in paragraphs (27), (28), (29) or (30) below, and R 8 is as defined in paragraphs (33), (34), (35), (36), (37), (38), (39), (40), (41), (42), (43), (44), or (107) below. (27)R 7 is hydrogen or (1-2C) alkyl. (28)R 7 is hydrogen or methyl. (29)R 7 is hydrogen. (30)R 7 is methyl. (31)n is 1. (32)n is 2. (33)R 8is (3-8C)cycloalkyl, aryl, 4- to 6-membered heterocyclyl, or 5- or 6-membered heteroaryl, each of which is optionally joined by one or more R 9 optionally substituted with R 9 is as defined herein. (34)R 8 is (3-8C)cycloalkyl, phenyl, 4- to 6-membered heterocyclyl, or 5- or 6-membered heteroaryl, each of which is optionally joined by one or more R 9 optionally substituted with R 9 is as defined herein. (35)R 8 is (3-6C)cycloalkyl, phenyl, 4- to 6-membered heterocyclyl, or 5- or 6-membered heteroaryl, each of which is optionally joined by one or more R 9 optionally substituted with R 9 is as defined herein. (36)R 8 is a 5- or 6-membered cycloalkyl, phenyl, 5- or 6-membered heterocyclyl, or 6-membered heteroaryl, each of which is optionally joined by one or more R 9 optionally substituted with R 9 is as defined herein. (37)R 8 is cyclohexyl, phenyl, 5- or 6-membered heterocyclyl, or 6-membered heteroaryl, each of which is optionally substituted by one or more R 9 optionally substituted with R 9 is as defined herein. (38)R 8 is cyclohexyl, phenyl, tetrahydrofuran, tetrahydropyran, or pyridyl, each of which is selected from the group consisting of one or more R 9 optionally substituted with R 9 is as defined herein. (39)R 8is cyclohexyl, phenyl, or pyridyl, each of which is represented by one or more R 9 optionally substituted with R 9 is as defined herein. (40)R 8 has the following structure: [ka] [In the formula, R 9 is as defined above (or as in any one of paragraphs (48), (49), (50) or (51) below), and each m independently has any one of 0, 1, 2 or 3 (or as defined in paragraphs (45), (46) or (47) below). (41)R 8 has the following structure: [ka] [In the formula, R 9 is as defined above or as in any one of paragraphs (48), (49), (50) or (51) below. (42)R 8 has the following structure: [ka] It has any one of the following. (43)R 8 is cyclohexyl. (44)R 8 is phenyl. (45) Each m is independently 0, 1, or 2. (46) Each m is independently 0 or 1. (47) Each m is 0. (48)Each R 9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy. (49)Each R 9 is independently selected from the group consisting of halogen, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy. (50)Each R 9 is independently selected from the group consisting of halogen, methyl, methoxy, trifluoromethyl, or trifluoromethoxy. (51)Each R 9 is independently selected from the group consisting of fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy. (52) Y1 is -CH2-, -C(=O)-, or -CHR y2a - and R y2a is selected from halo, methyl, methoxy, CF3, -OCF3 or hydroxymethyl. (53) Y1 is —CH2—. (54) Y2 is -CH2-, -C(=O)-, -CHR y2a -, -CH2-CH2-, -CH2-CHR y2b -, or -CHR y2a -CH2-; R y2a is selected from halo, methyl, methoxy, CF3, -OCF3 or hydroxymethyl; R y2b is selected from halo, cyano, hydroxy, methyl, methoxy, CF3, -OCF3 or hydroxymethyl. (55) Y2 is -CH2-, -CHR y2a -, -CH2-CH2-, -CH2-CHR y2b -, or -CHR y2a -CH2-; R y2a is selected from halo, methyl, or hydroxymethyl; R y2b is selected from halo, cyano, hydroxy, methyl, methoxy, CF3, -OCF3 or hydroxymethyl. (56) Y2 is -CH2- or -CH2-CH2-. (57) Y2 is —CH2—. (58) Y1 is —CH2— and Y2 is —CH2—. (59)R 11A is hydrogen, methyl or ethyl. (60)R 11A is hydrogen or methyl. (61)R 11A is hydrogen. (62)R 11 is a group of formula (A) or (B) shown below: [ka] [In the formula, R 11B , R 11C , R 11D or R 11E are each as defined herein, or: R 11B and R 11C is as defined in any one of paragraphs (65), (66), (67), (68), (69), (116), (117), (118), (119) or (120) below; R 11D is as defined in any one of paragraphs (70), (71), (72), (73), (121), (122), (123) or (124) below; R 11E is as defined in any one of paragraphs (74), (75), (76), (77), (78), (79) or (80) below; (63)R 11 is a group of formula (A) shown below: [ka] [In the formula, R 11B , R 11C or R 11D are each as defined herein, or R 11B and R 11C is as defined in any one of paragraphs (65), (66), (67), (68), (69), (116), (117), (118), (119) or (120) below; R 11D is as defined in any one of paragraphs (70), (71), (72), (73), (121), (122), (123) or (124) below; (64)R 11 is a group of formula (B) shown below: [ka] [In the formula, R 11E is as defined herein, or R 11E is as defined in any one of paragraphs (74), (75), (76), (77), (78), (79) or (80) below; (65)R 11B and R 11C are each independently selected from the group consisting of hydrogen, halo, and (1-4C)alkyl, and any (1-4C)alkyl group is optionally substituted with halo, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, or a 4-, 5-, or 6-membered N-linked heterocycle that is optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, or (1-4C)alkoxy. (66)R 11B and R 11C are each independently selected from the group consisting of hydrogen, halo, and (1-2C)alkyl, and any (1-2C)alkyl group is optionally substituted with halo, hydroxy, cyano, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino, (1-2C)alkoxy, or a 4-, 5-, or 6-membered N-linked heterocycle optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, or (1-4C)alkoxy. (67)R 11B and R 11Cis hydrogen and the other is selected from the group consisting of hydrogen, halo, (1-2C)alkyl, and any (1-2C)alkyl group is optionally substituted with halo, hydroxy, cyano, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino, (1-2C)alkoxy, or a 4-, 5-, or 6-membered N-linked heterocycle optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-2C)alkyl, or (1-2C)alkoxy. (68)R 11B and R 11C is hydrogen and the other is selected from the group consisting of hydrogen, fluoro, (1-2C)alkyl, and any (1-2C)alkyl group is optionally substituted with halo, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino, or a 4-, 5-, or 6-membered N-linked heterocycle optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, or (1-4C)alkoxy. (69)R 11B and R 11C is hydrogen and the other is selected from the group consisting of hydrogen, fluoro, (1-2C)alkyl, and any (1-2C)alkyl group is optionally substituted with chloro, fluoro, di-[(1-2C)alkyl]amino or a 5- or 6-membered N-linked heterocycle optionally further substituted with one or more substituents selected from chloro, fluoro, hydroxy, (1-2C)alkyl, or (1-2C)alkoxy. (70)R 11D is hydrogen, halo or (1-2C)alkyl. (71)R 11D is hydrogen, chloro, fluoro, methyl or ethyl. (72)R 11D is hydrogen, fluoro or methyl. (73)R 11D is hydrogen or fluoro. (74)R 11Eis selected from the group consisting of hydrogen, chloro, fluoro, (1-4C)alkyl, (4-6C)cycloalkyl, (4-6C)cycloalkyl-(1-2C)alkyl, where any (1-4C)alkyl, (4-6C)cycloalkyl, or (4-6C)cycloalkyl-(1-2C)alkyl group is optionally substituted with one or more substituents selected from chloro, fluoro, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, (4-6C)cycloalkoxy, phenyl, or 4- to 6-membered heterocyclyl; and any phenyl or 4- to 6-membered heterocyclic ring is optionally further substituted with one or more substituents selected from chloro, fluoro, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (4-6C)cycloalkyl, or (4-6C)cycloalkoxy. (75)R 11E is selected from the group consisting of hydrogen, (1-4C)alkyl, (5-6C)cycloalkyl, (5-6C)cycloalkyl-(1-2C)alkyl, where any (1-4C)alkyl, (5-6C)cycloalkyl, or (5-6C)cycloalkyl-(1-2C)alkyl group is optionally substituted with one or more substituents selected from chloro, fluoro, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, (4-6C)cycloalkoxy, phenyl, or 4- to 6-membered heterocyclyl; and any phenyl or 4- to 6-membered heterocyclic ring is optionally further substituted with one or more substituents selected from chloro, fluoro, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (4-6C)cycloalkyl, or (4-6C)cycloalkoxy. (76)R 11Eis selected from the group consisting of halogen, (1-4C)alkyl, where any (1-4C)alkyl group is optionally substituted with one or more substituents selected from chloro, fluoro, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, (4-6C)cycloalkoxy, phenyl, or 4- to 6-membered heterocyclyl; and any phenyl or 4- to 6-membered heterocyclic ring is optionally further substituted with one or more substituents selected from chloro, fluoro, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (4-6C)cycloalkyl, or (4-6C)cycloalkoxy. (77)R 11E is (1-4C)alkyl and is optionally substituted with halo, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy or a 4-, 5- or 6-membered N-linked heterocycle which is optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl or (1-4C)alkoxy. (78)R 11E is (1-4C) alkyl. (79)R 11E is methyl or ethyl. (80)R 11E is methyl. (81) A2 is N, CH or CR 12 Selected from; A3 is N, CH or CR 13 Selected from; A4 is N, CH or CR 14 Selected from; provided that only one of A2, A3 or A4 may be N; R 12 , R 13 or R 14 is as defined above, or R 12 is as defined in any one of paragraphs (89), (90), (91) or (92); R 13 is as defined in any one of paragraphs (93), (94) or (95); R 14 is as defined in any one of paragraphs (96), (97) or (98). (82) A2 is N, CH or CR 12 Selected from; A3 is N, CH or CR 13 Selected from; A4 is selected from N or CH; provided that only one of A2, A3 or A4 may be N; R 12 and R 13 is as defined above, or R 12 is as defined in any one of paragraphs (89), (90), (91) or (92); R 13 is as defined in any one of paragraphs (93), (94) or (95). (83) A2 is selected from N or CH; A3 is N, CH or CR 13 Selected from; A4 is selected from N or CH; provided that only one of A2, A3 or A4 may be N; R 13 is as defined above, or R 13 is as defined in any one of paragraphs (93), (94) or (95). (84) A2 is CH; A3 is CH or CR 13 and; A4 is CH; R 13 is as defined above, or R 13 is as defined in any one of paragraphs (93), (94) or (95). (85) A2 is CH; A3 is CH; A4 is CH; (86) A2 is CH or CR 12 and; A3 is CH; A4 is CH; R 12 is as defined above, or R 12 is as defined in any one of paragraphs (89), (90), (91) or (92); (87) A2 is CH; A3 is CH; A4 is CH or CR 14 and; R 14 is as defined above, or R 14 is as defined in any one of paragraphs (96), (97) or (98). (88) A2, A3, and A4 are all CH. (89)R 12 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted with one or more halo or (1-2C)alkoxy; or R 12 is -(CHR p ) f -Z 12 [In the formula, R p is hydrogen or methyl; f is 0 or 1; Z 12 -OR 20 , -NR 21 R 22 , -C(O)NR 21 R 22 or -NR 23 C(O)R 24 and; R 20is (1-3C) alkyl, (4-6C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR q ) e -(4-6C)cycloalkyl, -(CHR q ) e -phenyl, -(CHR q ) e -[4- to 6-membered heterocyclyl] or -(CHR q ) e -[5- or 6-membered heteroaryl], and R q is hydrogen or methyl, and e is 0 or 1; R 21 and R 22 is hydrogen, (1-4C) alkyl, (2-4C) alkanoyl, (4-6C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR r ) d -(3-7C)cycloalkyl, -(CHR r ) d -phenyl, -(CHR r ) d -[4- to 6-membered heterocyclyl] or -(CHR r ) d -[5- or 6-membered heteroaryl]; R r is hydrogen or methyl, and d is 0 or 1; or R 21 and R 22 are linked together with the nitrogen atom to which they are attached so that they form a 4- to 6-membered heterocyclic ring; R 23 is hydrogen or (1-2C) alkyl; R 24 is (1-4C) alkyl, (2-4C) alkynyl, (4-6C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR s ) c -(4-6C)cycloalkyl, -(CHR s ) c-phenyl, -(CHR s ) c -[4- to 6-membered heterocyclyl] or -(CHR s ) c -[5- or 6-membered heteroaryl], and R s is hydrogen or methyl, and c is 0 or 1; R 20 , R 21 , R 22 , R 23 Or R 24 or R 21 and R 22 Any ring formed when R are linked may each contain one or more R a ]. (90)R 12 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted with one or more halo or (1-2C)alkoxy; or R 12 is -(CHR p ) f -Z 12 [In the formula, R p is hydrogen or methyl; f is 0 or 1; Z 12 -OR 20 , -NR 21 R 22 , -C(O)NR 21 R 22 or -NR 23 C(O)R 24 and; R 20 is (1-2C) alkyl, (5-6C) cycloalkyl, phenyl, carbon-bonded 5- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR q ) e -(5-6C)cycloalkyl, -(CHR q ) e -phenyl, -(CHR q ) e-[5- to 6-membered heterocyclyl] or -(CHR q ) e -[5- or 6-membered heteroaryl], and R q is hydrogen or methyl, and e is 0 or 1; R 21 and R 22 is hydrogen, (1-2C) alkyl, (2-3C) alkanoyl, (5-6C) cycloalkyl, phenyl, carbon-bonded 5- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR r ) d -(5-6C)cycloalkyl, -(CHR r ) d -phenyl, -(CHR r ) d -[5- to 6-membered heterocyclyl] or -(CHR r ) d -[5- or 6-membered heteroaryl]; R r is hydrogen or methyl, and d is 0 or 1; or R 21 and R 22 are linked together with the nitrogen atom to which they are attached so that they form a 5- to 6-membered heterocyclic ring; R 23 is hydrogen or (1-2C) alkyl; R 24 is (1-2C) alkyl, (2-3C) alkynyl, (5-6C) cycloalkyl, phenyl, carbon-bonded 5- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR s ) c -(5-6C)cycloalkyl, -(CHR s ) c -phenyl, -(CHR s ) c -[5- to 6-membered heterocyclyl] or -(CHR s ) c -[5- or 6-membered heteroaryl], and R s is hydrogen or methyl, and c is 0 or 1; R 20 , R21 , R 22 , R 23 Or R 24 or R 21 and R 22 Any ring formed when R are linked may each contain one or more R a ]. (91)R 12 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more fluoro or (1-2C)alkoxy. (92)R 12 is selected from fluoro, (1-2C) alkyl, (1-2C) alkoxy. (93)R 13 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted with one or more halo or (1-2C)alkoxy; or R 13 is -(CHR o ) h -Z 13 [In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 13 -OR 25 , -NR 26 R 27 , -C(O)NR 26 R 27 or -NR 28 C(O)R 29 and; R 25 is (1-3C) alkyl, (4-6C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR n ) i -(4-6C)cycloalkyl, -(CHR n ) i -phenyl, -(CHR n )i -[4- to 6-membered heterocyclyl] or -(CHR n ) i -[5- or 6-membered heteroaryl], and R n is hydrogen or methyl, and i is 0 or 1; R 26 and R 27 is hydrogen, (1-4C) alkyl, (2-4C) alkanoyl, (4-6C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR m ) j -(4-6C)cycloalkyl, -(CHR m ) j -phenyl, -(CHR m ) j -[4- to 6-membered heterocyclyl] or -(CHR m ) j -[5- or 6-membered heteroaryl]; R m is hydrogen or methyl, and j is 0 or 1; or R 26 and R 27 are linked together with the nitrogen atom to which they are attached so that they form a 4- to 6-membered heterocyclic ring; R 28 is hydrogen or (1-2C) alkyl; R 29 is (1-4C) alkyl, (2-4C) alkynyl, (4-6C) cycloalkyl, phenyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR l ) k -(4-6C)cycloalkyl, -(CHR l ) k -phenyl, -(CHR l ) k -[4- to 6-membered heterocyclyl] or -(CHR l ) k -[5- or 6-membered heteroaryl], and R l is hydrogen or methyl, and k is 0 or 1; R25 , R 26 , R 27 , R 28 Or R 29 or R 26 and R 27 Any ring formed when R are linked may each contain one or more R a ]. (94)R 13 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted with one or more halo or (1-2C)alkoxy; or R 13 is -(CHR o ) h -Z 13 [In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 13 -OR 25 , -NR 26 R 27 , -C(O)NR 26 R 27 or -NR 28 C(O)R 29 and; R 25 is (1-2C) alkyl, (5-6C) cycloalkyl, phenyl, carbon-bonded 5- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR n ) i -(5-6C)cycloalkyl, -(CHR n ) i -phenyl, -(CHR n ) i -[5- to 6-membered heterocyclyl] or -(CHR n ) i -[5- or 6-membered heteroaryl], and R n is hydrogen or methyl, and i is 0 or 1; R 26 and R 27is hydrogen, (1-2C) alkyl, (2-3C) alkanoyl, (5-6C) cycloalkyl, phenyl, carbon-bonded 5- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR m ) j -(5-6C)cycloalkyl, -(CHR m ) j -phenyl, -(CHR m ) j -[5- to 6-membered heterocyclyl] or -(CHR m ) j -[5- or 6-membered heteroaryl]; R m is hydrogen or methyl, and j is 0 or 1; or R 26 and R 27 are linked together with the nitrogen atom to which they are attached so that they form a 5- to 6-membered heterocyclic ring; R 28 is hydrogen or (1-2C) alkyl; R 29 is (1-2C) alkyl, (2-3C) alkynyl, (5-6C) cycloalkyl, phenyl, carbon-bonded 5- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR l ) k -(5-6C)cycloalkyl, -(CHR l ) k -phenyl, -(CHR l ) k -[5- to 6-membered heterocyclyl] or -(CHR l ) k -[5- or 6-membered heteroaryl], and R l is hydrogen or methyl, and k is 0 or 1; R 25 , R 26 , R 27 , R 28 Or R 29 or R 26 and R 27 Any ring formed when R are linked may each contain one or more R a ]. (95)R 13 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted with one or more halo or (1-2C)alkoxy; or R 13 is -(CHR o ) h -Z 13 [In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 12 -OR 25 , -NR 26 R 27 , or -C(O)NR 26 R 27 and; R 25 is (1-4C) alkyl, carbon-linked 4- to 8-membered heterocyclyl, or -(CHR n ) i -[4- to 8-membered heterocyclyl], and R n is hydrogen or methyl, and i is 0 or 1; R 26 and R 27 is hydrogen, (1-6C) alkyl, carbon-linked 4- to 8-membered heterocyclyl, or -(CHR m ) j -[4- to 8-membered heterocyclyl]; R m is hydrogen or methyl, and j is 0 or 1; ; or R26 and R27, together with the nitrogen atom to which they are attached, are linked such that they form a 4- to 8-membered heterocyclic ring; R 25 , R 26 , R 27 or R 26 and R 27 Any ring formed when R are linked may each contain one or more R a ]. (96)R14 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted with one or more halo or (1-2C)alkoxy; or R 14 is -(CHR k ) m -Z 14 [In the formula, R k is hydrogen or methyl; m is 0 or 1; Z 12 -OR 30 , -NR 31 R 32 , -C(O)NR 31 R 32 or -NR 33 C(O)R 34 and; R 30 is (1-3C) alkyl, (4-6C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR j ) o -(4-6C)cycloalkyl, -(CHR j ) o -[4- to 6-membered heterocyclyl] or -(CHR j ) o -[5- or 6-membered heteroaryl], and R j is hydrogen or methyl, and o is 0 or 1; R 31 and R 32 is hydrogen, (1-4C) alkyl, (2-4C) alkanoyl, (4-6C) cycloalkyl, carbon-bonded 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR i ) p -(4-6C)cycloalkyl, -(CHR i ) p -[4- to 6-membered heterocyclyl] or -(CHR i ) p -[5- or 6-membered heteroaryl]; Ri is hydrogen or methyl, and p is 0 or 1. or R 31 and R 32 are linked together with the nitrogen atom to which they are attached so that they form a 4- to 6-membered heterocyclic ring; R 33 is hydrogen or (1-2C) alkyl; R 34 is (1-4C) alkyl, (2-4C) alkynyl, (4-6C) cycloalkyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR h ) q -(4-6C)cycloalkyl, -(CHR h ) q -[4- to 6-membered heterocyclyl] or -(CHR h ) q -[5- or 6-membered heteroaryl], and R h is hydrogen or methyl, and q is 0 or 1; R 30 , R 31 , R 32 , R 33 Or R 34 , or R 31 and R 32 Any ring formed when R are linked may be formed by one or more R a ]. (97)R 14 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted with one or more halo or (1-2C)alkoxy; or R 14 is -(CHR k ) m -Z 14 [In the formula, R k is hydrogen or methyl; m is 0 or 1; Z 12 -OR 30 , -NR31 R 32 , -C(O)NR 31 R 32 or -NR 33 C(O)R 34 and; R 30 is (1-2C) alkyl, (5-6C) cycloalkyl, carbon-bonded 5- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR j ) o -(5-6C)cycloalkyl, -(CHR j ) o -[5- to 6-membered heterocyclyl] or -(CHR j ) o -[5- or 6-membered heteroaryl], and R j is hydrogen or methyl, and o is 0 or 1; R 31 and R 32 is hydrogen, (1-2C) alkyl, (2-3C) alkanoyl, (5-6C) cycloalkyl, carbon-bonded 5- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR i ) p -(5-6C)cycloalkyl, -(CHR i ) p -[5- to 6-membered heterocyclyl] or -(CHR i ) p -[5- or 6-membered heteroaryl]; R i is hydrogen or methyl, and p is 0 or 1. or R 31 and R 32 are linked together with the nitrogen atom to which they are attached so that they form a 5- to 6-membered heterocyclic ring; R 33 is hydrogen or (1-2C) alkyl; R 34 is (1-2C) alkyl, (2-3C) alkynyl, (5-6C) cycloalkyl, carbon-bonded 5- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR h ) q-(5-6C)cycloalkyl, -(CHR h ) q -[5- to 6-membered heterocyclyl] or -(CHR h ) q -[5- or 6-membered heteroaryl], and R h is hydrogen or methyl, and q is 0 or 1; R 30 , R 31 , R 32 , R 33 Or R 34 , or R 31 and R 32 Any ring formed when R are linked may be formed by one or more R a ]. (98)R 14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy; or R 14 is -(CHR k ) m -Z 14 [In the formula, R k is hydrogen; m is 0 or 1; Z 12 -OR 30 , -NR 31 R 32 , -C(O)NR 31 R 32 or -NR 33 C(O)R 34 and; R 30 is (1-4C) alkyl, (3-7C) cycloalkyl, carbon-bonded 4- to 8-membered heterocyclyl, -(CHR j ) o -(3-7C)cycloalkyl, or -(CHR j ) o -[4- to 8-membered heterocyclyl], and R jis hydrogen or methyl, and o is 0 or 1; R 31 and R 32 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, carbon-bonded 4- to 8-membered heterocyclyl, -(CHR i ) p -(3-7C)cycloalkyl, or -(CHR i ) p -[4- to 8-membered heterocyclyl]; R i is hydrogen or methyl, and p is 0 or 1. or R 31 and R 32 are linked together with the nitrogen atom to which they are attached so that they form a 4- to 8-membered heterocyclic ring; R 33 is hydrogen or methyl; R 34 is (1-6C) alkyl, (3-7C) cycloalkyl, carbon-bonded 4- to 8-membered heterocyclyl, -(CHR h ) q -(3-7C)cycloalkyl, or -(CHR h ) q -[4- to 8-membered heterocyclyl], and R h is hydrogen or methyl, and q is 0 or 1; R 30 , R 31 , R 32 Or R 34 , or R 31 and R 32 Any ring formed when R are linked may be formed by one or more R a ]. (99)Each R a is oxo, halogen, cyano, hydroxy, (1-4C) alkyl, or -L 1 -X 1 -Q 1 base are independently selected from the group consisting of L 1is absent or (1-2C) alkylene; X 1 is absent or -O-, -C(O)-, -C(O)-O-, -OC(O)-, -S(O) 0~2 -, -C(O)-N(R 14a )-, -N(R 14a )-C(O)-, -NR 14a -, -SO2N(R 14a )- or -N(R 14a )SO2-, and R 14a is hydrogen or (1-2C) alkyl; Q 1 is selected from the group consisting of hydrogen, (1-4C) alkyl, or (3-6C) cycloalkyl. (100) each R a is oxo, halogen, cyano, hydroxy, (1-2C) alkyl, or -L 1 -X 1 -Q 1 base are independently selected from the group consisting of L 1 is absent or (1-2C) alkylene; X 1 is absent or -O-, -C(O)-, -C(O)-O-, -OC(O)-, -S(O) 0~2 -, -C(O)-N(R 14a )-, -N(R 14a )-C(O)-, -NR 14a -, -SO2N(R 14a )- or -N(R 14a )SO2-, and R 14a is hydrogen or (1-2C) alkyl; Q 1 is selected from the group consisting of hydrogen, (1-2C) alkyl, or (3-6C) cycloalkyl. (101) Each R a is oxo, halogen, cyano, hydroxy, (1-2C) alkyl, or -L 1 -X 1 -Q1 base are independently selected from the group consisting of L 1 is absent or (1-2C) alkylene; X 1 is absent or -O-, -C(O)-, -C(O)-O-, -OC(O)-, -S(O) 0~2 -, -C(O)-N(R 14a )-, -N(R 14a )-C(O) or -NR 14a -, and R 14a is hydrogen or (1-2C) alkyl; Q 1 is selected from the group consisting of hydrogen or (1-2C) alkyl. (102)Each R a is oxo, halogen, cyano, hydroxy, (1-2C) alkyl, or -L 1 -X 1 -Q 1 base are independently selected from the group consisting of L 1 does not exist; X 1 is absent, or -O-, -C(O)-, -S(O) 0~2 -, -C(O)-N(R 14a )-, -N(R 14a )-C(O) or -NR 14a -, and R 14a is hydrogen or (1-2C) alkyl; Q 1 is selected from the group consisting of hydrogen or (1-2C) alkyl.

[0077] Specific compounds according to the invention also include, for example, compounds of formula (II), or pharmaceutically acceptable salts, hydrates and / or solvates thereof, unless otherwise indicated, wherein R 2 , R 4 (and R 5a and R 5b ), R 6 (and R7 ,n,R 8 , m, and R 9 ), R 11 (and R 11B , R 11C and R 11d ), R 11A , Y1, Y2, A2 (and R 12 ), A3 (and R 13 ), A4 (and R14) and R a Each of these, as well as any associated substituents, has any of the meanings defined above, particularly in any of paragraphs (1) to (102) above.

[0078] In particular, in compounds of formula (II): R 2 is as defined in paragraph (1) or (2) above; R 4 is as defined in any one of paragraphs (3) to (13) above; R 5a is as defined in any one of paragraphs (14) to (16) above; R sb is as defined in any one of paragraphs (17) to (20) above; R 6 is as defined in any one of paragraphs (21) to (26) above; R 7 is as defined in any one of paragraphs (27) to (30) above; n is as defined in any one of paragraphs (31) to (33) above; R 8 is as defined in any one of paragraphs (34) to (44) above; m is as defined in any one of paragraphs (45) to (47) above; R 9 is as defined in any one of paragraphs (48) to (51) above; Y1 is as defined in paragraphs (52), (53) or (57) above; Y2 is as defined in paragraphs (54), (55), (56) or (57) above; R 11 is as defined in any one of paragraphs (62) to (64) above; R 11B and R 11C is as defined in any one of paragraphs (65) to (69) above; R 11D is as defined in any one of paragraphs (70) to (73) above; R 11E is as defined in any one of paragraphs (74) to (80) above; A2, A3 and A4 are as defined in any one of paragraphs (81) to (88) above; R 12 is as defined in any one of paragraphs (89) to (92) above; R 13 is as defined in any one of paragraphs (93) to (95) above; R 14 is as defined in any one of paragraphs (96) to (98) above; R a is as defined in any one of paragraphs (99) to (102) above.

[0079] Furthermore, in the compound of formula (II), R 6 , R 8 , A1, A2, A3A4, R 10 The group, and any associated substituents, may be as defined above or as defined in any one of paragraphs (103) to (124) below: (103)R 6is a (1-4C) alkyl, (1-4C) haloalkyl, (3-6C) cycloalkyl, or a 4- to 7-membered heterocyclyl ring containing one heteroatom selected from N, O, or S, or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined above, in particular n is as defined in paragraph (31) or (32) above, and R 7 is as defined in paragraph (27), (28), (29) or (30) above, and R 8 is as defined in paragraphs (33), (34), (35), (36), (37), (38), (39), (40), (41), (42), (43) or (44) above, or in paragraph (107) below. (104)R 6 is a 5- or 6-membered heterocyclyl ring containing one heteroatom selected from (1-4C)alkyl, (1-4C)haloalkyl, or O or S; or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined above, in particular n is as defined in paragraph (31) or (32) above, and R 7 is as defined in paragraph (27), (28), (29) or (30) above, and R 8 is as defined in paragraphs (33), (34), (35), (36), (37), (38), (39), (40), (41), (42), (43) or (44) above, or in paragraph (107) below. (105)R 6is a (1-3C) alkyl, (1-3C) haloalkyl, tetrahydrofuran, tetrahydropyran or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined above, in particular n is as defined in paragraph (31) or (32) above, and R 7 is as defined in paragraph (27), (28), (29) or (30) above, and R 8 is as defined in paragraphs (33), (34), (35), (36), (37), (38), (39), (40), (41), (42), (43) or (44) above, or in paragraph (107) below. (106)R 6 is methyl, ethyl, trifluoromethyl, trifluoroethyl or a group having a structure according to formula (A) shown below: [ka] [where n, R 7 and R 8 are each as defined above, in particular n is as defined in paragraph (31) or (32) above, and R 7 is as defined in paragraph (27), (28), (29) or (30) above, and R 8 is as defined in paragraphs (33), (34), (35), (36), (37), (38), (39), (40), (41), (42), (43) or (44) above, or in paragraph (107) below. (107)R 8 has the following structure: [ka] [In the formula, R 9 is as defined above, and in particular, R 9is as defined in paragraphs (48), (49), (50) or (51) above. (108) A1 is N, CH or CR 10 Selected from; A2 is N, CH or CR 10 Selected from; A3 is selected from N or CH; A4 is N, CH or CR 14 Selected from; however, Only one or two of A1, A2, A3 or A4 may be N; Only one of A1 and A2 is CR 10 It can be; R 10 is as defined above, and in particular, R 10 is as defined in paragraph (114) or (115) below; R 14 is as defined above, and in particular, R 14 is as defined in paragraph (96), (97), or (98) above; (109) A1 is N, CH or CR 10 Selected from; A2 is N, CH or CR 10 Selected from; A3 is N, CH or CR 13 Selected from; A4 is selected from N or CH; however, Only one or two of A1, A2, A3 or A4 may be N; Only one of A1 and A2 is CR 10 It can be; R 10 is as defined above, and in particular, R 10 is as defined in paragraph (114) or (115) below; R 13 is as defined above, and in particular, R 13is as defined in paragraph (93), (94) or (95) above; (110) A1 is N, CH or CR 10 Selected from; A2 is N, CH or CR 10 Selected from; A3 is selected from N or CH; A4 is selected from N or CH; however, Only one or two of A1, A2, A3 or A4 may be N; Only one of A1 and A2 is CR 10 It can be; R 10 is as defined above, and in particular, R 10 is as defined in paragraph (114) or (115) below; (111)A1 is CH or CR 10 Selected from; A2 is CH or CR 10 Selected from; A3 is CH; A4 is CH; however, Only one of A1 and A2 is CR 10 It can be; R 10 is as defined above, and in particular, R 10 is as defined in paragraph (114) or (115) below; (112) A1 is CR 10 and; A2 is CH; A3 is CH; A4 is CH; R 10 is as defined above, and in particular, R 10 is as defined in paragraph (114) or (115) below; (113) A1 is CH; A2 is CR 10 and; A3 is CH; A4 is CH; R 10 is as defined above, and in particular, R 10 is as defined in paragraph (114) or (115) below; (114)R 10 is a group of formula (IIA) or (IIB) shown below: [ka] [In the formula, [ka] represents the attachment point with A1 or A2, and R 11 and R 11A is as defined above (for example, in paragraphs (59) to (64) above). (115)R 10 is the group shown below: [ka] [In the formula, [ka] represents the attachment point with A1 or A2, and R 11 is as defined above (e.g., in paragraphs (62) to (64) above). (116)R 11B and R 11C is hydrogen, halo, (1-4C) alkyl, and -C(O)NR 11F R 11G R 11F and R 11G are each independently selected from hydrogen or (1-4C)alkyl; R 11B and / or R 11CAny (1-4C)alkyl group present in the group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, or a 4-, 5-, or 6-membered N-linked heterocycle optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, or (1-4C)alkoxy; (117)R 11B and R 11C is hydrogen, halo, (1-2C) alkyl, and -C(O)NR 11F R 11G R 11F and R 11G are each independently selected from hydrogen or (1-2C)alkyl; R 11B and / or R 11C Any (1-2C)alkyl group present in the group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino, (1-2C)alkoxy, or a 4-, 5-, or 6-membered N-linked heterocycle optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, or (1-4C)alkoxy; (118)R 11B and R 11C is hydrogen and the other is hydrogen, halo, (1-2C) alkyl, and —C(O)NR 11F R 11G and R 11F and R 11G are each independently selected from hydrogen or (1-2C)alkyl; R 11B and / or R 11CAny (1-2C)alkyl group present in the group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino, (1-2C)alkoxy, or a 4-, 5-, or 6-membered N-linked heterocycle optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-2C)alkyl, or (1-2C)alkoxy; (119)R 11B and R 11C is hydrogen and the other is hydrogen, fluoro, (1-2C) alkyl and —C(O)NR 11F R 11G and R 11F and R 11G are each independently selected from hydrogen or (1-2C)alkyl; R 11B and / or R 11C Any (1-2C)alkyl group present in the group is optionally substituted with one or more substituents selected from halo, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino, (1-2C)alkoxy or a 4-, 5- or 6-membered N-linked heterocycle optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, or (1-4C)alkoxy; (120)R 11B and R 11C is hydrogen and the other is hydrogen, fluoro, (1-2C) alkyl and —C(O)NR 11F R 11G and R 11F and R 11G are each independently selected from hydrogen or (1-2C)alkyl; R 11B and / or R 11CAny (1-2C)alkyl group present in the group is optionally substituted with one or more substituents selected from chloro, fluoro, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino, (1-2C)alkoxy or a 5- or 6-membered N-linked heterocycle optionally further substituted with one or more substituents selected from chloro, fluoro, hydroxy, cyano, (1-2C)alkyl, or (1-2C)alkoxy; (121)R 11D is selected from hydrogen, halo, (1-2C)alkyl and —C(O)H, wherein any (1-2C)alkyl or —C(O)H group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino, (1-2C)alkoxy, (4-6C)cycloalkoxy, phenyl, or 4- to 6-membered heterocyclyl; any phenyl or 4- to 6-membered heterocyclic ring is optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-2C)alkyl, (1-2C)alkoxy, (4-6C)cycloalkyl, (4-6C)cycloalkoxy, or (1-2C)alkyl; (122)R 11D is selected from hydrogen, halo, (1-2C)alkyl and —C(O)H, wherein any (1-2C)alkyl or —C(O)H group is optionally substituted with one or more substituents selected from halo, hydroxy, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino or 4- to 6-membered heterocyclyl; (123)R 11D is selected from hydrogen, chloro, fluoro, methyl and ethyl, and any methyl or ethyl is optionally substituted with one or more substituents selected from chloro, fluoro, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino or 5- or 6-membered heterocyclyl; (124)R 11Dis selected from hydrogen, fluoro, or methyl, and any methyl is optionally substituted with one or more substituents selected from -NMe2 or morpholine.

[0080] Appropriately, R 2 is as defined in numbered paragraph (1). Most appropriately, R 2 is as defined in numbered paragraph (2).

[0081] Appropriately, R 4 is as defined in any one of the numbered paragraphs (5) to (13). More appropriately, R 4 is as defined in any one of the numbered paragraphs (9) to (13). Most appropriately, R 4 is as defined in any one of the numbered paragraphs (11), (12) or (13).

[0082] Appropriately, R 5a is as defined in the numbered paragraph (15) or (16). Most suitably, R 5a is as defined in numbered paragraph (16).

[0083] Appropriately, R 5b is as defined in the numbered paragraph (19) or (20). Most suitably, R 5b is as defined in numbered paragraph (20).

[0084] Appropriately, R 6 is as defined in any one of numbered paragraphs (22) to (26) or (103) to (106). More appropriately, R 6 is as defined in any one of numbered paragraphs (24) to (26), or (104) to (106). Even more suitably, R 6is as defined in any one of numbered paragraphs (25), (26), (105) or (106). Most suitably, R 6 is as defined in the numbered paragraphs up to (26).

[0085] Appropriately, R 7 is as defined in any one of the numbered paragraphs (28) to (30). Most appropriately, R 7 is as defined in the numbered paragraph (29) or (30).

[0086] Suitably, n is as defined in numbered paragraph (31) or (32). Most suitably, n is as defined in numbered paragraph (31).

[0087] Appropriately, R 8 is as defined in any one of the numbered paragraphs (37) to (44) or (107). More appropriately, R 8 is as defined in any one of the numbered paragraphs (40) to (44) or (107). Most appropriately, R 8 is as defined in any one of the numbered paragraphs (42), (43), (44) or (107).

[0088] Suitably, m is as defined in numbered paragraph (46) or (47). Most suitably, m is as defined in numbered paragraph (47).

[0089] Appropriately, R 9 is as defined in the numbered paragraph (50) or (51). Most suitably, R 9 is as defined in numbered paragraph (51).

[0090] Suitably, Y1 is as defined in numbered paragraph (52) or (53). Most suitably, Y1 is as defined in numbered paragraph (53).

[0091] Suitably, Y2 is as defined in any one of numbered paragraphs (55) to (57). Most suitably, Y2 is as defined in numbered paragraphs (56) or (57).

[0092] Suitably, Y1 and Y2 are as defined in numbered paragraph (58).

[0093] Appropriately, R 11A is as defined in any one of the numbered paragraphs (60) or (61). Most appropriately, R 11A is as defined in the numbered paragraph (61).

[0094] Appropriately, R 11 is as defined in either one of the numbered paragraphs (63) or (64).

[0095] Appropriately, R 11B and R 11C is as defined in any one of the numbered paragraphs (66) to (69) or (116) to (120). More appropriately, R 11B and R 11C is as defined in any one of numbered paragraphs (67), (68) or (69), or (117) to (120). Even more suitably, R 11B and R 11C is as defined in any one of numbered paragraphs (68), (69), (118), (119) or (120). Most suitably, R 11B and R 11C is as defined in numbered paragraph (69).

[0096] Appropriately, R 11D is as defined in any one of the numbered paragraphs (71), (72) or (73), or (121) to (124). More appropriately, R 11D is as defined in any one of numbered paragraphs (72), (73), (122), (123) or (124). Most suitably, R 11D is as defined in numbered paragraph (73).

[0097] Appropriately, R 11E is as defined in any one of the numbered paragraphs (77) to (80). Most appropriately, R 11E is as defined in the numbered paragraph (79) or (80).

[0098] Suitably, A2, A3 and A4 are as defined in any one of numbered paragraphs (84) to (88). Most suitably, A2, A3 and A4 are as defined in numbered paragraph (88).

[0099] Suitably, A1, A2, A3 and A4 are as defined in any one of numbered paragraphs (108) to (113). More suitably, A1, A2, A3 and A4 are as defined in any one of numbered paragraphs (109) to (113). Even more suitably, A1, A2, A3 and A4 are as defined in any one of numbered paragraphs (109) to (113). Even more suitably, A1, A2, A3 and A4 are as defined in any one of numbered paragraphs (110) to (113). Most suitably, A2, A3 and A4 are as defined in any one of numbered paragraphs (111), (112) or (113).

[0100] Appropriately, R 12is as defined in any one of the numbered paragraphs (90), (91) and (92) above. Most appropriately, R 12 is as defined in numbered paragraph (92) above.

[0101] Appropriately, R 10 is as defined in any one of the numbered paragraphs (114) or (115) above. More appropriately, R 10 is as defined in the numbered paragraph (115) above.

[0102] Appropriately, R 13 is as defined in any one of the numbered paragraphs (94) or (95) above. Most suitably, R 13 is as defined in the numbered paragraph (95) above.

[0103] Appropriately, R 14 is as defined in any one of the numbered paragraphs (97) or (98) above. Most appropriately, R 14 is as defined in the numbered paragraph (98) above.

[0104] Appropriately, R a is as defined in any one of the numbered paragraphs (100), (101) or (102) above. Most suitably, R a is as defined in the numbered paragraph (102) above.

[0105] In one particular group of compounds according to the invention, the compound has formula II, I-II, I-III, I-IV, IV or I-VI (which are sub-definitions of formula I): [ka] JPEG2024543183000032.jpg255162JPEG2024543183000033.jpg89170[In the formula, R4 , R 6 , Y1, Y2, A2, A3, A4, R 11 , R 11A and any related subgroups are as defined in any one of the numbered paragraphs above.], or a pharmaceutically acceptable salt, hydrate and / or solvate thereof.

[0106] In one embodiment of the compound of Formula II, I-II, I-III, I-IV, IV or I-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of numbered paragraphs (22) to (26) or (103) to (106); Y 1 is as defined in numbered paragraph (52) or (53); Y 2 is as defined in any one of the numbered paragraphs (55) to (57); R 11A is as defined in any one of the numbered paragraphs (59) to (61); R 11 is as defined in numbered paragraph (63) or (64); A2, A3 and A4 are as defined in any one of numbered paragraphs (81) to (88); All other groups are as defined in any one of the numbered paragraphs above.

[0107] In one embodiment of the compound of Formula II, I-II, I-III, I-IV, IV or I-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of numbered paragraphs (22) to (26) or (103) to (106); R 7 is as defined in any one of numbered paragraphs (28) to (30); n is as defined in the numbered paragraph (31) or (32); R 8 is as defined in any one of numbered paragraphs (37) to (44) or (107); Y 1 is as defined in numbered paragraph (52) or (53); Y 2 is as defined in any one of the numbered paragraphs (55) to (57); R 11A is as defined in any one of the numbered paragraphs (59) to (61); R 11 is as defined in numbered paragraph (63) or (64); R 11B and R 11C is as defined in any one of numbered paragraphs (66) to (69) or (116) to (120); R 11D is as defined in any one of numbered paragraphs (71) to (73) or (121) to (124); R 11E is as defined in any one of the numbered paragraphs (77) to (80); A2, A3 and A4 are as defined in any one of numbered paragraphs (84) to (88); All other groups are as defined in any one of the numbered paragraphs above.

[0108] In one embodiment of the compound of Formula II, I-II, I-III, I-IV, IV or I-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (9) to (13); R 6 is as defined in any one of numbered paragraphs (24) to (26) or (104) to (106); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (40) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in any one of the numbered paragraphs (59) to (61); R 11 is as defined in numbered paragraph (63) or (64); R 11B and R 11C is as defined in any one of numbered paragraphs (66) to (69) or (116) to (120); R 11D is as defined in any one of numbered paragraphs (71) to (73) or (121) to (124); R 11E is as defined in any one of the numbered paragraphs (77) to (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0109] In one embodiment of the compound of Formula II, I-II, I-III, I-IV, IV or I-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (11) to (13); R 6 is as defined in numbered paragraph (26) or (106); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (42) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in any one of the numbered paragraphs (59) to (61); R 11 is as defined in numbered paragraph (63) or (64); R 11B and R 11C is as defined in any one of numbered paragraphs (66) to (69) or (116) to (120); R 11D is as defined in any one of numbered paragraphs (71) to (73) or (121) to (124); R 11E is as defined in any one of the numbered paragraphs (77) to (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0110] In one embodiment of the compound of Formula II, I-II, I-III, I-IV, IV or I-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of numbered paragraphs (22) to (26) or (103) to (106); R 7 is as defined in any one of numbered paragraphs (28) to (30); n is as defined in the numbered paragraph (31) or (32); R 8 is as defined in any one of numbered paragraphs (37) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (60) or (61); R 11 is as defined in numbered paragraph (63) or (64); R 11B and R 11C is as defined in any one of numbered paragraphs (67) to (69) or (117) to (120); R 11D is as defined in any one of numbered paragraphs (72), (73), (122), (123) or (124); R 11Eis as defined in any one of the numbered paragraphs (78) to (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0111] In one embodiment of the compound of Formula II, I-II, I-III, I-IV, IV or I-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of numbered paragraphs (22) to (26) or (103) to (106); R 7 is as defined in any one of numbered paragraphs (28) to (30); n is as defined in the numbered paragraph (31) or (32); R 8 is as defined in any one of numbered paragraphs (37) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11 is as defined in numbered paragraph (63) or (64); R 11B and R 11C is as defined in any one of numbered paragraphs (69), (119) or (120); R 11D is as defined in the numbered paragraph (73) or (124); R11E is as defined in numbered paragraph (79) or (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0112] In one embodiment of the compound of Formula II, I-II, I-III, I-IV, IV or I-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (9) to (13); R 6 is as defined in any one of numbered paragraphs (24) to (26) or (104) to (106); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (40) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11 is as defined in numbered paragraph (63) or (64); R 11B and R 11C is as defined in any one of numbered paragraphs (67) to (69) or (116) to (120); R 11D is as defined in the numbered paragraph (73) or (124); R11E is as defined in any one of the numbered paragraphs (78) to (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0113] In one embodiment of the compound of Formula II, I-II, I-III, I-IV, IV or I-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (9) to (13); R 6 is as defined in any one of numbered paragraphs (24) to (26) or (104) to (106); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (40) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11 is as defined in numbered paragraph (63) or (64); R 11B and R 11C is as defined in any one of numbered paragraphs (67) to (69) or (116) to (120); R 11D is as defined in the numbered paragraph (73) or (124); R11E is as defined in any one of the numbered paragraphs (78) to (80); A2, A3 and A4 are as defined in any one of numbered paragraphs (84) to (88); R 12 is as defined in any one of the numbered paragraphs (90) to (92); R 13 is as defined in numbered paragraph (94) or (95); R 14 is as defined in numbered paragraph (97) or (98); R a is as defined in any one of numbered paragraphs (100) to (102); All other groups are as defined in any one of the numbered paragraphs above.

[0114] In one embodiment of the compound of Formula II, I-II, I-III, I-IV, IV or I-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (11) to (13); R 6 is as defined in numbered paragraph (26) or (106); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (42) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11Ais as defined in numbered paragraph (61); R 11 is as defined in numbered paragraph (63) or (64); R 11B and R 11C is as defined in numbered paragraph (69) or (120); R 11D is as defined in the numbered paragraph (73) or (124); R 11E is as defined in numbered paragraph (79) or (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0115] In one embodiment of the compound of Formula II, I-II, I-III, I-IV, IV or I-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in numbered paragraph (12); R 6 is as defined in numbered paragraph (26) or (106); R 7 is as defined in numbered paragraph (29); n is as defined in numbered paragraph (31); R 8 is as defined in numbered paragraph (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11is as defined in numbered paragraph (63); R 11B and R 11C is as defined in paragraph (69) or (120); R 11D is as defined in paragraph (73) or (124); R 11E is as defined in numbered paragraph (79); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0116] In one embodiment of the compound of Formula II, I-II, I-III, I-IV, IV or I-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in numbered paragraph (13); R 6 is as defined in numbered paragraph (106); R 7 is as defined in numbered paragraph (30); n is as defined in numbered paragraph (31); R 8 is as defined in numbered paragraph (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11 is as defined in numbered paragraph (64); R 11B and R 11C is as defined in paragraph (120); R11D is as defined in paragraph (124); R 11E is as defined in numbered paragraph (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0117] In one particular group of compounds according to the invention, the compounds have formula I-VII, I-VIII, I-IX, IX, I-XI or I-XII (which are sub-definitions of formula I): [ka] JPEG2024543183000035.jpg212170JPEG2024543183000036.jpg212170[In the formula, R 4 , R 6 , Y1, Y2, A2, A3, A4, R 11A , R 11B , R 11C , R 11D and any related subgroups are as defined in any one of the numbered paragraphs above.], or a pharmaceutically acceptable salt, hydrate and / or solvate thereof.

[0118] In one embodiment of the compound of Formula I-VII, I-VIII, I-IX, IX, I-XI or I-XII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of numbered paragraphs (22) to (26) or (103) to (106); Y 1is as defined in numbered paragraph (52) or (53); Y 2 is as defined in any one of the numbered paragraphs (55) to (57); R 11A is as defined in any one of the numbered paragraphs (59) to (61); R 11B and R 11C is as defined in any one of numbered paragraphs (66) to (69) or (116) to (120); R 11D is as defined in any one of numbered paragraphs (71) to (73) or (121) to (124); A2, A3 and A4 are as defined in any one of numbered paragraphs (81) to (88); All other groups are as defined in any one of the numbered paragraphs above.

[0119] In one embodiment of the compound of Formula I-VII, I-VIII, I-IX, IX, I-XI or I-XII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of numbered paragraphs (22) to (26) or (103) to (106); R 7 is as defined in any one of numbered paragraphs (28) to (30); n is as defined in the numbered paragraph (31) or (32); R 8 is as defined in any one of numbered paragraphs (37) to (44) or (107); Y 1is as defined in numbered paragraph (52) or (53); Y 2 is as defined in any one of the numbered paragraphs (55) to (57); R 11A is as defined in any one of the numbered paragraphs (59) to (61); R 11B and R 11C is as defined in any one of numbered paragraphs (66) to (69) or (116) to (120); R 11D is as defined in any one of numbered paragraphs (71) to (73) or (121) to (124); A2, A3 and A4 are as defined in any one of numbered paragraphs (84) to (88); All other groups are as defined in any one of the numbered paragraphs above.

[0120] In one embodiment of the compound of Formula I-VII, I-VIII, I-IX, IX, I-XI or I-XII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (9) to (13); R 6 is as defined in any one of numbered paragraphs (24) to (26) or (104) to (106); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (40) to (44) or (107); Y 1 and Y 2is as defined in numbered paragraph (58); R 11A is as defined in any one of the numbered paragraphs (59) to (61); R 11B and R 11C is as defined in any one of numbered paragraphs (66) to (69) or (116) to (120); R 11D is as defined in any one of numbered paragraphs (71) to (73) or (121) to (124); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0121] In one embodiment of the compound of Formula I-VII, I-VIII, I-IX, IX, I-XI or I-XII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (11) to (13); R 6 is as defined in numbered paragraph (26) or (106); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (42) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in any one of the numbered paragraphs (59) to (61); R11B and R 11C is as defined in any one of numbered paragraphs (66) to (69) or (116) to (120); R 11D is as defined in any one of numbered paragraphs (71) to (73) or (121) to (124); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0122] In one embodiment of the compound of Formula I-VII, I-VIII, I-IX, IX, I-XI or I-XII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of numbered paragraphs (22) to (26) or (103) to (106); R 7 is as defined in any one of numbered paragraphs (28) to (30); n is as defined in the numbered paragraph (31) or (32); R 8 is as defined in any one of numbered paragraphs (37) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (60) or (61); R 11B and R 11C is as defined in any one of numbered paragraphs (67) to (69) or (116) to (120); R 11D is as defined in any one of numbered paragraphs (72), (73), (122), (123) or (124); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0123] In one embodiment of the compound of Formula I-VII, I-VIII, I-IX, IX, I-XI or I-XII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of numbered paragraphs (22) to (26) or (103) to (106); R 7 is as defined in any one of numbered paragraphs (28) to (30); n is as defined in the numbered paragraph (31) or (32); R 8 is as defined in any one of numbered paragraphs (37) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11B and R 11C is as defined in numbered paragraph (69) or (120); R 11D is as defined in the numbered paragraph (73) or (124); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0124] In one embodiment of the compound of Formula I-VII, I-VIII, I-IX, IX, I-XI or I-XII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (9) to (13); R 6 is as defined in any one of numbered paragraphs (24) to (26) or (104) to (106); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (40) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11B and R 11C is as defined in any one of numbered paragraphs (67) to (69) or (116) to (120); R 11D is as defined in the numbered paragraph (73) or (124); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0125] In one embodiment of the compound of Formula I-VII, I-VIII, I-IX, IX, I-XI or I-XII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (9) to (13); R 6 is as defined in any one of numbered paragraphs (24) to (26) or (104) to (106); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (40) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11B and R 11C is as defined in any one of numbered paragraphs (67) to (69) or (116) to (120); R 11D is as defined in the numbered paragraph (73) or (124); A2, A3 and A4 are as defined in any one of numbered paragraphs (84) to (88); R 12 is as defined in any one of numbered paragraphs (90) to (92), (114) or (115); R 13 is as defined in numbered paragraph (94) or (95); R 14is as defined in numbered paragraph (97) or (98); R a is as defined in any one of numbered paragraphs (100) to (102); All other groups are as defined in any one of the numbered paragraphs above.

[0126] In one embodiment of the compound of Formula I-VII, I-VIII, I-IX, IX, I-XI or I-XII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (11) to (13); R 6 is as defined in numbered paragraph (26) or (106); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (42) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11B and R 11C is as defined in numbered paragraph (69) or (120); R 11D is as defined in the numbered paragraph (73) or (124); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0127] In one embodiment of the compound of Formula I-VII, I-VIII, I-IX, IX, I-XI or I-XII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in numbered paragraph (12); R 6 is as defined in numbered paragraph (26) or (106); R 7 is as defined in numbered paragraph (29); n is as defined in numbered paragraph (31); R 8 is as defined in numbered paragraph (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11B and R 11C is as defined in numbered paragraph (69) or (120); R 11D is as defined in the numbered paragraph (73) or (124); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0128] In one embodiment of the compound of Formula I-VII, I-VIII, I-IX, IX, I-XI or I-XII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in numbered paragraph (13); R6 is as defined in numbered paragraph (106); R 7 is as defined in numbered paragraph (29); n is as defined in numbered paragraph (31); R 8 is as defined in numbered paragraph (107); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11B and R 11C is as defined in numbered paragraph (120); R 11D is as defined in numbered paragraph (124); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0129] In one particular group of compounds according to the invention, the compounds have formula I-XIII, I-XIV, I-XV, I-XVI, I-XVII or I-XVIII (which are sub-definitions of formula I): [ka] JPEG2024543183000038.jpg224170JPEG2024543183000039.jpg224170[In the formula, R 4 , R 6 , Y1, Y2, A2, A3, A4, R 11A , R 11E and any related subgroups are as defined in any one of the numbered paragraphs above.], or a pharmaceutically acceptable salt, hydrate and / or solvate thereof.

[0130] In one embodiment of the compound of Formula I-XIII, I-XIV, I-XV, I-XVI, I-XVII or I-XVIII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of the numbered paragraphs (22) to (26); Y 1 is as defined in numbered paragraph (52) or (53); Y 2 is as defined in any one of the numbered paragraphs (55) to (57); R 11A is as defined in any one of the numbered paragraphs (59) to (61); R 11E is as defined in any one of the numbered paragraphs (77) to (80); A2, A3 and A4 are as defined in any one of numbered paragraphs (81) to (88); All other groups are as defined in any one of the numbered paragraphs above.

[0131] In one embodiment of the compound of Formula I-XIII, I-XIV, I-XV, I-XVI, I-XVII or I-XVIII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of the numbered paragraphs (22) to (26); R 7is as defined in any one of numbered paragraphs (28) to (30); n is as defined in the numbered paragraph (31) or (32); R 8 is as defined in any one of the numbered paragraphs (37) to (44); Y 1 is as defined in numbered paragraph (52) or (53); Y 2 is as defined in any one of the numbered paragraphs (55) to (57); R 11A is as defined in any one of the numbered paragraphs (59) to (61); R 11E is as defined in any one of the numbered paragraphs (77) to (80); A2, A3 and A4 are as defined in any one of numbered paragraphs (84) to (88); All other groups are as defined in any one of the numbered paragraphs above.

[0132] In one embodiment of the compound of Formula I-XIII, I-XIV, I-XV, I-XVI, I-XVII or I-XVIII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (9) to (13); R 6 is as defined in any one of the numbered paragraphs (24) to (26); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8is as defined in any one of the numbered paragraphs (40) to (44); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in any one of the numbered paragraphs (59) to (61); R 11E is as defined in any one of the numbered paragraphs (77) to (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0133] In one embodiment of the compound of Formula I-XIII, I-XIV, I-XV, I-XVI, I-XVII or I-XVIII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (11) to (13); R 6 is as defined in numbered paragraph (26); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of the numbered paragraphs (42) to (44); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in any one of the numbered paragraphs (59) to (61); R 11Eis as defined in any one of the numbered paragraphs (77) to (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0134] In one embodiment of the compound of Formula I-XIII, I-XIV, I-XV, I-XVI, I-XVII or I-XVIII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of the numbered paragraphs (22) to (26); R 7 is as defined in any one of numbered paragraphs (28) to (30); n is as defined in the numbered paragraph (31) or (32); R 8 is as defined in any one of the numbered paragraphs (37) to (44); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (60) or (61); R 11E is as defined in any one of the numbered paragraphs (78) to (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0135] In one embodiment of the compound of Formula I-XIII, I-XIV, I-XV, I-XVI, I-XVII or I-XVIII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of the numbered paragraphs (22) to (26); R 7 is as defined in any one of numbered paragraphs (28) to (30); n is as defined in the numbered paragraph (31) or (32); R 8 is as defined in any one of the numbered paragraphs (37) to (44); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11E is as defined in numbered paragraph (79) or (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0136] In one embodiment of the compound of Formula I-XIII, I-XIV, I-XV, I-XVI, I-XVII or I-XVIII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (9) to (13); R 6 is as defined in any one of the numbered paragraphs (24) to (26); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of the numbered paragraphs (40) to (44); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11E is as defined in any one of the numbered paragraphs (78) to (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0137] In one embodiment of the compound of Formula I-XIII, I-XIV, I-XV, I-XVI, I-XVII or I-XVIII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (9) to (13); R 6 is as defined in any one of the numbered paragraphs (24) to (26); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of the numbered paragraphs (40) to (44); Y 1 and Y 2is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11E is as defined in any one of the numbered paragraphs (78) to (80); A2, A3 and A4 are as defined in any one of numbered paragraphs (84) to (88); R 12 is as defined in any one of the numbered paragraphs (90) to (92); R 13 is as defined in numbered paragraph (94) or (95); R 14 is as defined in numbered paragraph (97) or (98); R a is as defined in any one of numbered paragraphs (100) to (102); All other groups are as defined in any one of the numbered paragraphs above.

[0138] In one embodiment of the compound of Formula I-XIII, I-XIV, I-XV, I-XVI, I-XVII or I-XVIII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (11) to (13); R 6 is as defined in numbered paragraph (26); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of the numbered paragraphs (42) to (44); Y1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11E is as defined in numbered paragraph (79) or (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0139] In one embodiment of the compound of Formula I-XIII, I-XIV, I-XV, I-XVI, I-XVII or I-XVIII, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in numbered paragraph (13); R 6 is as defined in numbered paragraph (26); R 7 is as defined in numbered paragraph (30); n is as defined in numbered paragraph (31); R 8 is as defined in numbered paragraph (44); Y 1 and Y 2 is as defined in numbered paragraph (58); R 11A is as defined in numbered paragraph (61); R 11E is as defined in numbered paragraph (80); A2, A3 and A4 are as defined in numbered paragraph (88); All other groups are as defined in any one of the numbered paragraphs above.

[0140] In one particular group of compounds according to the invention, the compounds have formula II-I, II-II, II-III, II-IV, II-V or II-VI (which are sub-definitions of formula II): [ka] JPEG2024543183000041.jpg120170[In the formula, R 4 , R 6 , Y1, Y2, A1, A2, A3 and A4 and any related subgroups are as defined in any one of the numbered paragraphs above.], or a pharmaceutically acceptable salt, hydrate and / or solvate thereof.

[0141] In one embodiment of the compound of Formula II-I, II-II, II-III, II-IV, II-V or II-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of numbered paragraphs (22) to (26) or (103) to (106); Y 1 is as defined in numbered paragraph (52) or (53); Y 2 is as defined in any one of the numbered paragraphs (55) to (57); A1, A2, A3 and A4 are as defined in any one of numbered paragraphs (108) to (113); All other groups are as defined in any one of the numbered paragraphs above.

[0142] In one embodiment of the compound of Formula II-I, II-II, II-III, II-IV, II-V or II-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of numbered paragraphs (22) to (26) or (103) to (106); R 7 is as defined in any one of numbered paragraphs (28) to (30); n is as defined in the numbered paragraph (31) or (32); R 8 is as defined in any one of numbered paragraphs (37) to (44) or (107); Y 1 is as defined in numbered paragraph (52) or (53); Y 2 is as defined in any one of the numbered paragraphs (55) to (57); A1, A2, A3 and A4 are as defined in any one of numbered paragraphs (109) to (113); All other groups are as defined in any one of the numbered paragraphs above.

[0143] In one embodiment of the compound of Formula II-I, II-II, II-III, II-IV, II-V or II-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (9) to (13); R 6 is as defined in any one of numbered paragraphs (24) to (26) or (104) to (106); R7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (40) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); A1, A2, A3 and A4 are as defined in any one of numbered paragraphs (110) to (113); R 10 is as defined in numbered paragraph (114) or (115); R 11A is as defined in any one of the numbered paragraphs (59) to (61); R 11 is as defined in numbered paragraph (63) or (64); R 11B and R 11C is as defined in any one of numbered paragraphs (66) to (69) or (116) to (120); R 11D is as defined in any one of numbered paragraphs (71) to (73) or (121) to (124); R 11E is as defined in any one of the numbered paragraphs (77) to (80); All other groups are as defined in any one of the numbered paragraphs above.

[0144] In one embodiment of the compound of Formula II-I, II-II, II-III, II-IV, II-V or II-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4is as defined in any one of the numbered paragraphs (11) to (13); R 6 is as defined in numbered paragraph (26) or (126); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (42) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); A1, A2, A3 and A4 are as defined in any one of numbered paragraphs (111) to (113); R 10 is as defined in numbered paragraph (114) or (115); R 11A is as defined in numbered paragraph (60) or (61); R 11 is as defined in numbered paragraph (63) or (64); R 11B and R 11C is as defined in any one of numbered paragraphs (66) to (69) or (116) to (120); R 11D is as defined in any one of numbered paragraphs (71) to (73) or (121) to (124); R 11E is as defined in any one of the numbered paragraphs (77) to (80); All other groups are as defined in any one of the numbered paragraphs above.

[0145] In one embodiment of the compound of Formula II-I, II-II, II-III, II-IV, II-V or II-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of numbered paragraphs (22) to (26) or (103) to (106); R 7 is as defined in any one of numbered paragraphs (28) to (30); n is as defined in the numbered paragraph (31) or (32); R 8 is as defined in any one of numbered paragraphs (37) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); A1, A2, A3 and A4 are as defined in numbered paragraph (112) or (113); R 10 is as defined in numbered paragraph (114) or (115); R 11A is as defined in numbered paragraph (60) or (61); R 11 is as defined in numbered paragraph (63) or (64); R 11B and R 11C is as defined in any one of numbered paragraphs (67) to (69) or (117) to (120); R 11D is as defined in any one of numbered paragraphs (72), (73), (122), (123) or (124); R 11Eis as defined in any one of the numbered paragraphs (78) to (80); All other groups are as defined in any one of the numbered paragraphs above.

[0146] In one embodiment of the compound of Formula II-I, II-II, II-III, II-IV, II-V or II-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of numbered paragraphs (5) to (13); R 6 is as defined in any one of numbered paragraphs (22) to (26) or (103) to (106); R 7 is as defined in any one of numbered paragraphs (28) to (30); n is as defined in the numbered paragraph (31) or (32); R 8 is as defined in any one of numbered paragraphs (37) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); A1, A2, A3 and A4 are as defined in numbered paragraph (112) or (113); R 10 is as defined in numbered paragraph (114) or (115); R 11A is as defined in numbered paragraph (61); R 11 is as defined in numbered paragraph (63) or (64); R 11B and R 11C is as defined in any one of numbered paragraphs (69), (119) or (120); R 11D is as defined in the numbered paragraph (73) or (124); R 11E is as defined in numbered paragraph (79) or (80); All other groups are as defined in any one of the numbered paragraphs above.

[0147] In one embodiment of the compound of Formula II-I, II-II, II-III, II-IV, II-V or II-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (9) to (13); R 6 is as defined in any one of numbered paragraphs (24) to (26) or (104) to (106); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (40) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); A1, A2, A3 and A4 are as defined in numbered paragraph (112) or (113); R 10 is as defined in numbered paragraph (114) or (115); R 11A is as defined in numbered paragraph (61); R 11 is as defined in numbered paragraph (63) or (64); R 11Band R 11C is as defined in any one of numbered paragraphs (67) to (69) or (116) to (120); R 11D is as defined in the numbered paragraph (73) or (124); R 11E is as defined in any one of the numbered paragraphs (78) to (80); All other groups are as defined in any one of the numbered paragraphs above.

[0148] In one embodiment of the compound of Formula II-I, II-II, II-III, II-IV, II-V or II-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in any one of the numbered paragraphs (11) to (13); R 6 is as defined in numbered paragraph (26) or (126); R 7 is as defined in numbered paragraph (29) or (30); n is as defined in numbered paragraph (31); R 8 is as defined in any one of numbered paragraphs (42) to (44) or (107); Y 1 and Y 2 is as defined in numbered paragraph (58); A1, A2, A3 and A4 are as defined in numbered paragraph (112) or (113); R 10 is as defined in numbered paragraph (114) or (115); R 11A is as defined in numbered paragraph (61); R 11is as defined in numbered paragraph (63) or (64); R 11B and R 11C is as defined in numbered paragraph (69) or (120); R 11D is as defined in the numbered paragraph (73) or (124); R 11E is as defined in numbered paragraph (79) or (80); All other groups are as defined in any one of the numbered paragraphs above.

[0149] In one embodiment of the compound of Formula II-I, II-II, II-III, II-IV, II-V or II-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in numbered paragraph (12); R 6 is as defined in numbered paragraph (26); R 7 is as defined in numbered paragraph (29); n is as defined in numbered paragraph (31); R 8 is as defined in numbered paragraph (44); Y 1 and Y 2 is as defined in numbered paragraph (58); A1, A2, A3 and A4 are as defined in numbered paragraph (112); R 10 is as defined in numbered paragraph (114); R 11A is as defined in numbered paragraph (61); R 11 is as defined in numbered paragraph (63); R 11B and R 11C is as defined in numbered paragraph (69); R 11D is as defined in numbered paragraph (73); R 11E is as defined in numbered paragraph (79); All other groups are as defined in any one of the numbered paragraphs above.

[0150] In one embodiment of the compound of Formula II-I, II-II, II-III, II-IV, II-V or II-VI, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, where appropriate: R 4 is as defined in numbered paragraph (13); R 6 is as defined in numbered paragraph (106); R 7 is as defined in numbered paragraph (30); n is as defined in numbered paragraph (31); R 8 is as defined in numbered paragraph (107); Y 1 and Y 2 is as defined in numbered paragraph (58); A1, A2, A3 and A4 are as defined in numbered paragraph (113); R 10 is as defined in numbered paragraph (115); R 11A is as defined in numbered paragraph (61); R 11 is as defined in numbered paragraph (64); R 11B and R 11Cis as defined in numbered paragraph (120); R 11D is as defined in numbered paragraph (124); R 11E is as defined in numbered paragraph (80); All other groups are as defined in any one of the numbered paragraphs above.

[0151] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 2 is as defined in paragraph (2) above.

[0152] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 4 is as defined in paragraph (10) above.

[0153] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 4 is as defined in paragraph (11) above.

[0154] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 4 is as defined in paragraph (12) above.

[0155] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 4 is as defined in paragraph (13) above.

[0156] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) or (106) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (39) or (107) above.

[0157] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) or (106) above, and R 7 is as defined in paragraph (28) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (39) or (107) above.

[0158] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6is as defined in paragraph (26) or (106) above, and R 7 is as defined in paragraph (29) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (39) or (107) above.

[0159] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) or (106) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (39) or (107) above.

[0160] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) or (106) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (40) or (107) above.

[0161] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6is as defined in paragraph (26) or (106) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (41) or (107) above.

[0162] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) or (106) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (42) or (107) above.

[0163] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6 is as defined in paragraph (26) or (106) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (43) or (107) above.

[0164] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 6is as defined in paragraph (26) or (106) above, and R 7 is as defined in paragraph (27) above, n is as defined in paragraph (31) above, and R 8 is as defined in paragraph (44) or (107) above.

[0165] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Y1 is as defined in paragraph (52) above.

[0166] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Y1 is as defined in paragraph (53) above.

[0167] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Y2 is as defined in paragraph (55) above.

[0168] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Y2 is as defined in paragraph (56) above.

[0169] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Y2 is as defined in paragraph (57) above.

[0170] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, Y1 and Y2 are as defined in paragraph (58) above.

[0171] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11A is as defined in paragraph (59) above.

[0172] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11A is as defined above in paragraph (60).

[0173] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11A is as defined above in paragraph (61).

[0174] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined above in paragraph (63).

[0175] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined above in paragraph (64).

[0176] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined in paragraph (63) above, and R 11B and R 11C is as defined in paragraph (66) or (117) above.

[0177] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined in paragraph (63) above, and R 11B and R 11C is as defined in paragraph (67) or (118) above.

[0178] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined in paragraph (63) above, and R 11B and R 11C is as defined in paragraph (68) or (119) above.

[0179] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined in paragraph (63) above, and R 11B and R 11C is as defined in paragraph (69) or (120) above.

[0180] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined in paragraph (63) above, and R 11D is as defined in paragraph (70) or (121) above.

[0181] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined in paragraph (63) above, and R 11D is as defined in paragraph (71) or (122) above.

[0182] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined in paragraph (63) above, and R 11D is as defined in paragraph (72) or (123) above.

[0183] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined in paragraph (63) above, and R 11D is as defined in paragraph (73) or (124) above.

[0184] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined above in paragraph (64), and R 11E is as defined above in paragraph (74).

[0185] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined above in paragraph (64), and R 11E is as defined above in paragraph (75).

[0186] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined above in paragraph (64), and R 11E is as defined in paragraph (76) above.

[0187] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined above in paragraph (64), and R 11E is as defined above in paragraph (77).

[0188] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined above in paragraph (64), and R 11E is as defined above in paragraph (78).

[0189] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined above in paragraph (64), and R 11E is as defined above in paragraph (79).

[0190] In one embodiment of a compound of Formula I or Formula II or any appropriate sub-definition of Formula I or Formula II (as defined by Formulas II-I-XVIII or Formulas II-I-II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R 11 is as defined above in paragraph (64), and R 11E is as defined above in paragraph (80).

[0191] In one embodiment of the compound of Formula I or any appropriate sub-definition of Formula I (as defined by Formulas II-I-XVIII), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A2, A3 and A4 are as defined in paragraph (81) above, and R 12 is as defined above in paragraph (89), and R 13 is as defined above in paragraph (93), and R 14 is as defined above in paragraph (96).

[0192] In one embodiment of the compound of Formula I or any appropriate sub-definition of Formula I (as defined by Formulas II-I-XVIII), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A2, A3 and A4 are as defined in paragraph (82) above, and R 12 is as defined above in paragraph (89), and R 13 is as defined above in paragraph (93).

[0193] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XVIII), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A2, A3 and A4 are as defined in paragraph (83) above, and R 13 is as defined above in paragraph (93).

[0194] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XVIII), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A2, A3 and A4 are as defined above in paragraph (84), and R 13 is as defined above in paragraph (93).

[0195] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XVIII), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A2, A3 and A4 are as defined above in paragraph (85).

[0196] In one embodiment of the compound of Formula I or any appropriate sub-definition of Formula I (as defined by Formulas II-I-XVIII), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A2, A3 and A4 are as defined in paragraph (86) above, and R 12 is as defined above in paragraph (89).

[0197] In one embodiment of the compound of Formula I or any appropriate sub-definition of Formula I (as defined by Formulas II-I-XVIII), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A2, A3 and A4 are as defined in paragraph (87) above, and R 14 is as defined above in paragraph (96).

[0198] In one embodiment of a compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XVIII), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A2, A3 and A4 are as defined above in paragraph (88).

[0199] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XVIII), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R a is as defined above in paragraph (99).

[0200] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XVIII), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R a is as defined above in paragraph (100).

[0201] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XVIII), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R a is as defined above in paragraph (101).

[0202] In one embodiment of the compound of Formula I or any suitable sub-definition of Formula I (as defined by Formulas II-I-XVIII), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, R a is as defined above in paragraph (102).

[0203] In one embodiment of the compound of Formula II or any appropriate sub-definition of Formula II (as defined by Formulas II-I to II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A1, A2, A3 and A4 are as defined in paragraph (108) above, and R 10 is as defined in paragraph (114) or (115) above, and R 13 is as defined above in paragraph (93), and R 14 is as defined above in paragraph (96).

[0204] In one embodiment of the compound of Formula II or any appropriate sub-definition of Formula II (as defined by Formulas II-I to II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A1, A2, A3 and A4 are as defined in paragraph (109) above, and R 10 is as defined in paragraph (114) or (115) above, and R 13 is as defined above in paragraph (93).

[0205] In one embodiment of the compound of Formula II or any appropriate sub-definition of Formula II (as defined by Formulas II-I to II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A1, A2, A3 and A4 are as defined in paragraph (110) above, and R 10 is as defined in paragraph (114) or (115) above.

[0206] In one embodiment of the compound of Formula II or any appropriate sub-definition of Formula II (as defined by Formulas II-I to II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A1, A2, A3 and A4 are as defined in paragraph (111) above, and R 10 is as defined in paragraph (114) or (115) above, and R 11 is as defined in paragraph (63) or (64) above.

[0207] In one embodiment of the compound of Formula II or any appropriate sub-definition of Formula II (as defined by Formulas II-I to II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A1, A2, A3 and A4 are as defined in paragraph (112) or (113) above, and R 10 is as defined in paragraph (114) or (115) above, and R 11 is as defined in paragraph (63) or (64) above, and R 11B and R11C is as defined in any one of paragraphs (67) to (69) or (118) to (120) above.

[0208] In one embodiment of the compound of Formula II or any appropriate sub-definition of Formula II (as defined by Formulas II-I to II-VI), or a pharmaceutically acceptable salt, hydrate and / or solvate thereof, A1, A2, A3 and A4 are as defined in paragraph (112) or (113) above, and R 10 is as defined in paragraph (114) or (115) above, and R 11 is as defined in paragraph (63) or (64) above, and R 11B and R 11C is as defined in any one of paragraphs (67) to (69) or (118) to (120) above, and R 11D is as defined in any one of paragraphs (71) to (73) or (122) to (124) above.

[0209] Particular compounds according to the invention include any of the compounds exemplified in this application, or a pharmaceutically acceptable salt or solvate thereof, in particular any of the following: N-(2-(2-(benzyloxy)-4,6-dihydroxybenzoyl)isoindolin-4-yl)acrylamide; (E)-N-(2-(2-(benzyloxy)-4,6-dihydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide; N-(2-(2-(benzyloxy)-4,6-dihydroxy-benzoyl)isoindolin-4-yl)-2-fluoroacrylamide; N-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)acrylamide; N-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-2-fluoroacrylamide; (E)-N-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide; N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)acrylamide; (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide; (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-(pyrrolidin-1-yl)but-2-enamide; (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-morpholinobuta-2-enamide hydrochloride; (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-(4-methylpiperazin-1-yl)but-2-enamide; N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)but-2-ynamide; (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)but-2-enamide; (E)-N-[2-[2-(cyclopentylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-4-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-4-yl]-4-(dimethylamino)but-2-enamide; N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]prop-2-enamide; N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]-3,4-dihydro-1H-isoquinolin-8-yl]prop-2-enamide; N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]-3,4-dihydro-1H-isoquinolin-7-yl]prop-2-enamide; (E)-N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]-3,4-dihydro-1H-isoquinolin-8-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]-3,4-dihydro-1H-isoquinolin-7-yl]-4-(dimethylamino)but-2-enamide; (E)-4-(Dimethylamino)-N-[2-(2-ethoxy-4,6-dihydroxy-3-methyl-benzoyl)isoindolin-4-yl]but-2-enamide; (E)-N-[2-[4,6-dihydroxy-3-methyl-2-(2,2,2-trifluoroethoxy)benzoyl]isoindolin-4-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-[2-(cyclopropylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-4-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-4-yl]-4-(dimethylamino)-N-methyl-but-2-enamide; (E)-N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-5-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-5-yl]-4-(dimethylamino)-N-methyl-but-2-enamide; (E)-N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)-3,4-dihydro-1H-isoquinolin-7-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)-3,4-dihydro-1H-isoquinolin-7-yl]-4-(dimethylamino)-N-methyl-but-2-enamide; (E)-N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-4-yl]-4-(dimethylamino)-N-methyl-but-2-enamide; (E)-N-[2-[2-(cyclopropylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-4-yl]-4-(dimethylamino)-N-methyl-but-2-enamide; N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-4-yl]-N-methyl-prop-2-enamide; (E)-4-(Dimethylamino)-N-(2-(2-ethoxy-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-N-methylbut-2-enamide; (E)-4-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-5-yl]oxy-N,N-dimethyl-but-2-enamide; (E)-4-((2-(4,6-dihydroxy-2-methoxy-3-methylbenzoyl)isoindolin-4-yl)oxy)-N,N-dimethylbut-2-enamide; N-(2-(4,6-dihydroxy-2-methoxy-3-methylbenzoyl)isoindolin-4-yl)-2-((dimethylamino)methyl)acrylamide; N-(2-(4,6-dihydroxy-2-methoxy-3-methylbenzoyl)isoindolin-4-yl)-2-(morpholinomethyl)acrylamide.

[0210] Particular compounds according to the invention include any of the compounds exemplified in this application, or a pharmaceutically acceptable salt or solvate thereof, in particular any of the following: [ka]

[0211] The various functional groups and substituents that make up the compounds of formula (I) or (II) or sub-formulae (II) to (I-XVIII) or II-I to II-VI are typically chosen so that the molecular weight of the compounds of formula (I) or (II) does not exceed 700. More typically, the molecular weight of the compounds is less than 650. More preferably, the molecular weight is less than 600.

[0212] Suitable pharmaceutically acceptable salts of the compounds of the present invention are, for example, sufficiently basic acid-addition salts of the compounds of the present invention, for example, acid-addition salts with inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, trifluoroacetic acid, formic acid, citric acid, methane sulfonate, or maleic acid. Furthermore, suitable pharmaceutically acceptable salts of the compounds of the present invention that are sufficiently acidic are alkali metal salts, for example, sodium or potassium salts, alkaline earth metal salts, for example, calcium or magnesium salts, ammonium salts, or salts with organic bases that form pharmaceutically acceptable cations, for example, salts with methylamine, dimethylamine, trimethylamine, piperidine, morpholine, or tris-(2-hydroxyethyl)amine.

[0213] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space are called "isomers." Isomers that differ in the arrangement of their atoms in space are called "stereoisomers." Stereoisomers that are not mirror images of one another are called "diastereomers," and those that are non-superimposable mirror images of each other are called "enantiomers." When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center and described by the R- and S-sequencing rules of Cahn and Prelog, or by the way the molecule rotates plane-polarized light and can be named dextrorotatory or levorotatory (i.e., (+)- or (-)-isomer, respectively). Chiral compounds can exist as either enantiomer or a mixture thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."

[0214] The compounds of the present invention may have one or more asymmetric centers; therefore, such compounds can be produced as individual (R)- or (S)-stereoisomers or mixtures thereof. Unless otherwise indicated, the description or naming of a particular compound in this specification and claims is intended to include both individual enantiomers and their mixtures, racemic or otherwise. Methods for determining stereochemistry and separating stereoisomers are well known in the art, for example, by synthesis from optically active starting materials or by resolution of racemates (see Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 2001). Some of the compounds of the present invention may have geometric isomeric centers (E- and Z-isomers).

[0215] It is to be understood that the present invention embraces all optical, diastereomeric, and geometric isomers and mixtures thereof that possess activity.

[0216] The present invention also encompasses compounds of the present invention as defined herein that contain one or more isotopic substitutions, e.g., H can be in any isotopic form, including 1H, 2H (D), and 3H (T); C can be in any isotopic form, including 12C, 13C, and 14C; O can be in any isotopic form, including 16O and 18O, etc.

[0217] It is also to be understood that some compounds of Formula (I) or Formula (II), or subformulas (II)-(I-XVIII) or II-I-II-VI, can exist in solvated as well as unsolvated forms, such as, for example, hydrated forms, etc. It is to be understood that the present invention encompasses all such solvated forms that possess activity.

[0218] It is also to be understood that some compounds of formula (I) or formula (II), or subformulas (II) to (I-XVIII) or II-I to II-VI, may exhibit polymorphism, and that the present invention encompasses all such forms that possess activity.

[0219] Compounds of formula (I) or formula (II), or sub-formulas (II) to (I-XVIII) or II-I to II-VI, can exist in a number of different tautomeric forms, and references to compounds of formula (I) or formula (II), or sub-formulas (II) to (I-XVIII) or II-I to II-VI include all such forms. For the avoidance of doubt, where a compound may exist in one of several tautomeric forms, only one will be described or shown in detail, while all others are encompassed by formula (I) or formula (II), or sub-formulas (II) to (I-XVIII) or II-I to II-VI. Tautomeric forms include, for example, the keto, enol, and enolate forms for the following tautomeric pairs: keto / enol (illustrated below), imine / enamine, amide / iminoalcohol, amidine / amidine, nitroso / oxime, thioketone / enethiol, and nitro / aci-nitro.

[0220] [ka]

[0221] Compounds of formula (I) or (II), or subformulas (II)-(I-XVIII) or II-I-II-VI, containing an amine functional group can also form N-oxides. References herein to compounds of formula (I) or (II), or subformulas (II)-(I-XVIII) or II-I-II-VI, containing an amine functional group also include N-oxides. When a compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form N-oxides. Particular examples of N-oxides are the N-oxides of tertiary amines or nitrogen atoms of nitrogen-containing heterocycles. N-oxides can be formed by treatment of the corresponding amine with an oxidizing agent, such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid); see, for example, Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience. More specifically, the N-oxides can be prepared by the procedure of LW Deady (Syn. Comm. 1977, 7, 509-514) in which the amine compounds are reacted with m-chloroperoxybenzoic acid (mCPBA) in an inert solvent such as dichloromethane.

[0222] The compounds of formula (I) or (II), or sub-formulas (II)-(I-XVIII) or II-I-II-VI, can be administered in the form of prodrugs that are broken down in the human or animal body to release the compounds of the invention. Prodrugs can be used to modify the physical and / or pharmacokinetic properties of the compounds of the invention. Prodrugs can be formed when the compounds of the invention contain a suitable group or substituent to which a property-modifying group can be attached. Prodrugs include, for example, in vivo cleavable ester derivatives that can be formed at a carboxy or hydroxy group in a compound of formula (I) or (II), or sub-formulas (II)-(I-XVIII) or II-I-II-VI, and in vivo cleavable amide derivatives that can be formed at a carboxy or amino group in a compound of formula (I) or (II), or sub-formulas (II)-(I-XVIII) or II-I-II-VI.

[0223] The present invention therefore includes compounds of formula (I) or (II), or sub-formulas (II) to (I-XVIII) or II-I to II-VI, as defined above, when available by organic synthesis and when available in the human or animal body as cleavage of a prodrug thereof. The present invention therefore includes compounds of formula (I) or (II), or sub-formulas (II) to (I-XVIII) or II-I to II-VI, produced by organic synthetic means, and also compounds produced in the human or animal body as metabolism of precursor compounds which are compounds of formula (I) or (II), or sub-formulas (II) to (I-XVIII) or II-I to II-VI, such compounds may be synthetically produced compounds or metabolically produced compounds.

[0224] Suitable pharmaceutically acceptable prodrugs of compounds of Formula (I) or Formula (II), or sub-formulas (II) to (I-XVIII) or II-I to II-VI, are those based on sound medical judgment, such that they are free from undesirable pharmacological activity and are free from undue toxicity and are suitable for administration to the human or animal body.

[0225] Various forms of prodrugs are described, for example, in the following documents: a)Methods in Enzymology, Vol.42, p.309-396, edited by K.Widder, et al.(Academic Press, 1985); b)Design of Pro-drugs, edited by H.Bundgaard,(Elsevier, 1985); c)A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H.Bundgaard, Chapter 5 “Design and Application of Pro-drugs”, by H.Bundgaard p.113-191(1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285(1988); f) N.Kakeya, et al., Chem.Pharm.Bull., 32, 692(1984); g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, ACSSymposium Series, Volume 14; and h) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.

[0226] Suitable pharmaceutically acceptable prodrugs of compounds of formula (I) or (II), or sub-formulae (II) to (I-XVIII) or II-I to II-VI, containing a carboxy group are, for example, in vivo cleavable esters thereof. In vivo cleavable esters of compounds of formula I or (II), or sub-formulae (II) to (I-XVIII) or II-I to II-VI, containing a carboxy group are, for example, pharmaceutically acceptable esters which are cleaved in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically acceptable esters for carboxy include (1-6C)alkyl esters such as methyl, ethyl and tert-butyl, (1-6C)alkoxymethyl esters such as methoxymethyl ester, (1-6C)alkanoyloxymethyl esters such as pivaloyloxymethyl ester, 3-phthalidyl ester, (3-8C)cycloalkylcarbonyloxy-(1-6C)alkyl esters such as cyclopentylcarbonyloxymethyl and 1-cyclohexylcarbonyloxyethyl ester, 2-oxo-1,3-dioxolenylmethyl esters such as 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl ester and (1-6C)alkoxycarbonyloxy-(1-6C)alkyl esters such as methoxycarbonyloxymethyl and 1-methoxycarbonyloxyethyl ester.

[0227] Suitable pharmaceutically acceptable prodrugs of compounds of formula (I) or (II), or sub-formulae (II) to (I-XVIII) or II-I to II-VI, containing a hydroxy group, are, for example, in vivo cleavable esters or ethers thereof. An in vivo cleavable ester or ether of a compound of formula (I) or (II), or sub-formulae (II) to (I-XVIII) or II-I to II-VI, containing a hydroxy group, is, for example, a pharmaceutically acceptable ester or ether that is cleaved in the human or animal body to produce the parent hydroxy compound. Suitable pharmaceutically acceptable esters forming groups for hydroxy groups include inorganic esters, for example, phosphate esters (including phosphoramidate cyclic esters), and the like. Further suitable pharmaceutically acceptable ester forming groups for hydroxy groups include (1-10C)alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, (1-10C)alkoxycarbonyl groups such as ethoxycarbonyl, N,N-(1-6C)2carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups. Ring substituents in phenylacetyl and benzoyl groups include, for example, aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(1-4C)alkylpiperazin-1-ylmethyl. Suitable pharmaceutically acceptable ether forming groups for hydroxy groups include α-acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl groups.

[0228] Suitable pharmaceutically acceptable prodrugs of compounds of formula (I) or formula (II), or sub-formulae (II) to (I-XVIII) or II-I to II-VI, having a carboxy group are, for example, in vivo cleavable amides thereof, such as amides formed with amines, such as ammonia, (1-4C)alkylamines, such as methylamine, [(1-4C)alkyl]2amines, such as dimethylamine, N-ethyl-N-methylamine or diethylamine, (1-4C)alkoxy-(2-4C)alkylamines, such as 2-methoxyethylamine, phenyl-(1-4C)alkylamines, such as benzylamine and amino acids, such as glycine or its esters.

[0229] Suitable pharmaceutically acceptable prodrugs of compounds of formula (I) or (II), or subformulae (II) to (I-XVIII) or II-I to II-VI, having an amino group are, for example, in vivo cleavable amide derivatives thereof. Suitable pharmaceutically acceptable amides derived from an amino group include, for example, amides formed with (1-10C)alkanoyl groups, such as acetyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl groups. Ring substituents on phenylacetyl and benzoyl groups include, for example, aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl, and 4-(1-4C)alkyl)piperazin-1-ylmethyl.

[0230] The in vivo effects of a compound of Formula (I) or Formula (II), or sub-formulas (II)-(I-XVIII) or II-I-II-VI, may be exerted in part by one or more metabolic products formed in the human or animal body following administration of a compound of Formula (I) or Formula (II), or sub-formulas (II)-(I-XVIII) or II-I-II-VI. As described below, the in vivo effects of a compound of Formula (I) or Formula (II), or sub-formulas (II)-(I-XVIII) or II-I-II-VI, may also be exerted by metabolism of a precursor compound (prodrug).

[0231] While the invention may relate to any compound or particular group of compounds defined herein as an optional, preferred or suitable feature or otherwise in relation to a particular embodiment, the invention may relate to any compound or particular group of compounds that specifically excludes said optional, preferred or suitable feature or particular embodiment.

[0232] The present invention suitably excludes any individual compound that does not have biological activity as defined herein.

[0233] [Synthesis] The compounds of the present invention can be prepared by any suitable technique known in the art. Certain methods for the preparation of these compounds are further described in the accompanying examples.

[0234] In the description of synthetic methods described herein and in any referenced synthetic methods used to prepare starting materials, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of experiment and work-up procedure, can be selected by one skilled in the art.

[0235] It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reaction conditions employed.

[0236] It will be appreciated that during the synthesis of the compounds according to the invention in the processes defined herein, or during the synthesis of some of the starting materials, it may be desirable to protect some of the substituents to prevent their undesired reactions. The skilled chemist will understand when such protection is required and how such protecting groups can be introduced and subsequently removed.

[0237] For examples of protecting groups, see one of the many general texts on the subject, such as 'Protective Groups in Organic Synthesis' by Theodora Green (published by John Wiley & Sons, Inc.) Protecting groups can be removed by any convenient method described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such method being chosen to effect removal of the protecting group with minimal disturbance to other groups in the molecule.

[0238] Thus, for example, if the reactants contain groups such as amino, carboxy or hydroxy, it may be desirable to protect the group in some of the reactions mentioned herein.

[0239] Suitable protecting groups for amino or alkylamino groups include, for example, acyl groups, such as alkanoyl groups, for example, acetyl, alkoxycarbonyl groups, for example, methoxycarbonyl, ethoxycarbonyl, or t-butoxycarbonyl groups, arylmethoxycarbonyl groups, for example, benzyloxycarbonyl, or aroyl groups, for example, benzoyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, acyl groups, such as alkanoyl or alkoxycarbonyl groups, or aroyl groups, can be removed, for example, by hydrolysis with a suitable base, for example, an alkali metal hydroxide, for example, lithium hydroxide or sodium hydroxide. Alternatively, an acyl group, for example, a tert-butoxycarbonyl group, may be removed by treatment with a suitable acid, for example, hydrochloric acid, sulfuric acid, or phosphoric acid or trifluoroacetic acid, and an arylmethoxycarbonyl group, for example, a benzyloxycarbonyl group, may be removed, for example, by hydrogenation over a catalyst, for example, palladium-on-carbon, or by treatment with a Lewis acid, for example, boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example, dimethylaminopropylamine, or with hydrazine.

[0240] Suitable protecting groups for hydroxy groups include, for example, acyl groups, such as alkanoyl groups, for example, acetyl, aroyl groups, for example, benzoyl, or arylmethyl groups, for example, benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, acyl groups, such as alkanoyl or aroyl groups, can be removed, for example, by hydrolysis with a suitable base, for example, an alkali metal hydroxide, such as lithium, sodium hydroxide, or ammonia. Alternatively, arylmethyl groups, such as benzyl groups, can be removed, for example, by hydrogenation over a catalyst, for example, palladium on carbon.

[0241] A suitable protecting group for a carboxy group is, for example, an esterifying group, a methyl or ethyl group which may be removed, for example, by hydrolysis with a base such as, for example, sodium hydroxide, or a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid, for example trifluoroacetic acid, or a benzyl group which may be removed, for example, by hydrogenation over a catalyst, for example palladium on carbon.

[0242] Resins can also be used as protecting groups.

[0243] The methodology used to synthesize compounds of formula (I), or subformulas (II) to (I-XVIII), is 2 , R 4 , R 6 , R 11 , R 11A , Y1, Y2, A2, A3 and A4 and the nature of any substituents or associated subgroups thereof. Suitable methods for their preparation are further described in the accompanying examples.

[0244] After a compound of formula (I), or sub-formulas (II) to (I-XVIII), has been synthesized by any one of the methods defined herein, the methods may then include the following further steps: (i) removing any protecting groups present; (ii) converting a compound of formula (I) into another compound of formula (I); (iii) forming a pharmaceutically acceptable salt, hydrate or solvate thereof; and / or (iv) forming a prodrug thereof It may further include:

[0245] An example of (ii) above is where a compound of formula (I) is synthesized and then R 2 , R 4 , R 6 , R 11 , R 11A, where one or more of the Y1, Y2, A2, A3 and A4 groups can be further reacted to change the nature of the group, providing alternative compounds of formula (I).

[0246] The resulting compounds of formula (I), or subformulas (II)-(I-XVIII), can be isolated and purified using techniques well known in the art.

[0247] Compounds of formula (I) can be synthesized by the synthetic routes shown in the Examples section below.

[0248] [Biological activity] The pharmacological effects of the compounds of the present invention can be determined using the biological assays described in the Examples section herein.

[0249] Although the pharmacological properties of compounds of formula (I) or formula (II) may vary with structural variations, as expected, compounds of the present invention have been found to be active in the PMS2 in vitro assay described in the Examples section.

[0250] [Pharmaceutical composition] According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound according to the invention as defined above, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in association with a pharmaceutically acceptable diluent or carrier.

[0251] Compositions according to the invention may be in a form suitable for oral use (e.g. as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), topical use (e.g. as creams, ointments, gels, or aqueous or oily solutions or suspensions), administration by inhalation (e.g. as a finely divided powder or liquid aerosol), administration by insufflation (e.g. as a finely divided powder) or parenteral administration (e.g. as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular administration or as a suppository for rectal administration).

[0252] The compositions according to the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more coloring agents, sweeteners, flavoring agents and / or preservatives.

[0253] An effective amount of a compound according to the invention for use in therapy is an amount sufficient to treat or prevent, slow the progression of and / or alleviate the symptoms associated with the proliferative conditions described herein.

[0254] The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending on the individual treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain from 0.5 mg to 0.5 g (more suitably, 0.5 to 100 mg, e.g., 1 to 30 mg) of active agent, combined with an appropriate and convenient amount of excipients, which may vary, for example, from about 5 to about 98 weight percent of the total composition.

[0255] The size of an administered dose of a compound of formula I for therapeutic or prophylactic purposes will, of course, vary with the nature and severity of the condition, the age and sex of the animal or patient, and the route of administration, according to well-known principles of medicine.

[0256] When using the compounds of the present invention for therapeutic or prophylactic purposes, they are generally administered in a daily dose range, for example, 0.1 mg / kg to 75 mg / kg body weight, taking into account the need for divided doses. Generally, lower doses are administered when parenteral routes are used. Thus, for example, for intravenous or intraperitoneal administration, a dose range, for example, 0.1 mg to 30 mg / kg body weight, is generally used. Similarly, for administration by inhalation, a dose range, for example, 0.05 mg to 25 mg / kg body weight, is used. Oral administration may also be appropriate, particularly in tablet form. Typically, a unit dosage form contains about 0.5 mg to 0.5 g of the compounds of the present invention.

[0257] Therapeutic Uses and Applications The present invention provides compounds that function as inhibitors of PMS2 activity.

[0258] The compounds of formula (I) or formula (II), or pharmaceutically acceptable salts thereof, have potential therapeutic use in a variety of disease states where inhibition of PMS2 activity is beneficial.

[0259] Accordingly, the present invention provides a method of treating a disease or disorder in which inhibition of PMS2 activity would be beneficial in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0260] The present invention provides a method for inhibiting PMS2 activity in vitro or in vivo, said method comprising the step of contacting a cell with an effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0261] The present invention provides a method of treating a proliferative disorder in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0262] The present invention provides a method of treating cancer in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0263] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use in therapy.

[0264] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use as a pharmaceutical.

[0265] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a proliferative disorder.

[0266] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition for use in the treatment of cancer. In a particular embodiment, the cancer is a human cancer. In a particular embodiment, the cancer is a human cancer, in particular an estrogen-positive cancer, such as breast cancer, or an androgen receptor-positive cancer, such as prostate cancer.

[0267] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in inhibiting PMS2 activity.

[0268] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a disease or disorder in which inhibition of PMS2 activity is beneficial.

[0269] The present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of a proliferative disorder.

[0270] The present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of cancer.

[0271] The present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the inhibition of PMS2 activity.

[0272] The present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of a disease or disorder in which inhibition of PMS2 activity is beneficial.

[0273] "Proliferative disorder," "proliferative condition," and "proliferative disease" are used interchangeably herein and relate to unwanted or uncontrolled cell proliferation, either in vitro or in vivo, of excessive or abnormal cells that are unwanted, e.g., neoplastic or hyperplastic growth.

[0274] In the aspect of the invention outlined above, the proliferative disorder is suitably cancer, and the cancer is suitably a human cancer. In particular, the compounds according to the invention are useful in the treatment of any cancer in which mismatch repair inhibition is beneficial.Any suitable cancer can be targeted (e.g., adenoid cystic carcinoma, adrenal tumor, amyloidosis, anal cancer, appendix cancer, astrocytoma, ataxia-telangiectasia, Beckwith-Wiedemann syndrome, bile duct cancer (cholangiocarcinoma), Birt-Hogg-Dubé syndrome, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, Carney complex, central nervous system tumor, cervical cancer, colorectal cancer, Cowden disease, craniopharyngioma, desmoplastic infantile ganglioglioma, ependymoma, esophageal cancer, Ewing's sarcoma, eye cancer, eyelid cancer, familial adenomatous polyposis, familial GIST, familial malignant melanoma, etc.). Chromoma, familial non-VHL clear cell renal cell carcinoma, familial pancreatic cancer, gallbladder cancer, gastrointestinal stromal tumor (GIST), germ cell tumor, gestational trophoblastic disease, head and neck cancer, hereditary breast and ovarian cancer, hereditary diffuse gastric cancer, hereditary leiomyomatosis and renal cell carcinoma, hereditary mixed polyposis syndrome, hereditary pancreatitis, hereditary papillary renal cell carcinoma, juvenile polyposis syndrome, kidney cancer, lacrimal gland tumors, laryngeal and hypopharyngeal cancer, leukemia (acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), B-cell prolymphocytic leukemia, hairy cell leukemia, chronic lymphocytic leukemia (CLL), chronic myeloblastic leukemia (CRL), Myeloid leukemia (CML), chronic T-cell lymphocytic leukemia, eosinophilic leukemia), Li-Fraumeni syndrome, liver cancer, lung cancer (non-small cell lung cancer, small cell lung cancer), lymphoma (Hodgkin, non-Hodgkin), Lynch syndrome, mastocytosis, medulloblastoma, melanoma, meningioma, mesothelioma, multiple endocrine neoplasia type 1 and type 2, multiple myeloma, MUTYH (or MYH)-associated polyposis, myelodysplastic syndrome (MDS), cancer of the nasal cavity and paranasal sinuses, nasopharyngeal carcinoma, neuroblastoma, neuroendocrine tumors (e.g., of the gastrointestinal tract, lung, or pancreas), neurofibromatosis type 1 and type 2, nevoid basal cell carcinoma syndrome , oral or oropharyngeal cancer, osteosarcoma, ovarian / fallopian tube / peritoneal cancer, pancreatic cancer, parathyroid cancer, penile cancer, Peutz-Jeghers syndrome, pheochromocytoma, paraganglioma, pituitary tumors, pleuropulmonary blastoma, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcomas (e.g., Kaposi or soft tissue), skin cancer, small intestine cancer, stomach cancer, testicular cancer, thymoma and thymic carcinoma, thyroid cancer, tuberous sclerosis, uterine cancer, vaginal cancer, von Hippel-Lindau syndrome, vulvar cancer, Waldenström's macroglobulinemia, Werner's syndrome, Wilms' tumor, and xeroderma pigmentosum).Particular cancers of interest include hematological cancers, such as lymphomas (including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt's lymphoma (BL), and angioimmunoblastic T-cell lymphoma (AITL)), leukemias (including acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML)), multiple myeloma, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, endometrial cancer, gastro-esophageal cancer, neuroendocrine cancer, osteosarcoma, prostate cancer, pancreatic cancer, small intestine cancer, bladder cancer, rectal cancer, cholangiocarcinoma, CNS cancer, thyroid cancer, head and neck cancer, esophageal cancer, and ovarian cancer.

[0275] The compounds of the present invention may also be used to treat triplet repeat disorders.

[0276] Accordingly, a further aspect of the present invention provides a method of treating a triplet repeat disorder (e.g., Huntington's disease (HD), myotonic dystrophy type 1 (DM1), Fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar ataxias (SCAs)) in a patient in need of such treatment, said method comprising the step of administering to said patient a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.

[0277] According to a further aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use in the treatment of a triplet repeat disorder, in particular embodiments, the triplet repeat disorder is selected from the group consisting of Huntington's disease (HD), myotonic dystrophy type 1 (DM1), fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar degeneration (SCAs).

[0278] According to a further aspect of the present invention there is provided the use of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, in the manufacture of a medicament for the treatment of a triplet repeat disorder, in particular embodiments, the triplet repeat disorder is selected from the group consisting of Huntington's disease (HD), myotonic dystrophy type 1 (DM1), fragile X syndrome type A (FRAXA), Friedreich's ataxia (FRDA), and spinocerebellar degeneration (SCAs).

[0279] (Route of administration) The compounds of the present invention or pharmaceutical compositions containing these compounds can be administered to a subject by any convenient route of administration, whether systemic, peripheral, or local (i.e., at the desired site of action).

[0280] Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, e.g., patches, plasters, etc.); transmucosally (including, e.g., patches, plasters, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy, e.g., via aerosol, e.g., through the mouth or nose, using); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); by injection, including, e.g., intratumoral, subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intraarticular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; parenterally, e.g., by a depot or reservoir placement, subcutaneously or intramuscularly.

[0281] (combination therapy) The compounds of the present invention may be administered as a monotherapy, or may be administered in addition to conventional surgery or radiation therapy or chemotherapy or targeted agents, which may include one or more of the following categories: (i) As used in medical oncology, antiproliferative / antineoplastic agents and combinations thereof, including, but not limited to, alkylating agents (e.g., cisplatin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulfan, temozolamide, and nitrosoureas); antimetabolites (e.g., gemcitabine and antifolates, e.g., fluoropyrimidines such as 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumor antibiotics anti-mitotic agents (e.g., anthracyclines such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin, and mithramycin); anti-mitotic agents (e.g., vinca alkaloids such as vincristine, vinblastine, vindesine, and vinorelbine, and taxoids such as taxol and taxotere, and polokinase inhibitors); and topoisomerase inhibitors (e.g., epipodophyllotoxins such as etoposide and teniposide, amsacrine, camptothecins including topotecan, and irinotecan); (ii) Cytostatic agents, such as, but not limited to, steroid hormones including antiestrogens (e.g., tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene, and iodoxyfene), antiandrogens (e.g., bicalutamide, flutamide, nilutamide, and cyproterone acetate), LHRH antagonists or agonists (e.g., goserelin, leuprorelin, and buserelin), progestogens (e.g., megestrol acetate), and corticosteroids (e.g., dexamethasone, prednisone, and prednisolone), aromatase inhibitors (such as anastrozole, letrozole, vorazole, and exemestane), and inhibitors of 5α-reductase, such as finasteride; (iii) anti-invasion agents, for example, but not limited to, the c-Src kinase family inhibitor 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (AZD0530; International Patent Application Publication No. WO 01 / 94341), N-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825; J. Med. Chem., 2004, 47, 6658-6661), bosutinib (SKI-606), and metalloproteinase inhibitors, such as marimastat, inhibitors of urokinase-type plasminogen activator receptor function or antibodies against heparanase; (iv) inhibitors of growth factor function, including, but not limited to, growth factor antibodies and growth factor receptor antibodies (e.g., the anti-erbB2 antibody trastuzumab [Herceptin®], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetuximab [Erbitux, C225], and the antibody described by Stern et al. (Critical reviews in oncology / haematology, 2005, Vol. 54, and any growth factor or growth factor receptor antibody disclosed by I. M. Schmidt, M ... inhibitors of the platelet-derived growth factor family, such as imatinib and / or nilotinib (AMN107); inhibitors of serine / threonine kinases (e.g., Ras / Raf signaling inhibitors, such as farnesyltransferase inhibitors, e.g., sorafenib (BAY43-9006), tipifarnib (R115777) and lonafarnib (SCH66336)), inhibitors of cell signaling via MEK and / or AKT kinase, c-kit inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-1R kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; Aurora kinase inhibitors and cyclin-dependent kinase inhibitors, such as CDK2 and / or CDK4 inhibitors; (v) antiangiogenic agents, including, but not limited to, those that inhibit the effects of vascular endothelial growth factor [e.g., the anti-vascular endothelial growth factor antibody bevacizumab (Avastin™) and, for example, VEGF receptor tyrosine kinase inhibitors, such as vandetanib (ZD6474), vatalanib (PTK787), sunitinib (SU11248), axitinib (AG-013736), and pazopanib (GW786034); (vi) vascular damaging agents, such as, but not limited to, combretastatin A4 and compounds disclosed in International Patent Application Publications WO99 / 02166, WO00 / 40529, WO00 / 41669, WO01 / 92224, WO02 / 04434 and WO02 / 08213; (vii) endothelin receptor antagonists, such as zibotentan (ZD4054) or atrasentan; (viii) antisense therapy, including but not limited to those directed to the targets set forth above, e.g., ISIS2503, anti-ras antisense, etc.; (ix) Immunotherapeutic approaches, including, for example, cancer vaccines, antibodies, viruses (oncolytic viruses), and small molecule or cell therapy approaches to increase the immunogenicity of a patient's tumor cells and / or facilitate a cell-mediated anti-tumor response. Such therapies may include, but are not limited to, OX40 agonists, cGAS-STING agonists, ENPP1 inhibitors, CD38 inhibitors, TBK1 inhibitors, A2a receptor antagonists, PI3 kinase inhibitors, TLR7 / 8 agonists, IDO inhibitors, arginase inhibitors, BTK inhibitors, and bromodomain inhibitors; transduction of cancer antigens by microbial vectors; direct transduction of cancer antigens into antigen-presenting cells; treatment with cancer antigen-specific immune cells (e.g., CAR-T); treatment with antibodies, antibody fragments, and antibody-drug conjugates that enable the immune system to recognize tumor cells.

[0282] Such conjoint treatment may be achieved by the simultaneous, sequential or separate administration of the individual components of the treatment. Such combination products utilize the compounds of this invention within the dosage ranges described hereinabove and the other pharmaceutically active agent(s) within their approved dosage ranges.

[0283] According to one aspect of the present invention, there is provided a combination for use in the treatment of cancer (e.g. cancer involving solid tumors) comprising a compound according to the invention as defined above, or a pharmaceutically acceptable salt or solvate thereof, and an anti-tumor agent.

[0284] According to one aspect of the present invention, there is provided a combination for use in the treatment of a proliferative condition, such as cancer (e.g., a cancer associated with a solid tumor), comprising a compound according to the invention as defined above, or a pharmaceutically acceptable salt or solvate thereof, and any one of the anti-tumor agents set out in the specification above.

[0285] In a further aspect of the present invention, there is provided a compound according to the invention, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of cancer, optionally in combination with another anti-tumour agent selected from those set out in the specification above.

[0286] In a further aspect of the present invention there is provided a compound according to the invention or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of cancer, optionally in combination with a tyrosine kinase inhibitor, optionally selected from those set out hereinabove.

[0287] When the term "combination" is used herein, it is understood to mean simultaneous, separate or sequential administration. In one aspect of the present invention, "combination" means simultaneous administration. In another aspect of the present invention, "combination" means separate administration. In a further aspect of the present invention, "combination" means sequential administration. When administration is sequential or separate, a delay in administering the second component should not, for example, result in the loss of the beneficial effect of the combination.

[0288] According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound according to the present invention, or a pharmaceutically acceptable salt or solvate thereof, in combination with an anti-tumour agent (optionally selected from those set out in the specification above), in association with a pharmaceutically acceptable diluent or carrier.

[0289] [Combination therapy with immunomodulation therapy] (immune checkpoint inhibitors) Immune checkpoint proteins present in immune cells and / or cancer cells (e.g., CTLA4 (also known as cytotoxic T-lymphocyte-associated protein 4 and CD152), LAG3 (also known as lymphocyte-activation gene 3 and CD223), PD1 (also known as programmed cell death protein 1 and CD279), PD-L1 (also known as programmed death-ligand 1 and CD274), TIM-3 (also known as T-cell immunoglobulin mucin-3), and TIGIT (also known as T-cell immunoreceptor with Ig and ITIM domains) are molecular targets that have been found to play an important role in regulating anti-tumor immune responses. Inhibitors of these immune checkpoint proteins (e.g., CTLA4, LAG3, PD1, PD-L1, TIM-3, and / or TIGIT inhibitors) promote anti-tumor immune responses that can be used to effectively treat some forms of cancer.

[0290] (immunostimulants) Monoclonal antibodies, bispecific antibodies, recombinant ligands, and small molecule therapeutics that bind to stimulatory receptors on immune cells can facilitate effective anti-tumor responses. Such receptors may be involved in cell-to-cell contact, e.g., contact between tumor cells and immune cells or contact between two types of immune cells, while other receptors may bind to soluble factors that stimulate an immune response. In one such embodiment, the antibody, bispecific antibody, recombinant protein, or small molecule therapeutic can activate stimulatory receptors, including, but not limited to, 4-1BB, OX40, cGAS-STING, CD27, CD40, and DR3, which enhance anti-tumor immunity.

[0291] Modulators of antigen processing can facilitate the presentation of neoantigenic peptides on the cell surface to enhance effective anti-tumor responses. In one such embodiment, inhibitors of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 can stimulate anti-tumor immunity.

[0292] In one aspect, the invention relates to a combination comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor or immunostimulant as defined herein, or a pharmaceutically acceptable salt thereof, for use in the treatment of a proliferative disorder.

[0293] In another aspect, the invention relates to the use of a combination comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor or immunostimulant as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a proliferative disorder.

[0294] In another aspect, the present invention relates to a method of treating a proliferative disorder in a subject in need thereof, comprising administering to said subject a combination comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor or immunostimulant as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein.

[0295] In another aspect, the present invention relates to a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of a proliferative disorder, wherein the compound, or a pharmaceutically acceptable salt thereof, is for simultaneous, separate or sequential administration with an immune checkpoint inhibitor, or an immunostimulant, or a pharmaceutically acceptable salt thereof.

[0296] In another aspect, the present invention relates to an immune checkpoint inhibitor or immunostimulant, or a pharmaceutically acceptable salt thereof, for use in the treatment of a proliferative disorder, wherein the immune checkpoint inhibitor is in the case of simultaneous, separate or sequential administration with a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein.

[0297] In another aspect, the invention relates to the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein, in the manufacture of a medicament for the treatment of a proliferative disorder, wherein the medicament is for simultaneous, separate or sequential administration with an immune checkpoint inhibitor or an immunostimulant, or a pharmaceutically acceptable salt thereof.

[0298] In another aspect, the invention relates to the use of an immune checkpoint inhibitor or immunostimulant, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a proliferative disorder, wherein the medicament is for simultaneous, separate or sequential administration with a compound as defined herein, or a pharmaceutically acceptable salt thereof.

[0299] In another aspect, the present invention relates to a method of treating a proliferative disorder comprising the step of sequentially, separately or simultaneously administering to a subject in need thereof therapeutically effective amounts of a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein, and an immune checkpoint inhibitor or immunostimulant as defined herein, or a pharmaceutically acceptable salt thereof.

[0300] Any immune checkpoint inhibitor or immunostimulatory agent can be used in combination therapy as defined herein.

[0301] In one aspect, the immune stimulator is selected from a 4-1BB stimulator, an OX40 stimulator, a CD27 stimulator, a CD40 stimulator, and a DR3 stimulator. In another embodiment, the immune checkpoint inhibitor is selected from a PD1 inhibitor, a PD-L1 inhibitor, a LAG3 inhibitor, a CTLA-4 inhibitor, a TIM-3 inhibitor, and / or a TIGIT inhibitor. In a detailed embodiment, the immune checkpoint inhibitor is a PD1 or PD-L1 inhibitor.

[0302] PD-1 is a cell surface receptor protein present on immune cells, such as T cells. PD-1 plays an important role in promoting self-tolerance by downregulating the immune system and suppressing T cell activation. PD-1 protein is an immune checkpoint that monitors autoimmunity through a dual mechanism: it promotes apoptosis (programmed cell death) of antigen-specific T cells in lymph nodes, while simultaneously reducing apoptosis in regulatory T cells (anti-inflammatory suppressor T cells).

[0303] PD-1 therefore suppresses the immune system, which prevents autoimmune diseases but can also prevent the immune system from killing cancer cells.

[0304] PD1 binds to two ligands, PD-L1 and PD-L2. PD-L1 is of particular interest because it is highly expressed in several cancers, and its role in cancer immune evasion is therefore well established. Monoclonal antibodies targeting PD-1 to boost the immune system have been approved or are being developed for the treatment of cancer. Many tumor cells express PD-L1, the immunosuppressive PD-1 ligand; inhibiting the interaction between PD-1 and PD-L1 can enhance T-cell responses in vitro and mediate pro-oncogenic antitumor activity. This is known as immune checkpoint blockade.

[0305] Drugs that target PD-1 include, for example, pembrolizumab (Keytruda) and nivolumab (Opdivo). These drugs have been shown to be effective in treating several types of cancer, including melanoma of the skin, non-small cell lung cancer, renal cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. They are also being investigated for use against many other types of cancer. Drugs in development include, for example, BMS-936559 (Bristol Myers Squibb), MGA012 (MacroGenics), and MEDI-0680 (MedImmune).

[0306] Drugs that inhibit PD-L1 include, for example, atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi). These drugs have also been shown to be useful in treating different types of cancer, including bladder cancer, non-small cell lung cancer, and Merkel cell skin cancer (Merkel cell carcinoma). They are also being studied for use in other types of cancer.

[0307] LAG3 inhibitors include, for example, BMS-986016 / Relatlimab, TSR-033, REGN3767, MGD013 (bispecific DART combining PD-1 and LAG-3), GSK2831781, and LAG525.

[0308] CTLA-4 inhibitors include, for example, MDX-010 / ipilimumab, AGEN1884, and CP-675,206 / tremelimumab.

[0309] TIM-3 inhibitors include, for example, MBG453 (Novartis), TSR-022 (Tesaro), and LY3321367 (Lilly).

[0310] TIGIT inhibitors include, for example, tiragolumab (MTIG7192A; RG6058; Genentech / Roche), AB154 (Arcus Bioscience), MK-7684 (Merck), BMS-986207 (Bristol-Myers Squibb), and ASP8374 (Astellas Pharma; Potenza Therapeutics).

[0311] In one embodiment, the immune checkpoint inhibitor is selected from BMS-986016 / leratolimab, TSR-033, REGN3767, MGD013 (bispecific DART combining PD-1 and LAG-3), GSK2831781, LAG525, MDX-010 / ipilimumab, AGEN1884, and CP-675,206 / tremelimumab, pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, MBG453, TSR-022, LY3321367, tiragolumab (MTIG7192A; RG6058), AB154, MK-7684, BMS-986207, and / or ASP8374, or a pharmaceutically acceptable salt or solvate thereof.

[0312] [Combination therapy with DNA damage response modulators] The compounds of the present invention are particularly suitable for use in combination with agents that function as DNA damage response modulators, such as PARP inhibitors, ATM inhibitors and ATR inhibitors.

[0313] In one aspect, the invention relates to a combination comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and a DNA damage response modulator (e.g. a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor), or a pharmaceutically acceptable salt thereof, for use in the treatment of a proliferative disorder.

[0314] In another aspect, the invention relates to the use of a combination comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and a DNA damage response modulator (e.g. a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a proliferative disorder.

[0315] In another aspect, the present invention relates to a method of treating a proliferative disorder in a subject in need thereof, comprising administering to said subject a combination comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and a DNA damage response modulator (e.g. a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor), or a pharmaceutically acceptable salt thereof, as defined herein.

[0316] In another aspect, the present invention relates to a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of a proliferative disorder, wherein the compound, or a pharmaceutically acceptable salt thereof, is administered simultaneously, separately or sequentially with a DNA damage response modulator (e.g., a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor), or a pharmaceutically acceptable salt thereof.

[0317] In another aspect, the invention relates to the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein, in the manufacture of a medicament for the treatment of a proliferative disorder, wherein the medicament is for simultaneous, separate or sequential administration with a DNA damage response modulator (e.g., a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor), or a pharmaceutically acceptable salt thereof.

[0318] In another aspect, the present invention relates to a method of treating a proliferative disorder, comprising the step of sequentially, separately or simultaneously administering to a subject in need thereof therapeutically effective amounts of a compound as defined herein, or a pharmaceutically acceptable salt thereof, as defined herein, and a DNA damage response modulator (e.g., a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor), or a pharmaceutically acceptable salt thereof.

[0319] Any DNA damage response modulator (eg, a PARP inhibitor, an ATM inhibitor and / or an ATR inhibitor) can be used in combination therapy as defined herein. [Example]

[0320] While particular embodiments of the present invention have been described above for purposes of reference and example, various modifications will be apparent to those skilled in the art without departing from the scope of the invention as defined by the appended claims. [Abbreviation] Boc is tert-butyloxycarbonyl DAST is diethylaminosulfur trifluoride DBU is 1,8-diazabicyclo(5.4.0)undec-7-ene DCC is dicyclohexylcarbodiimide DCE is 1,1-dichloroethane DCM is dichloromethane DEA is diethanolamine DEAD is diethyl azodicarboxylate DIAD is diisopropyl azodicarboxylate DIBAL is diisobutylaluminum hydride DIPEA is N,N-diisopropylethylamine, Hunig's base DMA is N,N-dimethylacetamide DMAP is 4-(dimethylamino)pyridine DMF is N,N-dimethylformamide DMSO is dimethyl sulfoxide. EDC is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EtOAc is ethyl acetate h is the time HATU is N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide HBTU is (1H-benzotriazol-1-yloxy)(dimethylamino)-N,N-dimethylmethaniminium hexafluorophosphate HOBT is N-hydroxybenzotriazole HPLC is high pressure liquid chromatography. LAH is lithium aluminum hydride IPA is isopropyl alcohol LCMS, liquid chromatography-mass spectrometry LDA is lithium diisopropylamide LiHMDS is lithium bis(trimethylsilyl)amide mCPBA is meta-chloroperbenzoic acid MI is the molecular ion Min is minutes MgSO4 Anhydrous Magnesium Sulfate MW is microwave NBS is N-bromosuccinamide NCS is N-chlorosuccinamide NFOBS is N-fluoro-o-benzenedisulfonimide NFSI is N-fluorobenzenesulfonimide NHS is N-hydroxysuccinimide NIS is N-iodosuccinamide NMM is N-methylmorpholine NMP is 1-methyl-2-pyrrolidinone NMR is nuclear magnetic resonance. PdCl2(PPh3)2 is bis(triphenylphosphine)palladium chloride Pd(dppf)2Cl2 is [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II). Pd(dppf)2Cl2.DCM is the [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with DCM (Pd(dba)2) is bis(dibenzylideneacetone)palladium Rbf round bottom flask RT is retention time. SCX-2 is a silica-based sorbent with chemically bonded propylsulfonic acid functional groups. SFC stands for supercritical fluid chromatography TBAF is tetra-n-butylammonium fluoride TBDMS is tert-butyldimethylsilyl TFAA is trifluoroacetic anhydride TFA is trifluoroacetic acid THF is tetrahydrofuran T3P is propylphosphonic anhydride Ts is p-toluenesulfonyl XPhos-Pd-G1 is 2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II) chloride XPhos-Pd-G2 is chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II).

[0321] [Analysis method] Commercially available starting materials, reagents, and dry solvents were used as supplied. Flash or glass column chromatography was performed using Merck silica gel 230-400 mesh size. Flash chromatography was also performed on a combi-flash RF Teledyne Isco instrument. Preparative TLC was performed on Merck plates.

[0322] (liquid chromatography-mass spectrometry) (Method-A) Waters Acquity UPLC with binary solvent manager, PDA detector, and Acquity QDA performance mass detector; Column: X-Bridge BEH C18, 50 × 2.1 mm, 2.5 micron; Column temperature: 35 °C; Autosampler temperature: 5 °C; Mobile phase A: 0.1% (v / v) formic acid in water (pH = 2.70); Mobile phase B: 0.1% formic acid in water (v / v):acetonitrile (10:90); Mobile phase gradient details: t = 0 min (97% A, 3% B) flow rate: 0.8 mL / min; t = 0.75 min (97% A, 3% B) flow rate: 0.8 mL / min; Gradient to t = 2.7 min (2% A, 98% B) flow rate: 0.8 mL / min; Gradient to t = 3 min (0% A, 100% B) flow rate: 1 mL / min; t = 3.5 min (0% A, 100% B) flow rate: 1 mL / min B) Flow rate: 1 mL / min; gradient (97% A, 3% B) until t = 3.51 min; flow rate: 0.8 mL / min; run ended at t = 4 min (97% A, 3% B), flow rate: 0.8 mL / min, analysis time 4 min. Mass detector parameters: ionization mode cycled in positive and negative modes with cone voltages of 10 V and 30 V and capillary voltage of 0.8 kV; source and probe temperatures were 120 °C and 600 °C, respectively.

[0323] (Method-D) Waters Acquity UPLC with quaternary solvent manager, PDA detector, and SQ detector; Column: X-Bridge BEH C18, 50 × 2.1 mm, 2.5 micron; Column temperature: 35 °C; Autosampler temperature: 5 °C; Mobile phase A: 0.1% (v / v) formic acid in water (pH = 2.70); Mobile phase B: 0.1% (v / v) formic acid in water:acetonitrile (10:90); Mobile phase gradient details: t = 0 min (97% A, 3% B) flow rate: 0.8 mL / min; t = 0.75 min (97% A, 3% B) flow rate: 0.8 mL / min; Gradient to t = 2.7 min (2% A, 98% B) flow rate: 0.8 mL / min; Gradient to t = 3 min (0% A, 100% B) flow rate: 1 mL / min; t = 3.5 min (0% A, 100% B) flow rate: 1 mL / min B) Flow rate: 1 mL / min; gradient (97% A, 3% B) until t = 3.51 min; flow rate: 0.8 mL / min; run ended at t = 4 min (97% A, 3% B), flow rate: 0.8 mL / min, analysis time 4 min. Mass detector parameters: ESI capillary probe, ionization mode cycled in positive and negative modes with cone voltages of 10 V and 30 V and capillary voltage of 0.8 kV, source and probe temperatures were 120 °C and 400 °C, respectively.

[0324] (Method-E) Waters Acquity UPLC with binary solvent manager, PDA detector, and Acquity QDA performance mass detector; Column: Welch Xtimate C18, 50 × 2.1 mm, 1.8 micron; Column temperature: 35 °C; Autosampler temperature: 5 °C; Mobile phase A: 0.1% (v / v) formic acid in water (pH = 2.70); Mobile phase B: 0.1% formic acid in water (v / v):acetonitrile (10:90); Mobile phase gradient details: t = 0 min (97% A, 3% B) flow rate: 0.8 mL / min; t = 0.75 min (97% A, 3% B) flow rate: 0.8 mL / min; Gradient to t = 2.7 min (2% A, 98% B) flow rate: 0.8 mL / min; Gradient to t = 3 min (0% A, 100% B) flow rate: 1 mL / min; t = 3.5 min (0% A, 100% B) flow rate: 1 mL / min B) Flow rate: 1 mL / min; gradient (97% A, 3% B) until t = 3.51 min; flow rate: 0.8 mL / min; run ended at t = 4 min (97% A, 3% B), flow rate: 0.8 mL / min, analysis time 4 min. Mass detector parameters: ionization mode cycled in positive and negative modes with cone voltages of 10 V and 30 V and capillary voltage of 0.8 kV; source and probe temperatures were 120 °C and 600 °C, respectively.

[0325] (Method-H) The Waters 996 Photodiode Array Detector was equipped with a Waters Micromass ZQ detector. Column: XTIMATE C18 5 μm 4.6 × 150 mm. Column temperature: 35 °C. Autosampler temperature: 15 °C. Mobile phase A: 5 mM ammonium acetate and 0.1% formic acid in Milli-Q water (pH = 3.50). Mobile phase B: methanol. Mobile phase gradient details: T = 0 min (90% A, 10% B); T = 7.0 min (10% A, 90% B); gradient to T = 9.0 min (0% A, 100% B); gradient to T = 14.00 min (0% A, 100% B); T = 14.01 min (90% A, 10% B); run termination at T = 17 min (90% A, 10% B). Flow rate: 1.0 mL / min. Run time: 17 min. UV detection method: PDA. Mass parameters: Probe: ESI, Mode of ionization: positive and negative, Cone voltage: -30 and 10V, Capillary voltage: - 3.0KV, Extractor voltage: -2V, Rf lens: - 0.1V, Source temperature: -120°C, Probe temperature: - 400°C, Cone gas flow: - 100L / Hr, Desolvation gas flow: -800L / Hr.

[0326] (Analytical HPLC method) (Method A) The compounds were eluted using a Shimadzu LC20AP purification system equipped with a UV detector and a YMC-Actus Triart prep 250 x 20 mm, 5 μm column. Mobile phase A: 0.1% formic acid in Milli-Q water; mobile phase B: acetonitrile; gradient T = 0 min (63% A, 37% B); gradient T = 20 min (45% A, 55% B); gradient T = 20.01 min (2% A, 98% B); gradient T = 24 min (2% A, 98% B); gradient T = 24.01 min (63% A, 37% B) to T = 28 min (63% A, 37% B); flow rate = 16 ml / min; run time 28 min.

[0327] (Method B) A Buchi Prep Chrom C700 with UV detector system was used, using a YMC120 gm C18, 50 μm column. Compounds were eluted with mobile phase A: 0.1% formic acid in Milli Q water; mobile phase B: acetonitrile; gradient T = 0 min (100% A, 0% B); gradient (50% A, 50% B) to T = 30 min; gradient (2% A, 98% B) to T = 35 min; gradient (2% A, 98% B) to T = 35 min; gradient (100% A, 0% B) to T = 40 min (100% A, 0% B); flow rate = 80 ml / min. Analysis time: 40 min.

[0328] (Method C) A Waters 2545 system equipped with a UV detector was used with an X-Bridge Prep, C18, OBD (250 x 19) mm, 5 μm column. Compounds were eluted with mobile phase A: 5 mM ammonium bicarbonate in 0.05% ammonia / water. Mobile phase B: acetonitrile; gradient from T = 0 min (58% A, 42% B); to T = 22 min (2% A, 98% B); T = 22.01 min (2% A, 98% B); and T = 25 min (58% A, 42% B). Flow rate = 16 ml / min.

[0329] (Method D) A Waters 2545 system equipped with a UV detector was used with an X-Bridge Prep, C18, OBD (250 x 19) mm, 5 μm column. Compounds were eluted with mobile phase A: 0.05% ammonia in water, mobile phase B: acetonitrile; gradient T = 0 min (85% A, 15% B); gradient to T = 17 min (68% A, 32% B); T = 17.01 min (2% A, 98% B); T = 19 min (85% A, 15% B). Flow rate = 21 ml / min.

[0330] (Method E) A Waters 2545 system equipped with a UV detector was used with a YMC-ODS AQ C18 (250 x 20) mm, 5 μm column. Compounds were eluted with mobile phase A: 0.1% formic acid in water, mobile phase B: 20% A in acetonitrile; gradient T = 0 min (75% A, 25% B); gradient T = 19 min (60% A, 40% B); T = 19.01 min (2% A, 98% B); T = 25 min (75% A, 25% B). Flow rate = 17 ml / min.

[0331] [Compound Preparation] [Example 1]: N-(2-(2-(benzyloxy)-4,6-dihydroxybenzoyl)isoindolin-4-yl)acrylamide [ka]

[0332] A stirred solution of (4-aminoisoindolin-2-yl)(2-(benzyloxy)-4,6-dihydroxyphenyl)methanone (Intermediate 1) (0.2 g, 0.53 mmol, 1 eq.) in AcOH (5 mL) at 0 °C was treated with acrylic anhydride (CAS 2051-76-5, 0.067 g, 0.53 mmol, 1.0 eq.). The reaction mixture was stirred at room temperature for 1 h, poured into ice-cold water (5 mL), neutralized using saturated NaHCO solution, and extracted into ethyl acetate (3 × 50 mL). The combined organic layers were washed with brine solution (200 mL), dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (product was eluted with 1.7% MeOH in DCM) to give the title compound (0.085 g, 37% yield) as an off-white solid.

[0333] 1H NMR (DMSO-d6, 400 MHz): δ 4.50 (bs, 2H), 4.71 - 4.75 (m, 2H), 5.03 (s, 2H), 5.70 - 5.80 (m, 1H), 5.99 - 6.01 (m, 2H), 6.19 - 6.31 (m, 1H), 6.42 - 6.60 (m, 1H), 7.04 (d, J= 7.6 Hz, 1H), 7.15 - 7.31 (m, 6H), 7.62 - 7.65 (m, 1H), 9.51 (bs, 1H), 9.65 (bs, 1H), 9.78 (bs, 1H). LCMS (Method A) 1.538 min, MS ES+ 431.17 (M+1).

[0334] [Example 2]: (E)-N-(2-(2-(benzyloxy)-4,6-dihydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide [ka]

[0335] A stirred solution of (4-aminoisoindolin-2-yl)(2-(benzyloxy)-4,6-dihydroxyphenyl)methanone (Intermediate 1) (0.2 g, 0.52 mmol, 0.3 eq.) and (E)-4-(dimethylamino)but-2-enoic acid hydrochloride (CAS 848133-35-7; 0.292 g, 1.75 mmol, 1.0 eq.) in DMF (0.3 mL) in a 10 mL microwave tube at room temperature was treated with DCC (0.364 g, 1.75 mmol, 1 eq.). The reaction mixture was heated to 150 °C under microwave conditions for 15 min. The reaction mixture was poured into ice-cold water (70 mL) and washed with ethyl acetate (3 × 50 mL; the product is water soluble). The aqueous layer was concentrated under vacuum to give the crude material (0.60 g). The crude material was purified by preparative HPLC (Method B) to give the title compound (0.097 g, 26% yield) as an off-white solid.

[0336] 1H NMR (DMSO-d6, 400 MHz): δ 2.15 (s, 3H), 2.20 (s, 3H), 3.03 - 3.09 (dd, J= 4.8, 20 Hz, 2H), 4.51 (s, 2H), 4.74 (d, J= 12.8 Hz, 2H), 5.04 (s, 2H), 6.00 - 6.01 (m, 2H), 6.29 - 6.33 (m, 1H), 6.41 - 6.45 (m, 1H), 6.67 - 6.78 (m, 1H), 7.02 - 7.31 (m, 7H), 7.68 (d, J= 8 Hz, 1H), 9.53 (s, 1H), 9.60 (s, 1H), 9.68 (s, 1H). LCMS (Method A): 1.221 min, MS: ES+ 488.1 (M+1).

[0337] [Example 3]: N-(2-(2-(benzyloxy)-4,6-dihydroxy-benzoyl)isoindolin-4-yl)-2-fluoroacrylamide [ka]

[0338] A stirred solution of (4-aminoisoindolin-2-yl)(2-(benzyloxy)-4,6-dihydroxyphenyl)methanone (Intermediate 1) (0.1 g, 0.26 mmol, 1 eq.) in ethyl acetate (2 mL) was cooled to 0 °C; molecular sieves (0.05 g), TEA (0.214 g, 2.14 mmol, 8 eq.), 2-fluoroacrylic acid (CAS: 430-9-90; 047 g, 0.53 mmol, 2 eq.), and T3P (50% in ethyl acetate) (0.25 mL, 0.79 mmol, 3.0 eq.) were added. The resulting reaction mixture was stirred at room temperature for 16 h. The resulting reaction mixture was poured into water (25 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography (product was eluted with 5% methanol in DCM) to give the title compound (0.022 g, yield: 9.3%).

[0339] 1 H NMR (DMSO-d6, 400 MHz): δ 4.47 - 4.52 (m, 2H), 4.67 - 4.77 (m, 2H), 5.03 (s, 2H), 5.35 - 5.39 (m, 1H), 5.58 - 5.79 (m, 1H), 5.98 - 6.01 (m, 2H), 7.22 - 7.36 (m, 8H), 9.50 - 9.59 (m, 2H), 10.15 - 10.26 (m, 1H). LCMS (Method A): 1.579 min, MS ES+ 449.20 (M+1).

[0340] [Example 4]: N-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)acrylamide [ka]

[0341] A stirred solution of (4-aminoisoindolin-2-yl)(2-(benzyloxy)-4,6-dihydroxy-3-methylphenyl)methanone (Intermediate 2) (0.2 g, 0.51 mmol, 1 eq.) in AcOH (0.7 mL) at 0 °C was treated with acrylic anhydride (0.071 g, 0.56 mmol, 1.1 eq.). The reaction mixture was stirred at room temperature for 30 min, then neutralized using saturated NaHCO (pH = 6-7) and extracted into ethyl acetate (3 × 50 mL). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (product was eluted with 2.4% MeOH in DCM) to give the title compound (0.070 g, 0.16 mmol. Yield: 30.7%) as an off-white solid.

[0342] 1H NMR (DMSO-d6, 400 MHz): δ 1.97 (s, 3H), 4.44 - 4.50 (m, 1H), 4.57 - 4.61 (m, 1H), 4.72 - 4.78 (m, 3H), 4.90 - 4.93 (m, 1H), 5.69 - 5.82 (m, 1H), 6.18 - 6.32 (m, 2H), 6.41 - 6.59 (m, 1H), 7.02 - 7.18 (m, 1H), 7.23 - 7.34 (m, 6H), 7.66 (d, J= 8.0 Hz, 1H), 9.52 (d, J= 6.0 Hz, 1H), 9.56 (s, 1H), 9.78 (s, 1H). LCMS (Method A): 1.756 min, MS: ES+ 445.2. Analytical HPLC Method A: 6.425 min, 210 nm, 95.1%.

[0343] [Example 5]: N-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-2-fluoroacrylamide [ka]

[0344] A stirred solution of (4-aminoisoindolin-2-yl)(2-(benzyloxy)-4,6-dihydroxy-3-methylphenyl)methanone (Intermediate 2) (0.080 g, 0.0.20 mmol, 1.0 eq.) in ethyl acetate (2 mL) was cooled to 0 °C and treated with molecular sieves (0.5 g), TEA (0.166 g, 1.64 mmol, 8 eq.), 2-fluoroacrylic acid (0.036 g, 0.41 mmol, 2 eq.) (CAS: 430-9-9), and T3P (50% in EtOAc) (0.39 g, 0.61 mmol, 3.0 eq.). The resulting reaction mixture was stirred at room temperature for 16 h, then poured into water (25 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The resulting crude material was purified by preparative TLC (5% methanol in DCM) to give the title compound (0.010 g, yield: 10.6%).

[0345] 1 H NMR (DMSO-d6, 400 MHz): The compound is a mixture of rotamers: 1.97 (s, 3H), 4.45 - 4.54 (m, 2H), 4.59 - 4.79 (m, 3H), 4.90 - 4.93 (m, 1H), 5.36 - 5.40 (m, 2H), 5.49 - 5.70 (m, 1H), 6.31 (two singlets, 1H), 7.15 - 7.37 (m, 8H), 9.56 - 9.59 (m, 2H, DO interchangeable), 10.12 - 10.29 (bs, 1H, DO interchangeable). LCMS (Method A): 1.798 min, MS: ES+ 463.17 (M+1).

[0346] [Example 6]: (E)-N-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide [ka]

[0347] A stirred solution of (E)-4-(dimethylamino)but-2-enoic acid hydrochloride (CAS 848133-35-7; 0.141 g, 0.85 mmol, 1 eq.) and 4-(4-aminoisoindoline-2-carbonyl)-5-(benzyloxy)-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate) (Intermediate 2) (0.1 g, 0.25 mmol, 0.3 eq.) in a microwave vial at room temperature was treated with DCC (0.212 g, 1.03 mmol, 2 eq.) and DMF (0.1 mL). The resulting reaction mixture was heated to 150 °C and stirred for 15 min under microwave irradiation. The reaction mixture was poured into ice-cold water (100 mL) and extracted with ethyl acetate (3 × 50 mL). The desired product was water-soluble, and the aqueous layer was concentrated under vacuum. The crude material was purified by preparative HPLC (Method A). The pure fractions were lyophilized to give the title compound (0.030 g, 16.7% yield) as an off-white solid.

[0348] 1 H NMR (DMSO-d6, 400 MHz, D2O exchange): δ 1.97 (s, 3H), 2.23 (s, 3H), 2.32 (s, 3H), 3.04 - 3.05 (m, 1H), 3.11 - 3.13 (m, 1H), 4.40 - 4.57 (m, 2H), 4.70 - 4.80 (m, 3H), 4.86 - 4.89 (m, 1H), 6.27 (s, 1H), 6.38 - 6.42 (m, 1H), 6.62 - 6.80 (m, 1H), 7.01 - 7.24 (m, 1H), 7.24 - 7.33 (m, 6H), 7.55 (d, J= 20 Hz, 1H); LCMS (Method A): 1.331 min, 95.14 %, 254 nm MS: ES+ 502.4

[0349] [Example 7]: N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)acrylamide [ka]

[0350] A stirred solution of (4-aminoisoindolin-2-yl)(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylphenyl)methanone (Intermediate 3) (0.08 g, 0.2 mmol, 1 eq.) in AcOH (0.8 mL) at 0 °C was treated with acrylic anhydride (0.02 mL, 0.16 mmol, 1 eq.). The reaction mixture was stirred at room temperature for 30 min, neutralized with saturated NaHCO solution, and extracted into ethyl acetate (3 × 50 mL). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by preparative TLC (5% MeOH in DCM as solvent system) to give the title compound (0.038 g, yield: 33.4%) as an off-white solid.

[0351] 1H NMR (DMSO-d6, 400 MHz): δ 0.95 - 0.97 (m, 2H), 1.07 - 1.26 (m, 3H), 1.55 - 1.68 (m, 6H), 1.95 (s, 3H), 3.53 - 3..67 (m, 2H), 4.56 (s, 2H), 4.67 - 4.82 (m, 2H), 5.67 - 5.77 (m, 1H), 6.18 - 6.31 (m, 2H), 6.55 - 6.59 (m, 1H), 7.04, 7.20 (dd, J= 7.6 Hz, 1H), 7.23 - 7.28 (m, 1H), 7.63 (d, J= 8 Hz, 1H), 9.06 - 9.15 (m, br, 2H), 9.45 - 9.57 (m, br, 1H). LCMS (Method A): 1.957 min, MS: ES+ 451.4 (M+1). Analytical HPLC Method C [6.751 min, 254 nm, 95.4%.

[0352] [Example 8]: (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide [ka]

[0353] Two parallel batches were run on a 0.15 g scale: a stirred solution of (E)-4-(dimethylamino)but-2-enoic acid hydrochloride (CAS 848133-35-7; 0.15 g, 0.90 mmol, 1 eq.) and (4-aminoisoindolin-2-yl)(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylphenyl)methanone (Intermediate 3) (0.10 g, 0.27 mmol, 0.3 eq.) in DMF (0.05 mL) in a 10 mL microwave tube at room temperature was treated with DCC (0.37 g, 1.8 mmol, 2 eq.); the reaction mixture was heated to 150 °C and stirred for 15 min under microwave irradiation. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with water (60 mL). The aqueous layer was further washed with ethyl acetate (3 × 30 mL), and the aqueous layer was concentrated under reduced pressure. The crude material was purified by preparative HPLC (Method B) to give the title compound (0.045 g, yield: 13.0%) as an off-white solid.

[0354] 1 H NMR (DMSO-d6, 400 MHz,): δ 1.04 - 1.16 (m, 3H), 1.58 - 1.68 (m, 8H), 1.90 - 1.92 (s, 3H), 2.15 (s, 3H), 2.20 (s, 3H), 3.01 - 3.08 (m, 2H), 3.15 - 3.19 (m, 2H), 3.50 - 3.51 (m,1H), 3.65 (t, J= 7.2 Hz, 1H), 4.53 (s, 2H), 4.68 - 4.75 (m, 2H), 6.25 (s, 1H) 6.25 - 6.47 (m, 1H), 6.66 - 6.78 (m, 1H), 7.03 - 7.17 (m, 1H), 7.23 - 7.30 (m, 1H), 7.71 (d, J= 7.6 Hz, 1H), 9.43 (s, 1H), 9.51 - 9.53 (m, 1H). LCMS (Method A): 1.511 min, MS: ES+ 508.13 (M+1). Analytical HPLC Method A: 4.933 minutes 97.5%.

[0355] [Example 9]: (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-(pyrrolidin-1-yl)but-2-enamide [ka]

[0356] A stirred solution of (£)-4-(pyrrolidin-1-yl)but-2-enoic acid hydrochloride (CAS 848185-03-05; 0.263 g, 1.26 mmol, 1 eq.), (4-aminoisoindolin-2-yl)(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylphenyl)methanone (Intermediate 3) (0.150 g, 0.38 mmol, 0.3 eq.) in DMF (0.26 mL) at room temperature was treated with DCC (0.260 g, 1.26 mmol, 1 eq.). The reaction mixture was heated to 150 °C, stirred for 15 min, cooled, poured into ice-cold water (50 mL), and extracted with ethyl acetate (3 × 50 mL). The desired product was water-soluble. The aqueous layer was evaporated to give crude material (0.480 g) which was purified by preparative HPLC (Method C) followed by lyophilization to give the title compound (0.045 g, yield: 14.6%) as an off-white solid.

[0357] 1H NMR (DMSO-d6, 400 MHz): δ ppm 0.70 - 0.99 (m, 2H), 1.05 - 1.16 (m, 3H), 1.58 - 1.65 (m, 5H), 1.69 - 1.73 (m, 5H), 1.92 and 1.93 (two singlets, 3H), 2.44 - 2.46 (m, 2H), 3.18 - 3.26 (m, 2H), 3.50 - 3.52 (m, 1H), 3.63 - 3.67 (m, 1H), 4.53 (bs, 2H), 4.72 - 4.75 (m, 2H), 6.25 (s, 1H), 6.29 - 6.47 (m, 1H), 6.71 - 6.83 (m, 1H), 7.03 - 7.17 (m, 1H), 7.23 - 7.28 (m, 1H), 7.69 (t, J= 7.6 Hz, 1H), 9.45 - 9.66 (m, br, 2H). LCMS (Method A): 1.536 min, MS: ES+ 534.2 (M+1). Analytical HPLC (Method B): 5.540 min. 98.9%, 254 nm.

[0358] [Example 10]: (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-morpholinobuta-2-enamide hydrochloride [ka]

[0359] A stirred solution of (£)-4-morpholinobuta-2-enoic acid hydrochloride (CAS 1807940-64-2; 0.263 g, 1.26 mmol, 1 eq.), (4-aminoisoindolin-2-yl)(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylphenyl)methanone (Intermediate 3) (0.150 g, 0.38 mmol, 0.3 eq.) in DMF (0.26 mL) at room temperature was treated with DCC (0.260 g, 1.26 mmol, 1 eq.). The reaction mixture was heated to 150 °C, stirred for 15 min, cooled, poured into ice-cold water (50 mL), and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over Na SO and concentrated in vacuo. The crude material was purified by preparative HPLC (Method D) followed by lyophilization to give the title compound (0.037 g, 10.2% yield) as an off-white solid.

[0360] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 0.80 - 0.99 (m, 2H), 1.07 - 1.16 (m, 3H), 1.58 - 1.68 (m, 6H), 1.92 and 1.923 (two singlets, 3H), 2.33 - 2.36 (m, 2H), 2.47 (m, br, 2H), 3.07 - 3.15 (m, 2H), 3.50 - 3.51 (m, 1H), 3.57 - 3.64 (m, 5H), 4.52 - 4.56 (m, 2H), 4.68 - 4.79 (m, 2H), 6.32 (s, 1H), 6.42 - 6.47 (m, 1H), 6.64 - 6.79 (m, 1H), 7.03 - 7.17 (m, 1H), 7.23 - 7.30 (m, 1H), 7.67 (d, J= 8 Hz, 1H), 9.40 - 9.47 (m, 2H), 9.55 - 9.68 (m, 1H). LCMS (Method H): 8.646 min, MS: ES+ 550.7 (M+1). Analytical HPLC (Method B): 5.407 min. 95.04%, 254 nm.

[0361] [Example 11]: (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-(4-methylpiperazin-1-yl)but-2-enamide [ka]

[0362] A stirred solution of (£)-4-(4-methylpiperazin-1-yl)but-2-enoic acid (CAS 1472802-56-4: 0.250 g, 1.13 mmol, 1 eq.), (4-aminoisoindolin-2-yl)(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylphenyl)methanone (Intermediate 3) (0.130 g, 0.33 mmol, 0.3 eq.) in DMF (0.28 mL) at room temperature was treated with DCC (0.261 g, 1.27 mmol, 1 eq.). The reaction mixture was heated to 150 °C, stirred for 15 min, cooled, poured into ice-cold water (50 mL), and extracted with ethyl acetate (3 × 50 mL). The product was observed in both the organic and aqueous layers. The combined organic and aqueous layers were concentrated in vacuo and the crude material was purified by preparative HPLC (Method E) followed by lyophilization to give the title compound (0.020 g, yield: 7.1%) as an off-white solid.

[0363] 1H NMR (DMSO-d6, 400 MHz): δ ppm 0.7 - 1.0 (m, 2H), 1.15 - 1.23 (m, 4H), 1.58 - 1.61 (m, 7H), 1.92 (s, 3H), 2.19 - 2.20 (m, 3H), 2.33 - 2.41 (m, 3H), 3.07 - 3.08 (m, 1H), 3.12 - 3.13 (m, 1H), 3.63 - 3.64 (m, 2H), 4.52 (bs, 2H), 4.71 - 4.75 (m, 2H), 6.24 (s, 1H), 6.30 - 6.45 (m, 1H), 6.63 - 6.76 (m, 1H), 7.03 - 7.17 (m, 1H), 7.23 - 7.30 (m, 1H), 7.67 (d, J= 8 Hz, 1H), 9.46 (s, 1H), 9.68 (m, 1H). LCMS (Method A): 1.509 min, MS: ES+ 563.2 (M+1). Analytical HPLC (Method B): 5.180 min. 98%, 230 nm.

[0364] [Example 12]: N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)but-2-ynamide [ka]

[0365] A stirred solution of but-2-ynoic acid (CAS 590-93-2; 0.270 g, 3.21 mmol, 1 eq.), (4-aminoisoindolin-2-yl)(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylphenyl)methanone (Intermediate 3) (0.130 g, 0.33 mmol, 0.1 eq.), and DCC (0.662 g, 3.21 mmol, 1 eq.) in DMF (0.3 mL) was heated to 150 °C and stirred for 15 min. The reaction mixture was poured into ice-cold water (50 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over NaSO and concentrated in vacuo. The crude material was purified by flash column chromatography to give the title compound (0.015 g, yield: 4.8%) as an off-white solid.

[0366] 1 H NMR (DMSO-d6, 400 MHz) mixture of rotamers: δ 0.93 - 0.99 (m, 3H), 1.09 - 1.15 (m, 2H), 1.56 - 1.67 (m, 6H), 1.92 (two singlets, 3H), 2.00 and 2.07 (two singlets, 3H), 3.47 - 3.51 (m, 1H), 3.63 - 3.65 (m, 1H), 4.50 - 4.52 (m, 2H), 4.68 - 4.73 (m, 2H), 6.24 - 6.26 (two singlets, 1H), 7.21 - 7.29 (m, 2H), 7.40 - 7.44 (m, 1H), 9.40 (s, 1H), 9.47 (m, 1H), 10.25 - 10.37 (two singlets, 1H). LCMS (Method A): 2.002 min, 100 %, 254 nm MS: ES+ 463.1. Analytical HPLC Method B: 5.187 min, 98.04%, 254nm

[0367] [Example 13]: (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)but-2-enamide [ka]

[0368] A stirred solution of (£)-but-2-enoic acid (CAS: 107-93-7, 0.110 g, 1.26 mmol, 1 eq.) in EtOAc (1.1 mL) at 0 °C was treated with molecular sieves (catalytic), T3P (50% in EtOAc) (1.21 g, 3.8 mmol, 3 eq.), and TEA (0.51 g, 5.04 mmol, 4 eq.) and stirred for 5 min. (4-Aminoisoindolin-2-yl)(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylphenyl)methanone (Intermediate 3) (0.050 g, 0.13 mmol, 0.1 eq.) was added at 0 °C, and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was poured into ice-cold water (50 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The resulting crude material was purified by flash column chromatography followed by preparative HPLC purification (Method E) to give the title compound (0.020 g, yield: 3.3%) as a white solid.

[0369] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 0.91 - 1.24 (m, 5H), 1.5 - 1.68 (m, 6H), 1.82 - 1.89 (m, 3H), 1.92 (s, 3H), 3.44 - 3.49 (m, 1H), 3.63 - 3.66 (m, 1H), 4.51 (s, 2H), 4.70 - 4.79 (m, 2H), 6.12 - 6.31 (m, 2H), 6.71 - 6.85 (m, 1H), 7.02 - 7.16 (m, 1H), 7.22 - 7.30 (m, 1H), 7.62 - 7.67 (m, 1H), 9.39 - 9.56 (m, 3H). LCMS (Method A): 1.971 min, MS: ES+ 465.0 (M+1). Analytical HPLC (Method B): 8.167 min, 95%.

[0370] [Table 1] JPEG2024543183000058.jpg255155JPEG2024543183000059.jpg255154JPEG2024543183000060.jpg255155JPEG2024543183000061.jpg255168 JPEG2024543183000062.jpg255155JPEG2024543183000063.jpg255156JPEG2024543183000064.jpg255158JPEG2024543183000065.jpg244170

[0371] [Example 34]: (E)-4-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-5-yl]oxy-N,N-dimethyl-but-2-enamide [ka]

[0372] 2-Hydroxy-4,6-bis(methoxymethoxy)-3-methylbenzaldehyde A stirred solution of 2,4,6-trihydroxy-3-methylbenzaldehyde (see preparation of Intermediate 6) (5 g, 29.76 mmol, 1 eq.) in DCM (50 mL) at 0 °C was treated with DIPEA (19.19 g, 148 mmol, 5 eq.) and stirred for 5 min. MOM-Cl (7.18 g, 89 mmol, 3 eq.) was added at 0 °C, and the reaction mixture was stirred at room temperature for 30 min. The reaction mixture was poured into water (300 mL) and extracted with DCM (3 × 100 mL). The combined organic layers were dried over Na SO and concentrated in vacuo. The crude material was purified by flash chromatography (the product was eluted in 15% ethyl acetate in hexane) to give the title compound (4.4 g, quantitative yield) as a yellow solid.

[0373] 1H NMR (DMSO-d6, 400 MHz): δ 1.95 (s, 3H), 3.41 (s, 3H), 3.44 (s, 3H), 5.32 (d, J= 7.2 Hz, 4H), 6.44 (s, 1H), 10.12 (s, 1H), 12.39 (s, 1H). LCMS (Method A): 1.884 min, 1.991 min, MS: ES+ 256.88 (M+1)

[0374] 2-Methoxy-4,6-bis(methoxymethoxy)-3-methylbenzaldehyde A stirred solution of 2-hydroxy-4,6-bis(methoxymethoxy)-3-methylbenzaldehyde (4.4 g, 17.18 mmol, 1 eq.) in DMF (44 mL) at room temperature was treated with KCO (11.85 g, 85.93 mmol, 5 eq.) and KI (0.85 g, 5.15 mmol, 0.3 eq.) and stirred for 5 min. CHCl (3.63 g, 25.78 mmol, 1.5 eq.) was added, and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was poured into water (300 mL), extracted with EtOAc (3 × 100 mL), and the organic layer was washed with brine solution (100 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give the title compound (4.7 g, yield: 98.7%) as a yellow sticky solid; LCMS (Method A): 1.645 min, 1.691 min, 1.718 min, MS: ES+ 270.79 (M+1). The crude material was used in the next step without purification.

[0375] 2-Methoxy-4,6-bis(methoxymethoxy)-3-methylbenzoic acid Two parallel batches were carried out. A stirred solution of 2-methoxy-4,6-bis(methoxymethoxy)-3-methylbenzaldehyde (0.6 g, 2.22 mmol, 1 eq.) in THF:t-BuOH (1:3) (6 mL) at room temperature was treated with saturated aqueous NaClO (0.699 g, 7.70 mmol, 3.5 eq.) and NaHPO (1.70 g, 14.20 mmol, 6.4 eq.). 2-Methyl-2-butene (2.18 g, 31.11 mmol, 14 eq.) was added at room temperature, and the reaction mixture was stirred for 30 min, poured into a saturated solution of NH Cl (50 mL), and extracted with DCM (3 × 80 mL). The combined organic layers were dried over Na SO , filtered, and concentrated in vacuo to give the title compound acid (1.25 g, 97% yield, 4.37 mmol) as a yellow liquid. The crude material was used in the next step without purification.

[0376] (E)-4-Bromo-N,N-dimethylbut-2-enamide Four batches were run in parallel. A stirred solution of (E)-4-bromo-but-2-enoic acid (0.5 g, 12.12 mmol, 1 eq.) (CAS 13991-36-1) in DCM (10 mL) at 0 °C was treated with DMF (0.4 mL) and stirred for 10 min. Oxalyl chloride (0.576 g, 4.54 mmol, 1.5 eq.) was added to the reaction mixture at 0 °C and stirred for 2 h. Dimethylamine hydrochloride (0.37 g, 4.64 mmol, 1.5 eq.) and Na2CO3 (0.95 g, 9.09 mmol, 3.0 eq.) were added at 0 °C and the reaction mixture was stirred for 2 h. The reaction mixture was diluted with water (200 mL) and extracted with DCM (2 × 200 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give (E)-4-bromo-N,N-dimethylbut-2-enamide (2.1 g, yield: 90.6%) as a purple liquid.

[0377] 1H NMR (DMSO-d6, 400 MHz): δ 3.08 (s, 6H), 4.06 - 4.08 (m, 2H), 6.50 - 6.53 (m, 1H), 6.92 - 6.99 (m, 1H). LCMS (Method A): 1.032 min, MS: ES+ 193.73 (M+1).

[0378] t-Butyl (E)-5-((4-(dimethylamino)-4-oxobut-2-en-1-yl)oxy)isoindoline-2-carboxylate A stirred solution of t-butyl-5-hydroxyisoindoline-2-carboxylate (CAS 226070-47-9) (2 g, 8.5 mmol, 1 eq.) in DMF (20 mL) at 0 °C was treated with K2CO3 (3.52 g, 25.50 mmol, 3.0 eq.) and stirred for 10 min. (E)-4-Bromo-N,N-dimethylbut-2-enamide (2.42 g, 12.75 mmol, 1.5 eq.) was added at 0 °C, and the resulting reaction mixture was heated to 70 °C and stirred for 16 h. The reaction mixture was cooled to room temperature, poured into ice-cold water (200 mL), and extracted with EtOAc (3 × 200 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The resulting crude material was purified by flash chromatography (eluting with 6% MeOH in DCM) to give the title compound (0.6 g, yield: 20.4%) as a brown liquid. LCMS (Method A): 1.890 min, 1.943 min, MS: ES+ 347 (M+1), 247 (M-100).

[0379] (E)-4-(isoindolin-4-yloxy)-N,N-dimethylbut-2-enamide.HCl A stirred solution of t-butyl (E)-4-((4-(dimethylamino)-4-oxobut-2-en-1-yl)oxy)isoindoline-2-carboxylate (0.7 g, 2.02 mmol, 1 eq.) in DCM (7 mL) at 0 °C was treated dropwise with 4 M HCl in dioxane (7 mL). The resulting reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated under vacuum to yield a crude material which was further triturated with diethyl ether (2 × 5 mL) followed by high vacuum to afford the title compound (0.5 g, yield: quantitative). LCMS (Method A): 0.796 min, MS: ES+ 246.88 (M+1).

[0380] (E)-4-((2-(2-methoxy-4,6-bis(methoxymethoxy)-3-methylbenzoyl)isoindolin-5-yl)oxy)-N,N-dimethylbut-2-enamide A stirred solution of 2-methoxy-4,6-bis(methoxymethoxy)-3-methylbenzoic acid (0.60 g, 2.11 mmol, 1 eq.) in DMF (6 mL) at 0 °C was treated with DIPEA (0.72 mL, 4.23 mmol, 2.0 eq.) and HATU (1.20 g, 3.17 mmol, 1.5 eq.) and stirred for 30 min. (E)-4-(isoindolin-4-yloxy)-N,N-dimethylbut-2-enamide HCl (0.62 g, 2.53 mmol, 1.2 eq.) was added to the reaction mixture at 0 °C. The resulting reaction mixture was stirred at room temperature for 16 h, then poured into ice-cold water (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers were dried over Na SO , filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (product was eluted with 4% MeOH in DCM) to give the title compound (0.47 g, 36.8% yield) as an orange liquid. LCMS (Method A): 1.702 min, 1.759 min, 1.790 min, MS: ES+ 515 (M+1).

[0381] (E)-4-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-5-yl]oxy-N,N-dimethyl-but-2-enamide A stirred solution of (E)-4-((2-(2-methoxy-4,6-bis(methoxymethoxy)-3-methylbenzoyl)isoindolin-5-yl)oxy)-N,N-dimethylbut-2-enamide (0.43 g, 0.83 mmol, 1 eq.) in EtOH (4.3 mL) at 0° C. was treated dropwise with 4 M HCl in dioxane (2.15 mL). The resulting reaction mixture was stirred at room temperature for 4 h and then concentrated in vacuo. The crude material was purified by flash chromatography (product was eluted with 6% MeOH in DCM) and HPLC purification to give the title compound (0.02 g, yield: 9.1%) as a white solid.

[0382] 1 H NMR (DMSO-d6, 400 MHz): δ 1.92 (s, 3H), 2.87 (d, J= 4.8 Hz, 3H), 3.02 (d, J= 8.4 Hz, 3H), 3.14 (bs, 2H), 3.60 (s, 3H), 4.43 (bs, 2H), 4.67 - 4.75 (m, 2H), 6.25 (s, 1H), 6.66 - 6.73 (m, 2H), 6.90 (t, J= 7.6 Hz, 1H), 6.98 - 7.01 (m, 1H), 7.13 - 7.29 (m, 1H), 9.42 - 9.48 (m, 2H). LCMS (Method A): 1.360 min, MS: ES+426 (M+1).

[0383] [Example 35]: (E)-4-((2-(4,6-dihydroxy-2-methoxy-3-methylbenzoyl)isoindolin-4-yl)oxy)-N,N-dimethylbut-2-enamide Prepared using the method described for Example 34 above using t-butyl 4-hydroxyisoindoline-2-carboxylate (CAS 871013-92-2).

[0384] 1H NMR (DMSO-d6, 400 MHz): δ 1.92 (s, 3H), 2.85 - 3.05 (m, 6H), 3.61 (s, 3H), 4.37 - 4.54 (m, 2H), 4.70 - 4.83 (m, 4H), 6.25 (s, 1H), 6.58 - 6.66 (m, 1H), 6.75 (s, br, 1H), 6.85 - 6.98 (m, 2H), 7.22 - 7.30 (m, 1H), 9.44 - 9.52 (m, 2H), 11.07 (s, 1H). LCMS (Method A): 1.417 minutes, MS: ES+ 426.9 (M+1), 97%.

[0385] [Example 36]: N-(2-(4,6-dihydroxy-2-methoxy-3-methylbenzoyl)isoindolin-4-yl)-2-((dimethylamino)methyl)acrylamide [ka]

[0386] A stirred solution of malonic acid (1.0 g, 9.6 mmol, 1.0 eq.) (CAS: 141-82-2) in 1,4-dioxane (10 mL) at room temperature was treated with paraformaldehyde (0.63 g, 20 mmol, 2.3 eq.). Dimethylamine (2 M in THF) (5.0 mL, 10 mmol, 1.05 eq.) was added, and the resulting reaction mixture was heated to 70 °C and stirred for 1 h. The reaction mixture was concentrated in vacuo to give 2-((dimethylamino)methyl)acrylic acid (1.05 g, 84% yield).

[0387] 1 H NMR (D2O, 400 MHz): 2.50 (s, 6H), 3.59 (bs, 2H), 5.51 (s, 1H), 6.01 (s, 1H). LCMS (Method B): 0.59 min, MS: ES+ 130.1 (M+1).

[0388] A stirred solution of 2-((dimethylamino)methyl)acrylic acid (0.2 g, 1.548 mmol, 1.0 eq.) in DMF (4 mL) at 0 °C was treated with DIPEA (0.199 g, 1.548 mmol, 1.0 eq.), HOBt (0.20 g, 1.548 mmol, 1.0 eq.), and EDC.HCl (0.59 g, 3.09 mmol, 1.0 eq.); the reaction mixture was stirred at 0 °C for 5 min and then treated with (4-aminoisoindolin-2-yl)(4,6-dihydroxy-2-methoxy-3-methylphenyl)methanone (Intermediate 10) (0.072 g, 0.23 mmol, 0.15 eq.). The reaction mixture was heated to 120 °C under microwave irradiation for 2 h, then poured into water (50 mL) and extracted with EtOAc (2 × 100 mL). The combined organic layers were washed with brine solution (2 x 30 mL), dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by preparative HPLC purification, followed by lyophilization to give the title compound (0.016 g, yield: 8.1%).

[0389] 1 H NMR (DMSO-d6, 400 MHz, 348K): 1.96 (s, 3H), 2.87 (s, 3H), 2.92 (s, 3H), 3.65 (s, 3H), 3.84 (bs, 1H), 3.94 (bs, 1H), 4.39 (s, 1H), 4.46 (bs, 1H), 4.63 (bs, 1H), 4.71 (bs, 1H), 5.06 - 5.13 (m, 1H), 5.24 - 5.36 (m, 1H), 6.28 (s, 1H), 6.44 - 6.60 (m, 2H), 7.03 - 7.07 (m, 1H). No OH protons observed. LCMS (Method A): 1.435 minutes, MS: ES+ 426.17 (M+1), 99.7%.

[0390] [Example 37]: N-(2-(4,6-dihydroxy-2-methoxy-3-methylbenzoyl)isoindolin-4-yl)-2-(morpholinomethyl)acrylamide [ka]

[0391] A stirred solution of (4-aminoisoindolin-2-yl)(4,6-dihydroxy-2-methoxy-3-methylphenyl)methanone (Intermediate 10) (0.1 g, 0.32 mmol, 1 eq.) in ethyl acetate (1 mL) at 0 °C was treated with molecular sieves (catalyst), 2-(morpholinomethyl)acrylic acid (0.11 g, 0.64 mmol, 2 eq.) (CAS: 4432-44-4), T3P (50% in ethyl acetate) (0.304 g, 0.96 mmol, 3 eq.), and TEA (0.26 g, 2.58 mmol, 8 eq.). The reaction mixture was stirred at room temperature for 1 h and then concentrated in vacuo. The crude material was purified by flash chromatography (the product was eluted with 7% MeOH in DCM) to give the title compound (0.020 g, 13% yield) as a white solid.

[0392] 1 H NMR (DMSO-d6, 400 MHz, 350K): δ ppm 1.96 (s, 3H), 2.30 - 2.42 (m, 2H), 2.54 - 2.55 (m, 2H), 2.68 - 2.91 (m, 1H), 3.23 (s, 1H), 3.29 (s, br, 2H), 3.37 (s, 1H), 3.65 (s, 3H), 3.80 (s, br, 2H), 4.59 (d, J= 9.6 Hz, 2H), 4.83 (bs, 2H), 5.57 - 5.64 (m, 1H), 6.12 - 6.18 (m, 1H), 6.25 - 6.27 (m, 1H), 7.02 - 7.17 (m, 1H), 7.27 - 7.33 (m, 1H), 7.91 - 7.97 (m, 1H), 9.16 (bs, 2H), 10.20 - 10.46 (m, 1H). LCMS (Method A): 1.054 min, MS: ES+ 468.1 (M+1), 100%.

[0393] [Preparative HPLC purification method] Preparative HPLC Purification Method - Example 14 Purification was performed using a Shimadzu LC20AP purification system equipped with a UV detector. Column: XTIMATE C18, (21.2 × 250) mm, 5 μm; compounds were eluted with mobile phase A: 0.05% formic acid in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (64% A, 36% B), T = 12.00 min (64% A, 36% B), T = 12.01 min (02% A, 98% B), T = 14.00 min (02% A, 98% B), T = 14.01 min (64% A, 36% B), and T = 16 min (64% A, 36% B); flow rate = 16 ml / min; run time 16 min.

[0394] Preparative HPLC Purification Method - Example 15 Purification was performed using a Waters 2545 purification system equipped with a UV detector. Column: SUNFIRE Prep C18 OBD, (19 × 250) mm, 5 μm; compounds were eluted with mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile, with a gradient of T = 0 min (91% A, 09% B), T = 18.00 min (86% A, 14% B), T = 18.01 min (02% A, 98% B), and T = 20.00 min (02% A, 98% B); flow rate = 21 ml / min, T = 20.01 min (91% A, 09% B), T = 22 min (91% A, 09% B); flow rate = 18 ml / min; run time 22 min.

[0395] Preparative HPLC Purification Method - Example 19 Purification was performed using a Shimadzu LC20AP purification system equipped with a UV detector. Column: SHIM-PACK GIST C18, (20 × 250) mm, 5 μm; compounds were eluted with mobile phase A: water and mobile phase B: acetonitrile, with a gradient of T = 0 min (62% A, 38% B), T = 16.00 min (50% A, 50% B), T = 16.01 min (02% A, 98% B), T = 18.00 min (02% A, 98% B), T = 18.01 min (62% A, 38% B), and T = 21 min (62% A, 38% B); flow rate = 20 ml / min; run time: 21 min.

[0396] Preparative HPLC Purification Method - Example 20 Purification was performed using a Waters 2545 purification system equipped with a UV detector. Column: Xbridge Prep, C18, OBD (19 × 250) mm, 5 μm; compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (79% A, 21% B), T = 20.00 min (75% A, 25% B), T = 20.01 min (02% A, 98% B), T = 22.00 min (02% A, 98% B), T = 22.01 min (79% A, 21% B), T = 25 min (79% A, 21% B), and T = 25 min (79% A, 21% B). Flow rate: 18 ml / min; run time: 25 min.

[0397] Preparative HPLC Purification Method - Example 21 Purification was performed using a flash chromatography-SELEKT system equipped with a UV detector. Column: YMC 120g C18, 50 μm. Compounds were eluted with mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile, with a gradient of T = 0 min (95% A, 05% B), T = 35.00 min (60% A, 40% B), T = 35.01 min (02% A, 98% B), T = 38.00 min (02% A, 98% B), T = 38.01 min (95% A, 05% B), T = 42 min (95% A, 05% B), flow rate = 80 ml / min, run time 42 min.

[0398] Preparative HPLC Purification Method - Example 22 Purification was carried out using a flash chromatography-SELEKT system equipped with a UV detector. Column 2 * YMC C18, 120 gm, 50 μm; compounds were eluted with mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile with gradient (100% A, 00% B) at T=0 min; gradient (100% A, 00% B) at T=05.00 min to T=35.00 min (100% A, 00% B); gradient (80% A, 20% B) at T=37.00 min (02% A, 98% B); gradient (100% A, 00% B) at T=37.01 min to T=40.00 min (100% A, 00% B); flow rate = 75 ml / min; analysis time 40 min.

[0399] Preparative HPLC Purification Method - Example 23 Purification was performed using a Shimadzu LC20AP purification system equipped with a UV detector. Column: XTIMATE, C18, OBD (19 × 250) mm, 5 μm; compounds were eluted with mobile phase A: 0.1% formic acid in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (85% A, 15% B), T = 20.00 min (75% A, 25% B), T = 20.01 min (02% A, 98% B), T = 22.00 min (02% A, 98% B), T = 22.01 min (85% A, 15% B), T = 25 min (85% A, 15% B), flow rate = 20 ml / min, and run time 25 min.

[0400] (Preparative HPLC Purification Example 24) Purification was carried out using a Shimadzu LC20AP purification system equipped with a UV detector. Column: XTIMATE, C18, OBD (250 × 19) mm, 5 μm; compounds were eluted with mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile with a gradient of T = 0 min (100% A, 0.00% B); gradient (80% A, 20% B) to T = 2 min; gradient (80% A, 20% B) to T = 2 min; gradient (80% A, 20% B) to T = 2 min; gradient (80% A, 20% B) to T = 2 min; gradient (70% A, 30% B) to T = 15 min (70% A, 30% B); gradient (100% A, 0.00% B) to T = 15 min (70% A, 30% B); gradient (100% A, 0.00% B) to T = 20 min; flow rate = 20 ml / min; analysis time 20 min.

[0401] (Preparative HPLC Purification Example 25) Purification was performed using a flash chromatography-SELEKT purification system equipped with a UV detector. Column: YMC C18, 120 gm, 50 μm; compounds were eluted with mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile, with a gradient of T = 0 min (100% A, 00% B), T = 25.00 min (90% A, 10% B), T = 30.00 min (02% A, 98% B), T = 35.00 min (02% A, 98% B), T = 35.01 min (100% A, 00% B), T = 40 min (100% A, 00% B); flow rate = 80 ml / min; analysis time 40 min.

[0402] Preparative HPLC Purification Method - Example 26 Purification was performed using a Shimadzu LC20AP purification system equipped with a UV detector. Column: XTIMATE, C18, OBD 19 × 250 mm, 5 μm; compounds were eluted with mobile phase A: 0.1% formic acid in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (93% A, 07% B), T = 20.00 min (77% A, 23% B), T = 20.01 min (02% A, 98% B), T = 22.00 min (02% A, 98% B), T = 22.01 min (93% A, 07% B), and T = 25 min (93% A, 07% B); flow rate = 20 ml / min; run time 20 min.

[0403] Preparative HPLC Purification Method - Example 27 Purification was performed using a Shimadzu Nexera purification system equipped with a UV detector. Column: SUNFIRE C18 OBD 19 x 150 mm, 5 μm; compounds were eluted with mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile:tetrahydrofuran (90:10) at a gradient of T = 0 min (100% A, 00% B); gradient (91% A, 09% B) to T = 02.00 min; gradient (89% A, 11% B) from T = 02.00 min (91% A, 09% B) to T = 18.00 min; gradient (89% A, 11% B) from T = 18.01 min (02% A, 98% B); gradient (02% A, 98% B) to T = 20 min; gradient (100% A, 00% B) from T = 20.01 min (100% A, 00% B) to T = 22.00 min; flow rate = 21 ml / min.

[0404] Preparative HPLC Purification Method - Example 28 Purification was carried out using a flash chromatography-SELEKT purification system equipped with a UV detector. Column: YMC C18, 120 gm, 50 μm; compounds were eluted with mobile phase A: 0.05% formic acid in water, mobile phase B: acetonitrile, with a gradient of T=0 min (100% A, 00% B), T=05 min (100% A, 00% B), T=05.00 min (100% A, 00% B), T=30.00 min (75% A, 25% B), T=35.00 min (02% A, 98% B), T=40 min (100% A, 00% B); flow rate = 80 ml / min; run time 40 min.

[0405] Preparative HPLC Purification Method - Example 29 Purification was performed using a Waters 2545 purification system equipped with a UV detector. Column: SUNFIRE C18 OBD (19 × 150) mm, 5 μm; compounds were eluted with mobile phase A: 0.05% hydrochloric acid in water, mobile phase B: acetonitrile:mobile phase-A (80:20) with a gradient of T = 0 min (79% A, 21% B), T = 17 min (79% A, 21% B), T = 17.01 min (02% A, 98% B), T = 19.00 min (02% A, 98% B), T = 19.01 min (79% A, 21% B), T = 22 min (79% A, 21% B), flow rate = 10 ml / min; run time 22 min.

[0406] Preparative HPLC Purification Method - Example 30 Purification was performed using a Shimadzu LC20AP purification system equipped with a UV detector. Column: X-bridge Prep, C18, OBD (250 × 19) mm, 5 μm; compounds were eluted with mobile phase A: 0.05% ammonium hydroxide in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (75% A, 25% B), T = 15 min (50% A, 50% B), T = 15.01 min (02% A, 98% B), T = 17.00 min (02% A, 98% B), T = 17.01 min (75% A, 25% B), T = 20 min (75% A, 25% B), flow rate = 19 ml / min; run time: 20 min.

[0407] Preparative HPLC Purification Method - Example 31 Purification was performed using a Waters 2589 purification system equipped with a UV QDA detector. Column: XTIMATE, C18, OBD (250 × 19) mm, 5 μm; compounds were eluted with mobile phase A: 0.1% formic acid in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (85% A, 15% B), T = 15 min (70% A, 30% B), T = 15.01 min (02% A, 98% B), T = 17.00 min (02% A, 98% B), T = 17.01 min (85% A, 15% B), T = 20 min (85% A, 15% B), flow rate = 22 ml / min, and run time = 20 min.

[0408] Preparative HPLC Purification Method - Example 32 Purification was performed using a Waters 2545 purification system equipped with a UV QDA detector. Column: XTIMATE, C18, OBD (250 × 19) mm, 5 μm. Compounds were eluted with mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile:methanol (50:50) with a gradient of T = 0 min (62% A, 38% B), T = 15 min (61% A, 39% B), T = 15.01 min (02% A, 98% B), T = 17.00 min (02% A, 98% B), T = 17.01 min (62% A, 38% B), T = 22 min (62% A, 38% B), flow rate = 20 ml / min, run time 22 min.

[0409] Preparative HPLC Purification Method - Example 33 Purification was performed using a Waters 2545 purification system equipped with a UV QDA detector. Column: Xtimate C18 (250 mm × 21.2 mm × 5 μm); compounds were eluted with mobile phase A: 0.05% formic acid in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (86% A, 14% B), followed by a gradient of T = 15.00 min (75% A, 25% B), followed by a gradient of T = 15.01 min (2% A, 98% B), followed by a gradient of T = 17.00 min (2% A, 98% B), followed by a gradient of T = 17.01 min (86% A, 14% B) to T = 25.00 min (86% A, 14% B), followed by a flow rate of 20 ml / min, followed by a run time of 25 min.

[0410] Preparative HPLC Purification Method - Example 34 Purification was performed using a Waters 2545 purification system equipped with a UV QDA detector. Column: SHIMPACK GIST C18, (250 × 19) mm, 5 μm; compounds were eluted with mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile, with a gradient of T = 0 min (65% A, 35% B), T = 20.00 min (65% A, 35% B), T = 20.01 min (02% A, 98% B), T = 22.00 min (02% A, 98% B), T = 22.01 min (65% A, 35% B), T = 25 min (65% A, 35%), and T = 25 min (65% A, 35%).

[0411] Preparative HPLC Purification Method - Example 35 Purification was performed using a Waters 2545 purification system equipped with a UV detector. Column: SHIMPACK, C18, OBD (250 × 19) mm, 5 μm; compounds were eluted with mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile:methanol:isopropyl alcohol (65:25:10) with a gradient of T = 0 min (65% A, 35% B), T = 24.00 min (65% A, 35% B), T = 24.01 min (02% A, 98% B), T = 26.00 min (02% A, 98% B), T = 26.01 min (65% A, 35% B), and T = 28 min (65% A, 35% B). Flow rate: 20 ml / min; run time: 28 min.

[0412] Preparative HPLC Purification Method - Example 36 Purification was performed using a Shimadzu LC20AP purification system equipped with a UV detector. The column was an XBRIDGE C18 column, OBD (19 × 250) mm, 5 μm. Compounds were eluted with mobile phase A: 0.05% hydrochloric acid in water and mobile phase B: acetonitrile, with a gradient of T = 0 min (78% A, 22% B), followed by a gradient of T = 17 min (65% A, 35% B), T = 17.01 min (02% A, 98% B), followed by a gradient of T = 19.00 min (02% A, 98% B), followed by a gradient of T = 19.01 min (78% A, 22% B) to T = 22 min (78% A, 22% B). Flow rate: 20 mL / min. Analysis time: 22 min.

[0413] [Preparation of intermediates] [Intermediate 1]: (4-aminoisoindolin-2-yl)(2-(benzyloxy)-4,6-dihydroxyphenyl)methanone [ka]

[0414] 5-(benzyloxy)-4-methyl-6-(4-nitroisoindoline-2-carbonyl)-1,3-phenylenebis(4-methylbenzenesulfonate) A stirred solution of 2-(benzyloxy)-4,6-bis(tosyloxy)benzoic acid (Intermediate 4) (2.0 g, 3.56 mmol, 1 eq) in DMF (10 mL) at 0 °C was treated with HATU (1.73 g, 4.55 mmol, 1.3 eq) and DIPEA (0.6 mL, 4.63 mmol, 1.5 eq). The reaction mixture was stirred at 0 °C for 10 min. 4-Nitroisoindoline (CAS: 748735-45-7) (0.635 g, 3.87 mmol, 1.1 eq) was added at 0 °C, and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was poured into ice-cold water (200 mL), extracted with ethyl acetate (3 × 220 mL), dried over Na SO , filtered, and concentrated in vacuo. The crude material was purified by flash column chromatography (product was eluted with 23.6% ethyl acetate in hexane) to give the title compound (1.2 g, 47.7% yield) as a yellow solid.

[0415] LCMS (Method A): 2.565 min, MS: ES+ 715.23 (M+1).

[0416] 4-(4-aminoisoindoline-2-carbonyl)-5-(benzyloxy)-1,3-phenylenebis(4-methylbenzenesulfonate) A stirred solution of 5-(benzyloxy)-4-methyl-6-(4-nitroisoindoline-2-carbonyl)-1,3-phenylenebis(4-methylbenzenesulfonate) (1.2 g, 1.68 mmol, 1 eq.) in EtOH:HO (2:1) at room temperature was treated with Fe (0.56 g, 10.03 mmol, 6 eq.) and NHCl (1.35 g, 25.23 mmol, 15 eq.). The reaction mixture was heated at 70 °C and stirred for 3 h. The reaction mixture was cooled, passed through Celite beads using ethyl acetate (20 mL), poured into ice-cold water (20 mL), and extracted with ethyl acetate (2 × 20 mL). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give the title compound (0.75 g, 65.2% yield) as a brown sticky solid.

[0417] LCMS (Method A): 2.431 min, 2.487 min, MS: ES+ 685.2 (M+1).

[0418] [Intermediate 1]: (4-aminoisoindolin-2-yl)(2-(benzyloxy)-4,6-dihydroxyphenyl)methanone A stirred solution of 4-(4-aminoisoindoline-2-carbonyl)-5-(benzyloxy)-1,3-phenylenebis(4-methylbenzenesulfonate) (0.7 g, 1.02 mmol, 1 eq.) in EtOH:HO (4:1) at room temperature was treated with KOH (2.29 g, 40.89 mmol, 40 eq.). The reaction mixture was heated at 60 °C and stirred for 2 h. The reaction mixture was acidified using saturated KHSO solution (pH ∼7) and extracted into ethyl acetate (3 × 45 mL). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by normal phase column chromatography (product was eluted with 5% MeOH in DCM) to give the title compound (0.098 g, 25.5% yield) as an orange solid.

[0419] 1 H NMR (DMSO-d6, 400 MHz), the compound is a mixture of rotamers: δ 4.33 - 4.39 (m, 2H), 4.52 - 4.63 (m, 2H), 5.03 - 5.08 (m, 3H), 5.17 (s, 1H), 5.99 - 6.01 (two singlets, 2H), 6.37 - 6.52 (m, 2H), 6.91 - 6.98 (m, 1H), 7.22 - 7.30 (m, 5H), 9.45 - 9.54 (m, 2H). LCMS (Method A): 1.491 min, MS ES+ 377.22 (M+1).

[0420] [Intermediate 2]: (4-aminoisoindolin-2-yl)(2-(benzyloxy)-4,6-dihydroxy-3-methylphenyl)methanone [ka]

[0421] 4-Nitro-isoindoline Two parallel batches, each at a 6.5 g scale, were carried out. A stirred solution of 4-nitro-isoindoline-1,3-dione (CAS: 603-62-3) (6.5 g, 33.8 mmol, 1.0 eq.) in THF (130 mL) at 0 °C was treated dropwise with 1 M borane in THF (136.5 mL, 4 eq.). The reaction mixture was heated to 80 °C and stirred (16 h). The resulting reaction was slowly cooled to room temperature, and MeOH (13 mL) and 6 N HCl (32.5 mL) were added dropwise. The resulting reaction mixture was further heated to 65 °C and stirred for 1 h. The reaction mixture was concentrated under vacuum, and the crude material was neutralized using saturated NaHCO solution. Since the desired product was water soluble, the aqueous layer was lyophilized. The crude material was purified by reverse phase column chromatography (product was eluted with 63% MeCN in water) to give the title compound (1.0 g, yield: 7.9%) as a brown solid.

[0422] 1 H NMR (DMSO-d6, 400 MHz): δ 4.63 (s, 2H), 4.93 (s, 2H), 7.70 (t, J= 8 Hz, 16 Hz, 1H), 7.87 (d, J= 7.6 Hz, 1H), 8.22 (d, J= 8 Hz, 1H), 10.24 (bs, 2H). LCMS (Method A): 0.389 min, MS: ES+ 165.2 (M+1).

[0423] 5-(benzyloxy)-4-methyl-6-(4-nitroisoindoline-2-carbonyl)-1,3-phenylenebis(4-methylbenzenesulfonate) Three parallel batches, each at a 0.5 g scale, were carried out. 2-(Benzyloxy)-3-methyl-4,6-bis(tosyloxy)benzoic acid (Intermediate 6) (0.5 g, 0.86 mmol, 1 eq.), HATU (0.653 g, 1.72 mmol, 2 eq.), and TEA (0.095 g, 0.94 mmol, 1.1 eq.) in DMF (5 mL) were added to a microwave vial at 0 °C. 4-Nitroisoindoline (0.169 g, 1.03 mmol, 1.2 eq.) was added, and the reaction mixture was heated at 70 °C under microwave irradiation for 1 h. The reaction mixture was poured into ice-cold water (100 mL) and extracted with ethyl acetate (3 × 300 mL). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by flash column chromatography (the product was eluted in 32% ethyl acetate in hexanes) to give the title compound (1.0 g, 34.6% yield) as a pale yellow solid.

[0424] LCMS (Method A): 2.802 min, MS: ES+ 729.1 (M+1) 751.0 (M+23).

[0425] (4-(4-aminoisoindoline-2-carbonyl)-5-(benzyloxy)-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate))methanone A stirred solution of 5-(benzyloxy)-4-methyl-6-(4-nitroisoindoline-2-carbonyl)-1,3-phenylenebis(4-methylbenzenesulfonate) (0.5 g, 0.68 mmol, 1 eq.) in EtOH:HO (6 mL; 5:1 ratio) at room temperature was treated with Fe powder (0.230 g, 4.12 mmol, 6 eq.) and NHCl (0.551 g, 10.3 mmol, 15 eq.). The reaction mixture was heated to 80 °C and stirred for 2 h. The reaction mixture was slowly cooled to room temperature, filtered through a bed of Celite, washed with ethyl acetate (200 mL), and the combined filtrate was poured into ice-cold water (100 mL) and extracted with ethyl acetate (3 × 300 mL). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material was triturated with n-pentane (3×30 mL) and diethyl ether (3×30 mL) followed by drying to give the title compound (0.9 g, yield: 82.8%) as a pale yellow solid.

[0426] LCMS (Method A): 2.665 min, 36.18 %, 254 nm MS: ES+ 699.2 (M+1); 2.768 min, 57.34 %, 254 nm MS: ES+ 699.2 (M+1).

[0427] [Intermediate 2]: (4-aminoisoindolin-2-yl)(2-(benzyloxy)-4,6-dihydroxy-3-methylphenyl)methanone A stirred solution of (4-(4-aminoisoindoline-2-carbonyl)-5-(benzyloxy)-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate))methanone (0.5 g, 0.71 mmol, 1 eq.) in EtOH:HO (2:1) at room temperature was treated with KOH (1.14 g, 20.3 mmol, 40 eq.). The reaction mixture was heated to 60 °C and stirred for 2 h. The reaction mixture was slowly cooled to room temperature, acidified using a saturated solution of KHSO (pH ∼6–7), and extracted into ethyl acetate (3 × 100 mL). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (product was eluted with 2.1% MeOH in DCM) to give the title compound (0.2 g, yield: 71.6%) as an off-white solid.

[0428] 1 H NMR (DMSO-d6, 400 MHz): δ 1.97 - 1.98 (d, J= 2.0 Hz, 3H), 4.31 - 4.40 (m, 2H), 4.47 - 4.56 (m, 1H), 4.66 - 4.67 (m, 1H), 4.72 - 4.74 (m, 1H), 4.90 - 4.93 (m, 1H), 5.05 (s, 1H), 5.20 (s, 1H), 6.30 (d, J= 2.4 Hz, 1H), 6.36 - 6.53 (m, 2H), 6.91 - 6.98 (m, 1H), 7.28 - 7.38 (m, 5H), 9.47 - 9.54 (m, 2H). LCMS (Method A): 1.681 min, MS: ES+ 391.3.

[0429] [Intermediate 3]: 4-aminoisoindolin-2-yl)(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylphenyl)methanone [ka]

[0430] 5-(cyclohexylmethoxy)-4-methyl-6-(4-nitroisoindoline-2-carbonyl)-1,3-phenylenebis(4-methylbenzenesulfonate) [ka]

[0431] A stirred solution of 2-(cyclohexylmethoxy)-3-methyl-4,6-bis(tosyloxy)benzoic acid (Intermediate 5) (2 g, 3.40 mmol, 1 eq.) in DMF (20 mL) at 0 °C was treated with HATU (1.93 g, 5.07 mmol, 1.5 eq.) and DIPEA (0.87 g, 6.74 mmol, 2 eq.) and stirred for 15 min. 4-Nitroisoindoline hydrochloride (0.88 g, 4.4 mmol, 1.3 eq.) was added, and the resulting reaction mixture was stirred at room temperature for 16 h. The reaction mixture was poured into ice-cold water (80 mL) and extracted with ethyl acetate (3 × 60 mL). The combined organic layers were washed with ice-cold water (3 × 120 mL), dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (the product was eluted in 5% MeOH in DCM to give the title compound (2.0 g, yield: 80.1%) as a yellow solid).

[0432] LCMS (Method D): 3.165 min, 3.182 min, MS: ES+ 735.3 (M+1).

[0433] 4-(4-aminoisoindoline-2-carbonyl)-5-(cyclohexylmethoxy)-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate) [ka]

[0434] Two parallel batches were carried out on a 1.1 g scale: A stirred solution of 5-(cyclohexylmethoxy)-4-methyl-6-(4-nitroisoindoline-2-carbonyl)-1,3-phenylenebis(4-methylbenzenesulfonate) (1.1 g, 1.5 mmol, 1 eq.) in EtOH:HO (2:1) (10 mL) at room temperature was treated with Fe powder (0.5 g, 8.96 mmol, 6 eq.) and NHCl (1.2 g, 22.3 mmol, 15 eq.). The reaction mixture was heated to 70 °C, stirred for 3 h, cooled, and filtered through a bed of Celite, which was washed with ethyl acetate (200 mL). The organic layer was poured into ice-cold water (80 mL) and further extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give the title compound (1.6 g, yield: 75.8%) as a yellow solid. The crude material was used in the next step without purification.

[0435] LCMS (Method D): 3.154 min, 3.035 min, MS: ES+ 705.3 (M+1).

[0436] [Intermediate 3]: 4-aminoisoindolin-2-yl)(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylphenyl)methanone [ka]

[0437] Two parallel batches were carried out on a 0.4 g scale: A stirred solution of 4-(4-aminoisoindoline-2-carbonyl)-5-(cyclohexylmethoxy)-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate) (0.4 g, 0.56 mmol, 1 eq.) in EtOH:HO (2:1) (6 mL) at room temperature was treated with KOH (1.27 g, 22.7 mmol, 40 eq.). The reaction mixture was heated to 60 °C, stirred for 2 h, cooled, poured into ice-cold water (100 mL), and acidified using saturated KHSO solution. The product was extracted into ethyl acetate (3 × 60 mL), and the combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (product was eluted with 7% MeOH in DCM) to give the title compound (0.2 g, yield: 44.4%) as an off-white solid.

[0438] high temperature 1 H NMR (DMSO-d6, 400 MHz, 349.5K): δ 1.0 - 1.08 (m, 2H), 1.11 - 1.29 (m, 3H), 1.57 - 1.69 (m, 6H), 1.95 (s, 3H), 3.41 - 3.66 (m, 2H), 4.30 - 4.44 (m, 2H), 4.56 - 4.67 (m, 2H), 4.86 - 4.96 (m, 2H), 6.23 (s, 1H), 6.40 - 6.55 (m, 2H), 6.92 - 6.97 (m, 1H), 9.02 (s, br, 1H), 9.11 (s, br, 1H).LCMS (Method A): 1.917 min, 98.84%, 254 nm, MS: ES+ 397.5 (M+1). Analytical HPLC Method C: 6.457 min, 97.8%, 254 nm.

[0439] [Intermediate 4]: 2-(benzyloxy)-4,6-bis(tosyloxy)benzoic acid [ka]

[0440] 5-(benzyloxy)-4-formyl-1,3-phenylenebis(4-methylbenzenesulfonate) A solution of 2,4,6-trihydroxybenzaldehyde (CAS 487-70-7) (5 g, 32.2 mmol, 1.0 eq) in acetone (200 mL) at rt was treated with KCO (22.27 g, 161 mmol, 5.0 eq) and p-toluenesulfonyl chloride (12.90 g, 67.7 mmol, 2.1 eq). The reaction mixture was heated at 60 °C for 4 h, then slowly cooled to room temperature and concentrated under reduced pressure. The crude material was diluted with water (300 mL) and extracted into EtOAc (3 × 400 mL). The combined organic layers were washed with brine solution (200 mL), dried over sodium sulfate, and concentrated under reduced pressure to give a crude material which was purified by column chromatography using silica gel (eluting the product with 8.7% ethyl acetate in hexane) to give 4-formyl-5-hydroxy-1,3-phenylenebis(4-methylbenzenesulfonate) (Intermediate 7) (5.9 g, yield: 39.3%) as a yellow solid.

[0441] 1 H NMR (DMSO-d 6 , 400 MHz): δ 2.44 (d, J = 2.4Hz, 6H), 6.38 (d, J = 2.4 Hz, 1H), 6.66 (d, J = 2.4 Hz, 1H), 7.47 - 7.54 (m, 4H), 7.69 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.4 Hz, 2H), 9.89 (s, 1H), 11.52 (s, 1H). LCMS (Method A): 2.441 min, MS: ES+ 461.30 (M-1)

[0442] A solution of 4-formyl-5-hydroxy-1,3-phenylenebis(4-methylbenzenesulfonate) (Intermediate 7) (20 g, 1.0 eq) in DMF (200 mL) at 0 °C was treated with KCO (3.0 eq) and benzyl bromide (6.72 g, 1.3 eq). The reaction mixture was stirred at room temperature for 16 hours. The resulting reaction mixture was diluted with ethyl acetate (400 mL) and washed with cold brine solution (3 × 500 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The crude material (21.5 g) was purified by column chromatography using silica gel (eluting the product with 16% ethyl acetate in hexane) to give the title compound 5-(benzyloxy)-4-formyl-1,3-phenylenebis(4-methylbenzenesulfonate) (20 g, 83% yield) as an off-white solid.

[0443] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 2.44 (d, J = 2.4 Hz, 6H), 5.15 (s, 2H), 6.46 (d, J = 2 Hz, 1H), 7.07 (d, J = 2 Hz, 1H), 7.39 - 7.41 (m, 5H), 7.46 - 7.51 (m, 4H), 7.65 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 8.4 Hz, 2H), 10.00 (s, 1H). LCMS (Method A): 2.651 min, MS: ES+ 574.9 (M+23).

[0444] [Intermediate 4]: 2-(benzyloxy)-4,6-bis(tosyloxy)benzoic acid A solution of 5-(benzyloxy)-4-formyl-1,3-phenylenebis(4-methylbenzenesulfonate) (20 g, 1.0 eq.) in MeCN:water (200 mL) at room temperature was treated with NaClO (12.73 g, 3.7 eq.) and NaHPO (9.12 g, 2.0 eq.). The resulting reaction mixture was stirred at room temperature for 16 h. The MeCN was removed in vacuo, and the resulting aqueous solution was diluted with water (300 mL), neutralized with dilute HCl (pH ∼7), and then extracted with ethyl acetate (2 × 500 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure. The crude material was triturated with diethyl ether (2 × 200 mL) and n-pentane (100 mL) to afford the title compound (20.0 g, 97% yield) as an off-white solid.

[0445] 1 H NMR (DMSO-d6, 400 MHz): δ ppm 2.43 (s, 6H), 5.03 (s, 2H), 6.52 (d, J = 2 Hz, 1H), 6.85 (s, 1H), 7.32 - 7.37 (m, 5H), 7.47 - 7.49 (q, J = 6.4, 8 Hz, 4H), 7.70 (t, J = 8.4 Hz, 4H), 13.48 (bs, 1H). LCMS (Method A): 2.344 min, MS: ES+ 568.91 (M+1).

[0446] [Intermediate 5]: 2-(cyclohexylmethoxy)-3-methyl-4,6-bis(tosyloxy)benzoic acid [ka]

[0447] 5-(cyclohexylmethoxy)-4-formyl-6-methyl-1,3-phenylenebis(4-methylbenzenesulfonate) A stirred solution of 4-formyl-5-hydroxy-6-methyl-1,3-phenylene-bis(4-methylbenzenesulfonate) (Intermediate 8) (2.0 g, 4.19 mmol, 1.0 eq.) in DMF (20 mL) at 0 °C was treated with K2CO3 (2.89 g, 20.9 mmol, 5.0 eq.) and bromomethylcyclohexane (1.11 g, 6.29 mmol, 1.5 eq.) and stirred for 10 min. The reaction mixture was heated to 60 °C and stirred for 16 h. The reaction mixture was poured into ice-cold water (20 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (the product was eluted with 12% ethyl acetate in hexane) to give the title compound (1.4 g, yield: 58.3%).

[0448] 1 H NMR (DMSO-d6, 400 MHz): The compound is a mixture of rotamers: δ 0.97 - 1.00 (m, 2H), 1.11 - 1.26 (m, 3H), 1.67 - 1.73 (m, 5H), 1.77 and 1.83 (singlet, 3H), 2.33 - 2.45 (singlet, 6H), 3.49 and 3.70 (m, 2H), 5.77 (s, 1H), 6.44 and 6.70 (singlet, 1H), 7.48 - 7.53 (m, 4H), 7.71 - 7.81 (m, 4H), 9.86 and 9.90 (singlet, 1H). LCMS (Method D)...

Claims

1. The following structural formula (II): 【Chemistry 1】 [In the formula, R 2 is hydrogen or fluoro; R 4 is selected from the group consisting of hydrogen, halogen, (1-6C)alkyl, (1-6C)haloalkyl, (3-6C)cycloalkyl and (3-6C)cycloalkyl(1-2C)alkyl, said (1-6C)alkyl being selected from one or more R 5a wherein said (3-6C)cycloalkyl and (3-6C)cycloalkyl(1-2C)alkyl groups are optionally substituted by one or more R 5b where each R 5a is independently selected from halogen or (1-4C)alkoxy; 5b is independently selected from the group consisting of halogen, (1-4C)alkyl and (1-4C)alkoxy; R 6 is a (1-6C)alkyl, (1-6C)haloalkyl, (3-8C)cycloalkyl, or a 4- to 7-membered heterocyclyl ring containing one heteroatom selected from N, O or S, or A group having a structure according to formula (A): 【Chemistry 2】 (In the formula, R 7 is hydrogen or (1-3C)alkyl; n is 1 or 2; R 8 is (3-8C)cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is selected from one or more R 9 where R 9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, or (1-3C)haloalkoxy; Y 1 is -CH 2 -, -C(=O)-, or -CHR y2a - and R y2a is halo, cyano, methyl, methoxy, CF 3 , -OCF 3 or hydroxymethyl; Y 2 is -CH 2 -, -C(=O)-, -CHR y2a --, --CH 2 -CH 2 --, --CH 2 -CHR y2b - or -CHR y2a -CH 2 - and R y2a is halo, cyano, methyl, methoxy, CF 3 , -OCF 3 or hydroxymethyl; R y2b is halo, cyano, hydroxy, methyl, methoxy, CF 3 , -OCF 3 or hydroxymethyl; A 1 is N, CH, CR 10 Or CR 12 Selected from: A 2 is N, CH, CR 10 Or CR 12 Selected from: A 3 is N, CH or CR 13 Selected from: A 4 is N, CH or CR 14 Selected from: however, A 1 , A 2 , A 3 Or A 4 Only one or two of may be N; A 1 and A 2 One of them is CR 10 and R 10 represents a group of formula (IIA) or (IIB): 【Chemistry 3】 (In the formula, 【Chemistry 4】 A 1 Or A 2 represents the attachment point with R 11A is hydrogen or (1-3C)alkyl; R 11 is a group of the following formula (A) or (B): 【Chemistry 5】 (In the formula, R 11B and R 11C is hydrogen, halo, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl and -C(O)NR 11F R 11G R 11F and R 11G are each independently selected from hydrogen or (1-4C)alkyl; R 11B and / or R 11C Any (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl present in the group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, (3-6C)cycloalkoxy, phenyl, or 4- to 6-membered heterocyclyl; any phenyl or 4- to 6-membered heterocyclic ring is optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkoxy; R 11D is selected from hydrogen, halo, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl and -C(O)H, where any (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl or -C(O)H group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, (3-6C)cycloalkoxy, phenyl or 4- to 6-membered heterocyclyl; any phenyl or 4- to 6-membered heterocyclic ring is optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkoxy or (1-3C)alkyl; R 11E is selected from the group consisting of hydrogen, halo, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, where any (1-4C)alkyl, (3-6C)cycloalkyl or (3-6C)cycloalkyl-(1-2C)alkyl group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, (3-6C)cycloalkoxy, phenyl or 4- to 6-membered heterocyclyl; any phenyl or 4- to 6-membered heterocyclic ring is optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkoxy. R 12 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy; or R 12 is -(CHR p ) f -Z 12 (In the formula, R p is hydrogen or methyl; f is 0 or 1; Z 12 is -OR 20 , -NR 21 R 22 , -C(O)NR 21 R 22 Or -NR 23 C(O)R 24 and R 20 is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR q ) e -(3-7C)cycloalkyl, -(CHR q ) e -phenyl, -(CHR q ) e -[4- to 6-membered heterocyclyl] or -(CHR q ) e -[5- or 6-membered heteroaryl], R q is hydrogen or methyl, and e is 0 or 1; R 21 and R 22 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, phenyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR r ) d -(3-7C)cycloalkyl, -(CHR r ) d -phenyl, -(CHR r ) d -[4- to 6-membered heterocyclyl] or -(CHR r ) d -[5- or 6-membered heteroaryl]; R r is hydrogen or methyl and d is 0 or 1; or R 21 and R 22 are linked together with the nitrogen atom to which they are attached such that they form a 4- to 6-membered heterocyclic ring; R 23 is hydrogen or (1-2C)alkyl; R 24 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, phenyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR s ) c -(3-7C)cycloalkyl, -(CHR s ) c -phenyl, -(CHR s ) c -[4- to 6-membered heterocyclyl] or -(CHR s ) c -[5- or 6-membered heteroaryl], R s is hydrogen or methyl, c is 0 or 1; R 20 , R 21 , R 22 , R 23 Or R 24 Or R 21 and R 22 Any ring formed when a Optionally substituted with; or R 13 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted with one or more halo or (1-2C)alkoxy; or R 13 is -(CHR o ) h -Z 13 (In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 13 is -OR 25 , -NR 26 R 27 , -C(O)NR 26 R 27 Or -NR 28 C(O)R 29 and R 25 is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR n ) i -(3-7C)cycloalkyl, -(CHR n ) i -phenyl, -(CHR n ) i -[4- to 6-membered heterocyclyl] or -(CHR n ) i -[5- or 6-membered heteroaryl], R n is hydrogen or methyl, and i is 0 or 1; R 26 and R 27 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, phenyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR m ) j -(3-7C)cycloalkyl, -(CHR m ) j -phenyl, -(CHR m ) j -[4- to 6-membered heterocyclyl] or -(CHR m ) j -[5- or 6-membered heteroaryl]; R m is hydrogen or methyl and j is 0 or 1; or R 26 and R 27 are linked together with the nitrogen atom to which they are attached such that they form a 4- to 6-membered heterocyclic ring; R 28 is hydrogen or (1-2C)alkyl; R 29 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, phenyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR l ) k -(3-7C)cycloalkyl, -(CHR l ) k -phenyl, -(CHR l ) k -[4- to 6-membered heterocyclyl] or -(CHR l ) k -[5- or 6-membered heteroaryl], R l is hydrogen or methyl, k is 0 or 1; R 25 , R 26 , R 27 , R 28 Or R 29 Or R 26 and R 27 Any ring formed when a Optionally substituted with R 14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy; or R 14 is -(CHR k ) m -Z 14 (In the formula, R k is hydrogen or methyl; m is 0 or 1; Z 14 is -OR 30 , -NR 31 R 32 , -C(O)NR 31 R 32 Or -NR 33 C(O)R 34 and R 30 is (1-4C)alkyl, (3-7C)cycloalkyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR j ) o -(3-7C)cycloalkyl, -(CHR j ) o -[4- to 6-membered heterocyclyl] or -(CHR j ) o -[5- or 6-membered heteroaryl], R j is hydrogen or methyl, and o is 0 or 1; R 31 and R 32 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR i ) p -(3-7C)cycloalkyl, -(CHR i ) p -[4- to 6-membered heterocyclyl] or -(CHR i ) p -[5- or 6-membered heteroaryl]; R i is hydrogen or methyl, p is 0 or 1, or R 31 and R 32 are linked together with the nitrogen atom to which they are attached such that they form a 4- to 6-membered heterocyclic ring; R 33 is hydrogen or (1-2C)alkyl; R 34 is (1-6C) alkyl, (2-6C) alkynyl, (3-7C) cycloalkyl, carbon-linked 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, -(CHR h ) q -(3-7C)cycloalkyl, -(CHR h ) q -[4- to 6-membered heterocyclyl] or -(CHR h ) q -[5- or 6-membered heteroaryl], R h is hydrogen or methyl, and q is 0 or 1; R 30 , R 31 , R 32 , R 33 Or R 34 , or R 31 and R 32 Any ring formed when the are linked may be one or more R a Optionally substituted with Each R a is oxo, halogen, cyano, hydroxy, (1-4C) alkyl, or -L 1 -X 1 -Q 1 base are independently selected from the group consisting of: (In the formula, L 1 is absent or is (1-2C)alkylene; X 1 is absent or is —O—, —C(O)—, —C(O)—O—, —O—C(O)—, —S(O) 0~2 -, -C(O)-N(R 14a ) -, -N(R 14a )-C(O)-,-NR 14a -, -N(R 14a )-C(O)-NR 14a -, -SO 2 N (R 14a )- or -N(R 14a ) S.O. 2 -, R 14a is hydrogen or (1-2C)alkyl; Q 1 is selected from the group consisting of hydrogen, (1-4C) alkyl, (2-4C) alkenyl, (2-4C) alkynyl, or (3-6C) cycloalkyl. or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

2. The following structural formula (I): 【Chemistry 6】 [In the formula, R 2 , R 4 , R 6 , Y 1 , Y 2 , R 11A , R 11 , A 2 , A 3 , or A 4 or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

3. Formulas II, I-II, I-III, I-IV, IV, I-VI, I-VII, I-VIII, I-IX, I-X, I-XI, I-XII, I-XIII, I-XIV, I-XV, I-XVI, I-XVII and I-XVIII: 【Chemistry 7】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 [In the formula, R 4 , R 6 , Y 1 , Y 2 , A 2 , A 3 , A 4 , R 11 , R 11A , R 11B , R 11C , R 11D and R 11E or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

4. Formula II-I, II-II, II-III, II-IV, II-V or II-VI (which are sub-definitions of Formula II): 【Chemistry 8】 【change】 [In the formula, R 4 , R 6 , R 10 , Y 1 , Y 2 , A 1 , A 2 , A 3 , and A 4 or a pharma- ceutically acceptable salt, hydrate and / or solvate thereof.

5. R 6 is a (1-6C)alkyl, (1-6C)haloalkyl, (3-6C)cycloalkyl, or a 4- to 6-membered heterocyclyl ring containing one heteroatom selected from N, O, or S; or A group having a structure according to formula (A): 【Chemistry 9】 [In the formula, R 7 is hydrogen or (1-3C)alkyl; n is 1 or 2; R 8 is (3-8C)cycloalkyl, phenyl, 4- to 6-membered heterocyclyl, or 5- or 6-membered heteroaryl, each of which is represented by one or more R 9 optionally replaced by; Each R 9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, or (1-3C)haloalkoxy.

5. The compound according to any one of claims 1 to 4, which is: or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

6. R 6 is a group having a structure according to formula (A): 【Chemistry 10】 [In the formula, R 7 is hydrogen or methyl; n is 1; R 8 is cyclohexyl, phenyl, 6-membered heterocyclyl, or pyridyl, each of which is represented by one or more R 9 each R 9 is independently selected from the group consisting of halogen, methyl, methoxy, trifluoromethyl, or trifluoromethoxy.

6. The compound according to any one of claims 1 to 5, which is: or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

7. Y 1 But -CH 2 7. The compound according to any one of claims 1 to 6, wherein: - or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

8. Y 2 But -CH 2 --, --CHR y2a --, --CH 2 -CH 2 --, --CH 2 -CHR y2b - or -CHR y2a -CH 2 - and R y2a is selected from halo, methyl or hydroxymethyl; R y2b halo, cyano, hydroxy, methyl, methoxy, CF 3 , -OCF 3 or hydroxymethyl; or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

9. Y 1 But -CH 2 - and Y 2 But -CH 2 9. The compound according to any one of claims 1 to 8, wherein: - or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

10. A 2 , A 3 Or A 4 but the following options: (i) A 1 is N, CH or CR 10 Selected from: A 2 is N, CH or CR 10 Selected from: A 3 is selected from N or CH; A 4 is N, CH or CR 14 Selected from: however, A 1 , A 2 , A 3 Or A 4 Only one or two of may be N; A 1 and A 2 One of them is CR 10 is; (ii) A 1 is N, CH or CR 10 Selected from: A 2 is N, CH or CR 10 Selected from: A 3 is N, CH or CR 13 Selected from: A 4 is selected from N or CH; however, A 1 , A 2 , A 3 Or A 4 Only one or two of may be N; A 1 and A 2 One of them is CR 10 is; (iii) A 1 is N, CH or CR 10 Selected from: A 2 is N, CH or CR 10 Selected from: A 3 is selected from N or CH; A 4 is selected from N or CH; however, A 1 , A 2 , A 3 Or A 4 Only one or two of may be N; A 1 and A 2 One of them is CR 10 is; (iv) A 1 is CH or CR 10 Selected from: A 2 is CH or CR 10 Selected from: A 3 is CH; A 4 is CH; however, A 1 and A 2 Only one of the CR 10 It may be; (v) A 1 But, CR 10 and A 2 is CH; A 3 is CH; A 4 is CH; or (vi) A 1 is CH; A 2 But, CR 10 and A 3 is CH; A 4 is CH; or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

11. A 2 , A 3 and A 4 are all CH, or A 1 , A 3 and A 4 or a pharma- ceutically acceptable salt, hydrate or solvate thereof. The compound of any one of claims 1 to 10, wherein all are CH.

12. R 10 is a group of the following formula (IIA) or (IIB): 【Chemistry 11】 [In the formula, 【Chemistry 12】 A 1 Or A 2 represents the attachment point with R 11 and R 11A is as defined in claim 1.

12. The compound of any one of claims 1 to 11, which is: or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

13. R 10 is selected from the following groups: 【Chemistry 13】 [In the formula, 【Chemistry 14】 A 1 Or A 2 represents the attachment point with R 11 is as defined in claim 1. or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

14. R 11A 13. The compound of any one of claims 1 to 12, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, wherein is hydrogen or methyl.

15. R 11B and R 11C is hydrogen, halo, (1-4C)alkyl, and —C(O)NR 11F R 11G R 11F and R 11G are each independently selected from hydrogen or (1-4C)alkyl; R 11B and / or R 11C any (1-4C)alkyl group present in the group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, or a 4-, 5- or 6-membered N-linked heterocycle, said 4-, 5- or 6-membered N-linked heterocycle being optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, or (1-4C)alkoxy; 15. A compound according to any one of claims 1 to 14, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

16. R 11B and R 11C is hydrogen and the other is hydrogen, halo, (1-2C)alkyl, or -C(O)NR 11F R 11G R 11F and R 11G are each independently selected from hydrogen or (1-2C)alkyl; R 11B and / or R 11C any (1-2C)alkyl group present in the group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino, (1-2C)alkoxy, or a 4-, 5- or 6-membered N-linked heterocycle, said 4-, 5- or 6-membered N-linked heterocycle being optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-2C)alkyl, or (1-2C)alkoxy; 16. A compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

17. R 11B and R 11C is hydrogen and the other is hydrogen, fluoro, (1-2C)alkyl, or —C(O)NR 11F R 11G R 11F and R 11G are each independently selected from hydrogen or (1-2C)alkyl; R 11B and / or R 11C any (1-2C)alkyl group present in the group is optionally substituted with one or more substituents selected from chloro, fluoro, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino, (1-2C)alkoxy, or a 5- or 6-membered N-linked heterocycle, said 5- or 6-membered N-linked heterocycle being optionally further substituted with one or more substituents selected from chloro, fluoro, hydroxy, cyano, (1-2C)alkyl, or (1-2C)alkoxy; 17. A compound according to any one of claims 1 to 16, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

18. R 11E is (1-4C)alkyl and is optionally substituted with halo, hydroxy, cyano, [(1-4C)alkyl]amino, di-[(1-4C)alkyl]amino, (1-4C)alkoxy, or a 4-, 5- or 6-membered N-linked heterocycle, said 4-, 5- or 6-membered N-linked heterocycle being optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-4C)alkyl or (1-4C)alkoxy; 14. A compound according to any one of claims 1 to 13, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

19. R 11E 14. The compound according to any one of claims 1 to 13, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, wherein: is (1-4C)alkyl.

20. R 11D but: (i) selected from hydrogen, halo, (1-2C)alkyl and -C(O)H, wherein any (1-2C)alkyl or -C(O)H group is optionally substituted with one or more substituents selected from halo, hydroxy, cyano, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino, (1-2C)alkoxy, (4-6C)cycloalkoxy, phenyl or 4- to 6-membered heterocyclyl; any phenyl or 4- to 6-membered heterocyclic ring is optionally further substituted with one or more substituents selected from halo, hydroxy, cyano, (1-2C)alkyl, (1-2C)alkoxy, (4-6C)cycloalkyl, (4-6C)cycloalkoxy or (1-2C)alkyl; (ii) R 11D is selected from hydrogen, halo, (1-2C)alkyl and -C(O)H, wherein any (1-2C)alkyl or -C(O)H group is optionally substituted with one or more substituents selected from halo, hydroxy, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino or 4- to 6-membered heterocyclyl; (iii) R 11D is selected from hydrogen, chloro, fluoro, methyl and ethyl, where any methyl or ethyl is optionally substituted with one or more substituents selected from chloro, fluoro, [(1-2C)alkyl]amino, di-[(1-2C)alkyl]amino or 5- or 6-membered heterocyclyl; or (iv) R 11D is selected from hydrogen, fluoro or methyl, any methyl being -NMe 2 or morpholine, 18. A compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

21. R 12 but: (i) halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more fluoro or (1-2C)alkoxy; or (ii) fluoro, (1-2C) alkyl, (1-2C) alkoxy 21. The compound according to any one of claims 1 to 20, selected from: or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

22. R 13 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted with one or more halo or (1-2C)alkoxy; or R 13 But -(CHR o ) h -Z 13 [In the formula, R o is hydrogen or methyl; h is 0 or 1; Z 12 is -OR 25 , -NR 26 R 27 or -C(O)NR 26 R 27 and R 25 is (1-4C)alkyl, carbon-linked 4- to 8-membered heterocyclyl, or -(CHR n ) i -[4- to 8-membered heterocyclyl], R n is hydrogen or methyl, and i is 0 or 1; R 26 and R 27 is hydrogen, (1-6C)alkyl, carbon-linked 4- to 8-membered heterocyclyl, or -(CHR m ) j -[4- to 8-membered heterocyclyl]; R m is hydrogen or methyl, j is 0 or 1; or R 26 and R 27 are linked together with the nitrogen atom to which they are attached such that they form a 4- to 8-membered heterocyclic ring; R 25 , R 26 , R 27 Or R 26 and R 27 Any ring formed when a optionally replaced by; R a is as defined in claim 1.

22. The compound of any one of claims 1 to 21, which is: or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

23. (i) R 14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy; or R 14 But -(CHR k ) m -Z 14 [In the formula, R k is hydrogen; m is 0 or 1; Z 12 is -OR 30 , -NR 31 R 32 , -C(O)NR 31 R 32 Or -NR 33 C(O)R 34 and R 30 is (1-4C) alkyl, (3-7C) cycloalkyl, carbon-linked 4- to 8-membered heterocyclyl, -(CHR j ) o -(3-7C)cycloalkyl, or -(CHR j ) o -[4- to 8-membered heterocyclyl], R j is hydrogen or methyl, and o is 0 or 1; R 31 and R 32 is hydrogen, (1-6C) alkyl, (2-6C) alkanoyl, (3-7C) cycloalkyl, carbon-linked 4- to 8-membered heterocyclyl, -(CHR i ) p -(3-7C)cycloalkyl, or -(CHR i ) p -[4- to 8-membered heterocyclyl]; R i is hydrogen or methyl, p is 0 or 1, or R 31 and R 32 are linked together with the nitrogen atom to which they are attached such that they form a 4- to 8-membered heterocyclic ring; R 33 is hydrogen or methyl; R 34 is (1-6C) alkyl, (3-7C) cycloalkyl, carbon-linked 4- to 8-membered heterocyclyl, -(CHR h ) q -(3-7C)cycloalkyl, or -(CHR h ) q -[4- to 8-membered heterocyclyl], R h is hydrogen or methyl, and q is 0 or 1; R 30 , R 31 , R 32 Or R 34 , or R 31 and R 32 Any ring formed when the are linked may be one or more R a optionally replaced by; R a is as defined in claim 1; or (ii) R 14 cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy.

23. The compound according to any one of claims 1 to 22, selected from: or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

24. (i) Each R a is oxo, halogen, cyano, hydroxy, (1-4C)alkyl, or -L 1 -X 1 -Q 1 base are independently selected from the group consisting of L 1 is absent or is (1-2C)alkylene; X 1 is absent or is —O—, —C(O)—, —C(O)—O—, —O—C(O)—, —S(O) 0~2 -, -C(O)-N(R 14a ) -, -N(R 14a )-C(O)-,-NR 14a -, -SO 2 N (R 14a )- or -N(R 14a ) S.O. 2 -, R 14a is hydrogen or (1-2C)alkyl; Q 1 is selected from the group consisting of hydrogen, (1-4C)alkyl, or (3-6C)cycloalkyl; (ii) Each R a is oxo, halogen, cyano, hydroxy, (1-2C)alkyl, or -L 1 -X 1 -Q 1 base are independently selected from the group consisting of L 1 is absent or is (1-2C)alkylene; X 1 is absent or is —O—, —C(O)—, —C(O)—O—, —O—C(O)—, —S(O) 0~2 -, -C(O)-N(R 14a ) -, -N(R 14a )-C(O)-,-NR 14a -, -SO 2 N (R 14a )- or -N(R 14a ) S.O. 2 -, R 14a is hydrogen or (1-2C)alkyl; Q 1 is selected from the group consisting of hydrogen, (1-2C) alkyl, or (3-6C) cycloalkyl; (iii) Each R a is oxo, halogen, cyano, hydroxy, (1-2C)alkyl, or -L 1 -X 1 -Q 1 base are independently selected from the group consisting of L 1 is absent or is (1-2C)alkylene; X 1 is absent or is —O—, —C(O)—, —C(O)—O—, —O—C(O)—, —S(O) 0~2 -, -C(O)-N(R 14a ) -, -N(R 14 a )-C(O)- or -NR 14a -, R 14a is hydrogen or (1-2C)alkyl; Q 1 is selected from the group consisting of hydrogen or (1-2C)alkyl; or (iv) Each R a is oxo, halogen, cyano, hydroxy, (1-2C)alkyl, or -L 1 -X 1 -Q 1 base are independently selected from the group consisting of L 1 But it doesn't exist; X 1 is not present or is —O—, —C(O)—, —S(O) 0~2 -, -C(O)-N(R 14a ) -, -N(R 14a )-C(O)- or -NR 14a -, R 14a is hydrogen or (1-2C)alkyl; Q 1 is selected from the group consisting of hydrogen or (1-2C)alkyl; 24. A compound according to any one of claims 1 to 23, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.

25. The compound is: N-(2-(2-(benzyloxy)-4,6-dihydroxybenzoyl)isoindolin-4-yl)acrylamide; (E)-N-(2-(2-(benzyloxy)-4,6-dihydroxybenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide; N-(2-(2-(benzyloxy)-4,6-dihydroxy-benzoyl)isoindolin-4-yl)-2-fluoroacrylamide; N-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)acrylamide; N-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-2-fluoroacrylamide; (E)-N-(2-(2-(benzyloxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide; N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)acrylamide; (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-(dimethylamino)but-2-enamide; (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-(pyrrolidin-1-yl)but-2-enamide; (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-morpholinobuta-2-enamide hydrochloride; (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-4-(4-methylpiperazin-1-yl)but-2-enamide; N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)but-2-ynamide; (E)-N-(2-(2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)but-2-enamide; (E)-N-[2-[2-(cyclopentylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-4-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-4-yl]-4-(dimethylamino)but-2-enamide; N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]prop-2-enamide; N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]-3,4-dihydro-1H-isoquinolin-8-yl]prop-2-enamide; N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]-3,4-dihydro-1H-isoquinolin-7-yl]prop-2-enamide; (E)-N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-5-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]-3,4-dihydro-1H-isoquinolin-8-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]-3,4-dihydro-1H-isoquinolin-7-yl]-4-(dimethylamino)but-2-enamide; (E)-4-(dimethylamino)-N-[2-(2-ethoxy-4,6-dihydroxy-3-methyl-benzoyl)isoindolin-4-yl]but-2-enamide; (E)-N-[2-[4,6-dihydroxy-3-methyl-2-(2,2,2-trifluoroethoxy)benzoyl]isoindolin-4-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-[2-(cyclopropylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-4-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-4-yl]-4-(dimethylamino)-N-methyl-but-2-enamide; (E)-N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-5-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-5-yl]-4-(dimethylamino)-N-methyl-but-2-enamide; (E)-N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)-3,4-dihydro-1H-isoquinolin-7-yl]-4-(dimethylamino)but-2-enamide; (E)-N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)-3,4-dihydro-1H-isoquinolin-7-yl]-4-(dimethylamino)-N-methyl-but-2-enamide; (E)-N-[2-[2-(cyclohexylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-4-yl]-4-(dimethylamino)-N-methyl-but-2-enamide; (E)-N-[2-[2-(cyclopropylmethoxy)-4,6-dihydroxy-3-methyl-benzoyl]isoindolin-4-yl]-4-(dimethylamino)-N-methyl-but-2-enamide; N-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-4-yl]-N-methyl-prop-2-enamide; (E)-4-(dimethylamino)-N-(2-(2-ethoxy-4,6-dihydroxy-3-methylbenzoyl)isoindolin-4-yl)-N-methylbut-2-enamide; (E)-4-[2-(4,6-dihydroxy-2-methoxy-3-methyl-benzoyl)isoindolin-5-yl]oxy-N,N-dimethyl-but-2-enamide; (E)-4-((2-(4,6-dihydroxy-2-methoxy-3-methylbenzoyl)isoindolin-4-yl)oxy)-N,N-dimethylbut-2-enamide; N-(2-(4,6-dihydroxy-2-methoxy-3-methylbenzoyl)isoindolin-4-yl)-2-((dimethylamino)methyl)acrylamide; N-(2-(4,6-dihydroxy-2-methoxy-3-methylbenzoyl)isoindolin-4-yl)-2-(morpholinomethyl)acrylamide 25. The compound according to any one of claims 1 to 24, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, selected from any one of:

26. A pharmaceutical composition comprising a compound, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, according to any one of claims 1 to 25 in admixture with a pharma- ceutically acceptable diluent or carrier.

27. (i) for use in therapy; (ii) for use in the treatment of cancer; (iii) for use in the treatment of cancer, wherein the compound or pharmaceutical composition is administered in combination with another anti-cancer agent (e.g. a chemotherapeutic agent, an immune checkpoint inhibitor, an immunostimulant, or a DNA damage repair modulator); (iv) for use in the treatment of a triplet repeat disorder, A compound according to any one of claims 1 to 25, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 26.